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1 Introduction 
 
1.1 Chemical Genetics as a method to study biological systems 
Genetics has been used widely to study biology by manipulating the biological system at the 
level of the gene. It has been the benchmark enabling us to understand how genes and 
proteins function. In traditional genetics or ‘forward genetics’, the genome of a model 
organism is randomly mutated. Mutants that produce a change in a desirable phenotype or 
trait, such as growth, appearance or behaviour, are used to discover the identity of genes 
responsible for producing the phenotype. Advances in molecular biology have led to a 
second type of genetic approach called ‘reverse genetics’ where an already identified gene is 
mutated or deleted and the resultant phenotype studied, thereby providing a picture of the 
role of that gene in the organism. 
Traditional genetics also has some limitations. One major obstacle of traditional genetics is 
that mutations are usually constitutive. Mutations in essential proteins often lead to lethality 
at early stages of life and make it impossible for subsequent studies. In the case of non-lethal 
mutations, mutant organisms are often able to compensate for the loss of the gene, which 
obscures the effect of the original mutations. In mammals, genetic approaches are limited by 
their large diploid genome, large physical size and slow rate of reproduction. Another 
limitation of the genetic approach is that most mutations are not conditional — they cannot 
be turned on or off at will. Conditional mutations such as temperature-sensitive mutations 
usually cause an environmental stress to the organism, such as a temperature shift, which 
itself can have marked consequences and may mislead the interpretation of results. In 
addition, organisms that carry constitutive mutations may have time to compensate for their 
effects by upregulating related genes, which can obscure the initial effects of a mutation.  
In recent years, Chemical Biology has opened new avenues to overcome the limitations 
posed by classical genetics approaches. It is defined as the functional and mechanistical 
investigation of biological processes using chemical compounds as modifiers of biological 
activity. Chemical Genetics is the discipline that aims at studying gene function at the level 
of their products, the proteins, by identifying chemical compounds which induce or revert 
biological phenotypes. Chemical genomics/Chemogenomics is thus defined as the 
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systematic identification of small molecules that interact via a specific molecular recognition 
mode with target proteins encoded by the genome. The term chemogenomics is applied 
more specifically to target gene families in drug discovery.  
Chemical genetics complements the existing classical genetic strategies (e.g. mutagenesis) 
allowing for fine tunable in vivo-modulations of protein functions and cellular processes. It 
involves the study of biological systems using small molecule (‘chemical’) intervention, 
instead of only genetic intervention. Small molecules are used to induce alterations in gene 
products in mammalian systems, in a manner similar to mutations. This approach involves 
screening with chemical probes that potentially could interact with any target in the 
genome, while trying to identify specific phenotypes. On the other hand, chemical genetics 
is also analogous to introducing specific gene disruptions, here compounds that are known 
to specifically interact with a given target are used in broad phenotype screens to help 
identify the physiological role of that target.  
Chemical genomics has several outstanding advantages over classical genetics and 
molecular techniques for studying gene functions. Standard genetics approaches target one 
gene at a time and provide limited opportunity to control the extent of the downstream 
cellular effects. By contrast, chemicals can be targeted with spatio-temporal precision against 
a selected spectrum of proteins. They can be applied in defined dosages to distinct cells, 
organs, or developmental stages, often with rapid response times and reversible effects. 
Since the mechanism of action of chemical switches is similar across a range of organisms, 
their identification is of great interest for researchers working with different model systems. 
Finally, the chemicals can be used to inactivate a family of proteins with related sequences 
or structures in a single step. These ‘‘chemical family knock-downs’’ are being increasingly 
used as the method of choice for the functional characterisation of paralogous genes with 
redundant functions (1; 2). 
Such a chemical genetics study requires the involvement of at least three things: a selective 
small molecule, its protein partner, and biological screening (3). Instead of starting with a 
gene, the chemical genetics approach starts with small drug-like molecules to screen for 
protein targets and study their role in biological processes in general, as well as in disease 
related pathological situations. The result is a validated gene function and a potential drug 
candidate all in one step.  
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Small molecule compounds that specifically inhibit individual targets can be used to speed 
up this unravelling of the molecular dissection of the biology underlying various disease 
states, thereby providing multiple opportunities for “genome or proteome mining”. Cell 
permeable and selective small molecules can be used to perturb protein function rapidly, 
reversibly and conditionally with temporal and quantitative control in any biological 
system. The screening of small molecules against specific targets can thus aid in determining 
more potent drug leads. This chapter deals first with understanding the different types of 
approaches used in classical and chemical genetics which in turn determine the type of 
screening approach that would be used. This knowledge is essential in order to facilitate the 
synthesis of the respective small molecule libraries to be screened. This chapter will also deal 
with the presentation of small molecules in array formats and the development of assays to 
screen for active biological targets. Particular attention has been paid to illustrate the 
significance of each section through examples cited through literature surveys. This study 
involves techniques from cell biology, molecular biology, biochemistry and chemistry 
thereby illustrating the interdisciplinary nature of this work.  
 
1.1.1 Classical and chemical genetics approaches 
The two approaches in traditional genetics have been introduced in the previous section. 
Forward genetics is characterised by random mutations followed by phenotypic screening 
and gene identification (as seen in figure 1-1). In reverse genetics, deletion or mutation is 
done of a specific gene followed by phenotypic characterisation of this mutation. As 
observed in traditional genetics, the early stage of chemical genetics primarily involved 
‘forward chemical genetics’, in which natural products or a collection of synthetic 
compounds are screened for desired phenotypes, such as inhibition of tumour growth in 
vitro. The outcome of these studies pointed out the high specificity and potency of natural 
products towards important cellular proteins, leading the way to identify drug targets using 
chemical compounds as probes.  
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Figure 1-1. Differences in the classical and chemical genetics approaches  
(adapted from (3)).  
Forward genetics and forward chemical genetics employ the use of either random genetic mutations 
or screening of small molecule libraries to discover the respective gene or protein responsible for the 
desired phenotype. Hence, in the forward approach the direction is from phenotype to the 
identification of the molecular component. In the reverse approach, the phenotype resulting from the 
mutation or deletion of an already identified gene or inhibition of a protein by its known small 
molecule interaction partner is studied.  
 
Thus, in forward chemical genetics, small molecules are screened for the desired 
phenotypic effect on the biological system under investigation, thereby identifying the 
proteins and genes responsible for the phenotype being investigated. On the other hand, the 
reverse chemical genetics employs the use of small molecules against a protein (gene 
product) of interest in order to identify any resultant phenotypes. Classical genetics 
approaches, never the less, are still used today such as in understanding circadian rhythms 
in the fruit fly, Drosophila, using the forward genetics approach (4; 5) and the 
characterisation of the Myosin V gene in Drosophila (6) using reverse genetics. 
  
1.1.2 Application of small molecules in chemical genetics approaches 
In chemical genetics, with the advent of newer, more specific chemical reagents, it has been 
suggested that these compounds be used as baits to determine the interacting proteins and 
their coding genes responsible that are thought to be responsible for the observed effect (7). 
A medicinal drug compound having a molecular weight of less than 1000 Daltons, and 
typically between 300 and 700 Daltons is considered a small molecule (8).  
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Genetic analysis of the yeast, Saccharomyces cerevisiae has contributed much to our 
knowledge of eukaryotic cell regulation. By using phenotypic readouts such as cell viability 
and morphological alterations, the genetic interaction between two genes can be examined 
by mutations in both genes, which has been a powerful tool in yeast to discover and 
characterise biological pathways. (9; 10) Conditional loss of function of proteins by chemical 
inhibitors in yeasts has greatly facilitated such genetic analyses (11; 12). The examples listed 
in the table 1-1 below depict how chemical genetics has furthered our understanding of 
biology as we know it today through the use of small molecules. 
 
Drug Function known 
through classical 
studies 
Use of Chemical genetics 
has revealed 
References 
Cyclopamine Teratogen and an 
inhibitor of the Sonic 
hedgehog (Shh) 
pathway 
The role of cyclopamine in 
the Shh pathway through 
Smoothened was 
unravelled. 
Further elucidation of the 
role of the Shh pathway in 
hair follicle, limb and 
gastric gland development 
has been made possible. 
(13-16) 
Lactacystin Protease Inhibitor 
with 20S proteasome 
as the sole target 
 
Discovery of the 
proteasome in pathways 
such as antigen 
presentation, cell cycle 
control and cell fate 
determination 
 
(17; 18; 19) 
 
Leptomycin B Antifungal and anti-
bacterial activity 
Leptomycin B inhibits 
CRM1, a protein required 
for nuclear export 
(20; 21) 
Rapamycin Immunosuppressant 
with TOR (target of 
rapamycin) proteins 
as its targets 
Identification of TOR 
dependent cellular factors 
such as S6 kinases and 
Gln3 
(22; 23) 
Tacrolimus or 
FK 506 
Immunosupressant FK 506 inhibits T 
lymphocyte signal 
transduction and IL-2 
transcription by inhibiting 
the protein phosphatase 
Calcineurin 
(24; 25) 
 
Table 1-1. Chemical genetics has helped further the knowledge gained by classical genetics studies 
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1.1.3 Phenotype based forward chemical genetics 
Small molecules can help unravel key targets in biological pathways and this can be truly 
appreciated by the following examples. Anti-mitotic agents are important in anti-tumour 
studies. The majority of the known inhibitors of mitosis act on tubulin during mitotic 
spindle formation (26). In order to identify small molecules that can interact with other 
proteins important for mitosis, Mayer et al. (28) developed a screening procedure that 
targeted nucleolin phosphorylation in cells entering mitosis. Of the 139 positive compounds 
they obtained from this screen, they were able to narrow down one compound, Monastral. It 
arrested cells in mitosis with a monopolar spindle by inhibiting the mitotic motor protein 
kinesin Eg5, which is required for spindle bipolarity (27; 28). Thus a phenotype based 
forward chemical genetics screen helped identify a novel antimitotic molecule. Following 
this study, other selected inhibitors of Eg5 which have been reported are: dihydropyrazoles 
(29), terpendole E (30), and dimethylenastron (31). Similarly, screening of a microbial 
products library for shortened telomere length in yeast yielded three structurally unrelated 
antibiotics, chrolactomycin, UCS1025A, and radicicol (32). Of these, chrolactomycin was also  
found to inhibit human telomerase. Thus phenotype based forward chemical genetics 
approaches could be used in a yeast-based assay to discover small molecules acting on 
human telomerase. 
 
1.1.4 Target based reverse chemical genetics 
Protein kinases represent one of the largest protein families in the human genome with 
current estimates (excluding mutants and splice variants) running in excess of 500 members. 
Members of the protein kinase family are crucial elements in cellular signalling pathways, 
and are therefore of interest as drug targets for cancer, inflammation, etc. These enzymes 
play a pivotal role in gene expression regulation, cellular proliferation and cell 
differentiation. Not surprisingly, dysfunctions of protein kinases are associated with 
numerous severe pathological states and specially designed small molecule inhibitors have 
several potential therapeutic applications, notably in the areas of diabetes, immune diseases 
and cancer. Many kinase inhibitors have been discovered from natural products or through 
medicinal chemistry programs. Examples of small molecule kinase inhibitors used to probe 
cellular signalling pathways are as listed below (table 1-2). 
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Small Molecule 
Inhibitor 
Target Reference 
Flavopiridol cyclin dependent 
kinase 
(33) 
Gleevec/ Imatinib Bcr-Abl/ c-Kit (34; 35) 
U-0126 or PD98059 Mitogen 
Activated Protein 
Kinase Kinase 
(36) 
Wortmannin   PI3 kinase (37) 
Y-27632 Rho associated 
kinases 
(38) 
 
Table 1-2. Kinase inhibitors and their targets  
 
Similarly, protein phosphatases are key regulatory enzymes that dephosphorylate specific 
amino acid residues and are critical regulators of signal transduction under normal and 
pathological conditions such as cell growth and differentiation, cell cycle, metabolism, 
immune response and cytoskeletal function. Natural products such as dephostatin (from 
Streptomyces species) and karanjin (Pongamia pinnata fruits) are protein tyrosine 
phosphatase inhibitors that are being looked into for further modifications to improve their 
suitability as drugs (39).  
Target based reverse chemical genetics too has distinct advantages over the classical reverse 
genetics approach. MEK kinases comprise a family of related serine–threonine protein 
kinases that regulate mitogen-activated protein kinase signalling pathways. These stress-
activated kinases have been implicated in apoptosis, oncogenic transformation and 
inflammatory responses in various cell types. To define the function of MEK1 in cell cycle 
progression, cell growth and cell morphology, the effect of PD 184352 on these processes 
was tested in colon tumour cells. These studies found that MEK1 activity is required for: the 
progression of cells from the G1 to S phase of the cell cycle, anchorage independent growth, 
cell scattering and the conversion of cells from a flattened to a round morphology. Treating 
colon tumour-bearing mice with PD 184352 caused tumour size to shrink, indicating that 
MEK1 function is also required for in vivo colon tumour cell growth (PD 184352 had no 
effect in mice with leukaemia). In this study, a small-molecule MEK1 inhibitor was 
discovered and used to define the function of MEK1 in tumour processes. It is interesting to 
note that in the analogous reverse genetic approach, Mek1-deficient mouse embryos died in 
early embryogenesis and because it is an essential gene, its function could not be studied in 
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tumour processes from adult mice by reverse-genetic methods. In such cases, reverse 
chemical-genetic methods complement and extend reverse-genetics methods for studying 
specific gene product functions in vivo.  
Genome-based unbiased chemical screening will help discover small molecules that target 
novel proteins in specific pathways and networks. Molecular target identification is one of 
the key elements of chemical genomics screen with small molecules. To identify such target 
proteins, several approaches have been developed such as high-density, proteome-based 
affinity purification, genetic/genomic screening and in vivo and in vitro expression screening. 
It is necessary to systematically analyze these various approaches to test their feasibility for 
identification of the proteins whose activity is affected by chemicals. 
 
 
1.2 Sources and synthesis of small molecules 
1.2.1 Natural compound libraries 
There are a number of potential sources of small molecule collections. Traditionally, nature 
has been a rich source of molecules that effect biological systems, many of which act on 
specific protein targets. Natural products, which are both complex and diverse in structure, 
have been used for centuries as medicines and have had a profound impact on human lives. 
The introduction of the sulphonamide antibiotics in the 1930s and penicillin in the 1940s 
revolutionised medicinal practice by dramatically decreasing the fatality rates associated 
with bacterial infections. This thus led to the search for new natural products with 
antibacterial properties. Natural products also are likely to have evolved to penetrate cell 
membranes and interact with specific protein targets and their bioactivity is their advantage.  
Natural products screened for today also have antifungal and antiviral properties and are 
also useful in the oncological, cardiovascular, neurological and immune related diseases 
(40). The specificity of antibodies, T cell receptors as well as hormone and steroid receptors 
is also known to be flexible with respect to the structures they bind. Antigen presenting 
MHC molecules as well as proteasomes and peptide transporters are known to bind to 
peptide libraries from self proteins. Nature thus evolved the concept of diverse ligand-
receptor based libraries exploited in order to identify lead drug targets today. 
Novel natural products from microbial sources offer lead structures of the highest 
molecular diversity and complexity (41). Microbial peptide antibiotics are usually isolated 
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from their metabolites as mixtures of closely related molecules with some micro 
heterogeneity. Natural products produced by plants also offer a large variety of diversity 
within the same class of organic compound found in nature (42). Structurally related 
compounds have the ability to perform similar biological functions and are thus available as 
differently substituted parent compounds. Several marine-derived compounds such as 
cemadotin (microtubule interfering peptide, from sea slug) and yondelis (DNA interacting 
isoquinolone, from sea squirt) are in clinical trials, particularly as anti-cancer agents (43-46). 
Despite their diversity, natural products are obtained in low quantities. Also, difficulties 
associated with purification and characterisation, as well as their structural complexity 
makes natural product chemical derivatisation, a process especially relevant to drug 
discovery, extremely challenging. Thus slowly the focus shifted to generating synthetic 
analogue compound libraries which were natural product derived but had improved 
properties.  
 
1.2.2 Strategies for the synthesis of libraries 
Modern drug discovery often involves screening small molecules for their ability to bind to 
a preselected protein target. In this strategy, sets of discrete compounds are prepared 
simultaneously in arrays of physically separate reaction vessels or micro-compartments 
without interchange of intermediates during the assembly process. Several libraries are 
based on or inspired by the structures of natural compounds and are synthesised in an 
attempt to further develop more potent and active drug leads (47). For example, new classes 
of anti- tuberculosis compounds currently in preclinical testing include derivatives of the 
natural products capuramycin, oxazolidinones and beta-sulfonylcarboxamides (48). 
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1.2.2.1 Target oriented synthesis (TOS) and focussed library synthesis 
 
 
Figure 1-2. Comparison of target-oriented synthesis (TOS) versus focussed library synthesis and 
diversity-oriented synthesis (DOS) (adapted from (49)) 
In figure 1-2, the three approaches to synthesizing small molecules have been depicted. This includes 
the convergent TOS approach as well as the divergent focussed library synthesis and DOS 
approaches. The colours or shapes imply no specific meaning except that each unit represents a 
different compound. The grid represents the 3 dimensional chemical space. TOS and focussed library 
synthesis approaches transform a more complex target molecule into simpler structures using 
retrosynthetic analysis. In DOS, forward synthetic analysis is used to transform simpler starting 
materials into a more complex collection of compounds. 
 
Target oriented synthesis aims to synthesise a single target molecule, whereas a focussed 
library generates structurally similar target structures. Retrosynthetic analysis concepts 
focus on the existence of a defined target structure. In figure 1-2, the first approach uses 
target-oriented synthesis (TOS) and relies primarily on nature to discover small molecules 
with useful, macromolecule-perturbing properties. Natural compounds can be identified in 
screens of extract mixtures, isolated, and then structurally characterised by using a variety of 
spectroscopic techniques. Once such a structure has been identified, it can become a target 
for chemical synthesis. TOS aims to access a precise region of chemical space, which is often 
defined by a complex natural product known to have a useful function. Target-oriented 
syntheses of small molecules, individually or as collections (focussed libraries), can be 
planned effectively with retrosynthetic analysis. Retrosynthetic analysis technique involves 
transforming the structure of a synthetic target molecule to a sequence of progressively 
simpler structures along a pathway which ultimately leads to simple or commercially 
available starting materials for a chemical synthesis.  
With focussed screening, it should also be possible to use an assay that is more appropriate, 
rather than one that works well at a large scale. For example, it has been common for in vitro 
isolated receptor-binding assay formats to be developed for high-throughput screens, even 
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when greater value could be derived from a whole-cell functional approach. The second 
approach uses either medicinal chemistry or combinatorial chemistry and aims to explore a 
dense region of chemical space in proximity to a precise region known to have useful 
properties. The source of the starting or lead compounds can vary and may include a natural 
product, a known drug, or a rationally designed structure developed from a mechanistic 
hypothesis and/or a crystal structure of a macromolecule of interest. In this thesis, both 
target oriented synthesis and focussed library synthesis approaches will be used to screen 
for phenotypes and peptides. 
1.2.2.2 Diversity oriented synthesis (DOS) 
It is critical to the chemical genetics approach to have a library of compounds that have a 
high probability of being relatively selective; otherwise the ability to interpret the results 
becomes at least as complex as deciphering highly polygenetic phenotypes. To address this, 
diversity-oriented synthesis (DOS) has been proposed to provide arrays of complex small 
molecules that are easily synthesised. Drug discovery can also involve screening small 
molecules for their ability to modulate a biological pathway in cells or organisms, without 
regard for any particular protein target. This process is likely to benefit in the future from an 
evolving forward analysis of synthetic pathways, used in diversity oriented synthesis, that 
leads to structurally complex and diverse small molecules. Forward synthetic analysis is a 
problem-solving technique for transforming a collection of simple and similar starting 
materials into a collection of more complex and diverse products. 
DOS concerns the efficient synthesis of structurally diverse (and complex) small molecules 
(i.e. where the molecules differ in their (i) attached groups, (ii) stereochemistry, (iii) 
functional groups and (iv) molecular frameworks). Synthetic pathways in DOS are branched 
and divergent and the planning strategy extends simple and similar compounds to more 
complex and diverse compounds. In DOS there is no single target structure and therefore 
retrosynthetic analysis cannot be used directly and a forward synthetic analysis algorithm is 
required.  
Structural complexity is important because many of the small molecules known to disrupt 
protein-protein interactions are structurally complex natural products. The Shair lab recently 
demonstrated the power of diversity-oriented synthesis combined with phenotypic 
screening in the synthesis of a library of compounds based upon the natural product 
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galanthamine (50). From this library, they discovered a compound, secramine, which 
blocked protein trafficking from the golgi apparatus to the plasma membrane. Another 
significant result from this work was the lack of inhibition of protein trafficking by the 
parent compound galanthamine at concentrations as high as 100 mM. Diversity-oriented 
synthesis in combination with phenotype-based assays has emerged as a powerful tool for 
the study of biological systems. 
 
 
1.2.3 Synthesis of small molecule compound libraries using combinatorial chemistry 
methods 
Structural diversity is essential for lead generation, as compounds that look the same 
structurally are likely to share similar physical and biological properties. Early efforts to 
generate chemical diversity focussed on chemically synthesised peptides because they are 
composed of the same building blocks as proteins and were therefore thought to be good 
candidates for ligands that bind to proteins. Using combinatorial chemistry, a large number 
of variants of one particular core structure were created by combining different building 
blocks with suitable chemical reactions. Combinatorial chemical synthesis is thus a process 
by which multiple compounds (chemical libraries) are generated simultaneously, in a 
predictable fashion, by using techniques that involve parallel chemical transformations. 
However, the number of compounds that could be individually synthesised by conventional 
chemistry was limited by this approach.  
 
1.2.3.1 Solid phase synthesis 
In the 1960’s, Merrifield introduced the concept of solid phase synthesis (51; 52). Synthesis 
on solid supports essentially consisted of three key elements: the solid support, the linker 
element and the compound attached to the linker. In general, synthesis on solid supports 
thus involves two additional steps in synthesis compared to synthesis in solution involving 
the attachment of the starting material to the linker at the start of synthesis and the cleavage 
of the finished product from the linker at the end of synthesis. However, the types of 
chemistry performed in order to synthesise these libraries is governed by the types of linkers 
used and their stability during reactions. Libraries containing up to 10,000 and even more 
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compounds may use the spatially separate synthesis approach where compounds are 
synthesised in parallel but in separate reaction vessels such as microtiter plates. Biological 
evaluation of such libraries can provide specific information about each compound in the 
library. 
In solid phase synthesis, a pin or bead technique permits the synthesis of different molecules 
on each pin (i.e. "one molecule-one bead" (53)). The scale of the different peptides and 
oligonucleotides synthesised by the repetitive coupling of suitable individual monomeric 
building blocks was now sufficient for analysis (54). Alternatively, libraries containing more 
than 100,000 compounds may also be synthesised using photolithographic methods that 
allow for light directed spatially addressable parallel chemical synthesis (55). In this method, 
a silica wafer serves as a solid support. In general, larger libraries of compounds are 
synthesised by employing pooling strategies (56). This strategy uses beads and a repetitive 
splitting and pooling steps in order to generate all possible variations of different sequences 
of building blocks. Another pooling strategy developed by Houghten deconvolutes a soluble 
library after cleavage from the solid support (57). This method has successfully been used to 
identify high affinity ligands. However, since biological activity depends on the abundance 
of active compounds in each pool, the pool that shows greatest biological activity may not be 
the one with the most potent compounds. 
 
1.2.3.1.1 Solid-phase peptide synthesis (SPPS) using the tBOC method 
There are two main protocols that have been used for the chemical solid-phase synthesis of 
peptides (SPPS). When R. B. Merrifield invented SPPS in 1963, it was according to the tBoc 
method. T-Boc (or Boc) stands for tert-butyloxycarbonyl. To remove Boc from a growing 
peptide chain, acidic conditions are used (usually neat TFA). Removal of side-chain 
protecting groups and the peptide from the resin at the end of the synthesis is achieved by 
incubating in hydrofluoric acid (which can be dangerous); for this reason Boc chemistry is 
disfavoured nowadays. However for complex syntheses Boc is favourable. When 
synthesizing non-natural peptide analogues which are base-sensitive (such as depsi-
peptides), Boc is still the method of choice.  
In SPPS the monitoring of the completion of the Boc cleavage and of the coupling reaction is 
advantageous. Reliable methods detecting minute amounts of unreacted amino groups are 
essential for the monitoring of the coupling reaction. A range of colour tests for the 
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qualitative monitoring of the coupling reaction has been developed. The Kaiser test, which is 
based on the reaction of ninhydrin with amines and which is a very sensitive test for 
primary amines, is very often in use. Finally, the peptide linker-support is cleaved to obtain 
the peptide. Ideally, the cleavage reagent should also remove the amino acid side-chain-pro-
tecting groups. In the most commonly employed anchoring system to peptide acids and 
amides  are the 4-hydroxymethylphenylacetic acid (PAM) linker and  
4-methylbenzhydrylamine (MBHA) resin. The peptide-resin anchorage and side–chain 
protecting groups are cleaved by the use of anhydrous HF. Linkers which are cleaved under 
non-acidolytic conditions are also known. Among these is hydroxyl-crotonyl-aminomethyl 
(HYCRAM) where for the cleavage tetrakis-(triphenylphosphine)-palladium (Pd(PPh3)4) is 
used. 
 
1.2.3.1.2 Solid-phase peptide synthesis (SPPS) using the Fmoc method 
The second protocol uses the 9-fluorenylmethyloxycarbonyl (Fmoc) group for N-amino 
protection. The Fmoc method was introduced by R. C. Sheppard in 1971. Fmoc stands for 9-
fluorenylmethoxycarbonyl which describes the Fmoc protecting group. To remove the 
Fmoc-group from a growing peptide chain, basic conditions (usually 20% piperidine in 
DMF) are used. Removal of side-chain protecting groups and peptide from the resin is 
achieved by incubating in trifluoroacetic acid (TFA). The main advantage of Fmoc chemistry 
is that no hydrofluoric acid is needed. It is therefore used for most routine synthesis. 
During the synthesis, Fmoc is split off by a short treatment with piperidine in DMF. For 
coupling reactions DCC or DIC can be used and for the qualitative monitoring of the 
coupling reaction Kaiser test can be used. Side-chain protections that are compatible with N-
protection are removed at the same time as the appropriate anchoring linkages typically by 
the use of TFA. The Fmoc protocol is especially recommended for the synthesis of acid 
sensitive peptides and derivatives. The choice of an adequate combination of protecting 
groups/solid support is the first step to achieve a successful synthesis. 
The products of solid phase synthesis can be cleaved from the backbone matrix for solution 
screening (which is essential when the screening target is a cell), or the most active 
molecules displayed on the polymer surface may be detected using molecular targets 
(receptor, enzyme, antibody) pre-tagged with a means of detection (visible colour, 
fluorescence, radioactivity, chromophore, etc.) and then isolated and identified. Synthesis on 
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solid supports reduces time consuming purification and isolation steps as compared to the 
individual synthesis of compounds in solution.  
A random library may be defined as a library prepared from building blocks without bias 
towards a particular target. These are of a generic nature and are applicable to any screening 
tasks. Random peptide libraries can be displayed using the technique of phage display in 
order to facilitate screening of a phenotype. Peptide libraries have yielded ligands for many 
different protein targets such cyclin dependent kinases (58), Calmodulin (59) and fibroblast 
growth factors (60). Over the past decade, methods for the synthesis of chemical libraries of 
non-peptidic, low-molecular weight organic compounds have also been developed (61). 
Organic compounds libraries have the advantage of often being able to permeate the 
plasma membrane of target cells. These libraries have yielded compounds that are active in 
cell based assays (62). Mueller et al. have taken this a step further and selected gene therapy 
vectors using random peptide libraries displayed on adeno associated virus (63; 64). More 
dedicated peptide libraries are biased for particular domains and are constructed for more 
detailed preferences of ligand analysis. 
 
1.2.4 Combinatorial biology methods 
Although combinatorial biology methods will not be used in this thesis, combinatorial 
libraries can also be generated based on these methods. Combinatorial biology depends on 
the ability to link polypeptides to their encoding DNA. The methods for generating DNA-
encoded polypeptide libraries can be divided into two groups. In vitro methods use libraries 
in which polypeptides are accessible to exogenous ligands. Combinatorial biology exploits 
the ability to use libraries for in direct in vitro binding selections with immobilised target 
ligands and also enrich for polypeptides with particular binding specificities and affinities. 
Phage display is the predominant method for in vitro combinatorial biology. The method 
stems from the observation that polypeptides fused to certain bacteriophage coat proteins 
are displayed on the surfaces of phage particles that also contain the cognate DNA. Libraries 
of ‘fusion phage’ can be rapidly sorted to obtain clones with desired binding properties and 
phage can be readily amplified by passage through a bacterial host (65). Another approach 
to DNA-encoded libraries is provided by cell surface display in which polypeptides are 
displayed directly on bacterial or yeast cells that also contain the encoding plasmid DNA 
(66). 
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Phage-display combinatorial peptide libraries are typically screened by affinity selection 
with a particular target protein. In many cases, it is possible to identify, from the affinity-
selected peptides, members with a sequence that closely resembles segments (epitopes) of a 
natural interacting partner of the protein. A practical consequence of this phenomenon, 
termed ‘convergent evolution’, is that one can search whole genome databases for proteins 
containing segments that match consensus sequences shared by the selected peptides, and 
then experimentally determine whether or not they interact with the target. As an example, 
combinatorial peptide libraries have proven useful in defining the optimal ligand 
preferences of protein interaction modules, such as various SH2, SH3 and WW domains 
within proteins of interest, and suggesting potential interacting proteins (67; 68). 
In contrast, in vivo methods use polypeptide libraries that are expressed inside living cells 
along with a target protein of interest. An interaction between a particular library member 
and the target protein is detected by virtue of an effect on the host cell, such as a selective 
growth advantage, or changes to a physical property of the host cell. In vivo methods can be 
defined as those in which the protein-protein interaction under study is detected inside a 
living cell. The most widely used in vivo method for the detection of protein–protein 
interactions is the yeast two hybrid system (69). Interaction between the two proteins of 
interest (the ‘target’ and the ‘bait’) results in functional assembly of the two components of a 
signalling system: a DNA-binding domain and a transcriptional activation domain. As a 
result, transcriptional activation of a reporter gene occurs leading to a detectable phenotype, 
which can be screened for or directly selected. Although this describes the ‘standard’ yeast 
two-hybrid assay, it has given rise to a several variations (70; 71). 
 
 
1.3 Presenting small molecule libraries as arrays 
Macroarrays, the immediate predecessors to microarrays, are used for the expression 
analysis of tens or hundreds of genes (72). Macroarrays are usually printed on nylon 
membranes approximately 8 x 12 cm in size containing up to 5000 spots, each greater than 
300 microns in diameter. Microarrays, on the other hand, usually have 10,000 - 40,000 spots 
that are less than 200 microns in diameter in a 1.5 cm2 area. A recent popular approach for 
associating genes with specific signalling pathways is the use of nucleic acid microarrays, 
which contain immobilised cDNA fragments or short oligonucleotide probes. Microarrays 
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can comprise the entire human genome and novel techniques enable the detection of a 
specific target within several thousand transcripts (73). Using these tools, scientists are now 
in a position to identify genes that are specifically up- or downregulated in response to a 
defined stimulus (74).  
A review by Chiosis and Brodsky outlines some of the different methods used to present 
small molecules in a microarray format (75). Some of the key points to take into 
consideration while printing are compatibility with pre-existing library formats (mostly 
compounds are dissolved in DMSO) and prevention of cross-contamination by printing 
small molecules on glycerol droplets and aerosol deposition (76). Printing chemical libraries 
on microarrays is a well-known process. However, DNA chips and microarrays for 
genotyping and expression profiling give no information about the activities of enzymes 
that can be regulated by post-translational modifications or cleavage state. Microarrays have 
also successfully been used to find differentially expressed genes by analyzing large sets of 
patient samples, or by comparing normal with diseased tissues (77; 78).  
Recently, protein arrays have also been developed that have the potential to detect post-
translational changes in proteins, such as phosphorylation, acetylation, glycosylation, 
ubiquitination or other covalent protein modifications (79; 80). These modifications, which 
do not require de novo transcription, would be missed by analyzing changes exclusively at 
the mRNA level. Protein microarrays have used the capture of proteins to libraries of 
immobilised DNA sequences, peptides, antibodies, chemical motifs, or other proteins (79; 
81). The three major formats for protein arrays currently use plain glass slides (79), 3D gel 
pad chips (82) (‘‘matrix’’ chips), or nanowell chips (80; 83).  
Other types of arrays, such as sensor arrays, directly translate molecular interactions into 
optical or electrical signals (84). Aptamers, which are small nucleic acid molecules, and 
antibodies can function as biosensors for numerous diagnostic and screening applications 
(85). Both capture tools can recognise targets ranging from small molecules to complex 
multimeric structures with high specificity in vitro and in vivo (86). A systematic screen for 
potent aptamer-DNA sequences yielded, for example, high affinity biosensors for anthrax 
spores (87). Although all of the tools described earlier are powerful tools to associate genes 
and their products with certain pathways or processes, in most cases this association 
remains correlative. Further studies will be required to determine whether the role of the 
gene of interest is also causal in, for instance, the progression of a disease. Non-DNA 
Introduction 18 
 
 
microarrays, such as protein, peptide and small molecule microarrays, pose some 
fundamental obstacles that limit their rapid and widespread implementation as an 
alternative bioanalytical approach. These include for example, the prerequisite for numerous 
proteins in active and purified form, ineffectual immobilization strategies and inadequate 
means for quality control of the considerable numbers of multiple reagents. Below are lists 
of the different types of arrays and the different formats (supports) and the methods used to 
generate them. 
Array type Uses Reference 
Antibody arrays Cytokine profiling, identification of markers 
in cancer 
(88; 89) 
Protein chips Detection of cancer and protein- protein 
interactions 
(90; 91) 
Peptide arrays Identification of epitopes, study of protein - 
protein interactions 
(92-94; 95) 
Peptide Nucleic 
Acid arrays 
Detection of mismatch mutations and 
genetically modified organisms 
(96; 97) 
Lipid arrays Detect mediators of brain inflammation (98) 
Oligosaccharide/ 
Carbohydrate 
arrays 
Detection of cancer associated carbohydrates 
and antibodies against diseases such as 
arthritis 
(99; 100) 
Chemical 
microarrays 
Screen inhibitors of enzymes such as elastase (101) 
Sensor arrays Immunoassay of disease markers such as in 
cancer 
(102) 
 
Array support Uses Reference 
Plain glass slides Printing chemical microarrays (76) 
Filters  Peptide arrays (103) 
Microtiter plates Peptide arrays (104) 
HydroGel chip Used in DNA microarrays (105) 
Nanowell chips DNA microarrays (106) 
Compact disc based 
microarrays 
Peptide nucleic acid arrays (107) 
 
Method used to 
generate arrays 
Uses Reference 
Pin printing G protein coupled receptor (GPCR) arrays (108) 
Photolithographic 
synthesis  
Generation of peptide arrays (109) 
Covalent 
immobilisation 
Immobilisation on microtiter plates in protein 
and sensor arrays 
(110) 
Self assembling 
libraries 
Protein and chemical microarrays  (111; 112) 
In situ synthesis Generation of small molecule microarrays (113)  
   
Table 1-3. Different types of arrays and the supports and methods used to generate them.  
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1.4 Assay Platforms 
With the different genetic screening and array approaches being discussed in the previous 
sections, the focus of this section will be on the different assay methods that facilitate these 
screening approaches and further their application to biological systems. Several key factors 
contribute to the successful use of small molecules to explore biology. The relative selectivity 
of chemical probes that will be used must be known, the correlations between the cellular 
readouts used and the pathway or phenotype that is being assessed must be independently 
validated, all data must be fully integrated, allowing the user to navigate through biological 
pathways and supporting literature, assay results and detailed information on compounds.  
An assay can thus be defined as a method that is used to translate a biological effect into a 
measureable physico-chemical signal. One of the first steps in using or developing an assay 
is choosing between a “cell free” (biochemical) assay or a “cell based assay” system.  
 
1.4.1 Cell free assays 
In biological assays, the challenge is to be able to conduct the assay while maintaining the 
structural integrity of the biological molecule being studied. Several cell free assays use egg 
extracts to study intricate protein interactions. Egg extracts are naturally cell cycle 
synchronised and mimic the complex interplay of proteins that support cellular DNA 
replication and naturally-regulated DNA damage checkpoint activation (114). On the other 
hand, study of biological processes such as receptor mediated endocytosis mediated by cell 
surface receptor-ligand interactions requires the use of broken cell systems (115). Cell free 
assays provide advantages such as eliminating the need to separate bound and free forms of 
ligands (116). Table 1-4 lists some examples of cell free in vitro assays. 
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Cell free in vitro assays Example Reference 
Assays based on direct interaction 
Scintillation proximity assays 
(SPA) 
Lysosome to phagocyte targeting, 
identification of inhibitors of CD28 
necessary for T-cell response 
(117; 118) 
Electro-chemiluminescence Integrin-ligand interactions where 
ruthenium-conjugated monoclonal 
antibodies are used for the 
detection of either purified 
integrins or, more conveniently, 
integrin-expressing cell lysates, 
which are captured on beads coated 
with extracellular matrix or 
vascular ligand proteins 
(119) 
Absorbance assays based on enzyme activity 
Enzyme linked 
immunosorbent assay, ELISA 
in solution 
Antibody screen against human 
interferon alpha, screen molecules 
that compete with the natural 
ligands for binding to the active site 
of the Type-I interleukin-1 receptor 
(120; 121) 
ELISA on solid phase Development of bioassays for 
bovine herpes virus and hepatitis B 
diagnosis  
(122; 123) 
Reporter based assays 
Luminescence based assays Measure toxin activity by inhibition 
of protein synthesis using rabbit 
reticulocyte lysate containing 
luciferase mRNA 
(124) 
Fluorescence based assays Fluorescence polarization based 
molecular binding assay using the 
chemokine receptor CXCR4 and 
integral molecular lipoparticles 
(125) 
Scalability of cell free assays 
High throughput assays High-throughput AHL screening of 
bacteria or metagenomic libraries 
using cell free beta galactosidase 
expression, cell free assay for rapid 
oligo screening for the 
identification of new drug targets 
in pathogenic microbes 
(126; 127) 
Miniaturised assays High-density peptide-aptamer 
microarrays to detect proteins 
electrically in whole cell lysates 
(128) 
 
Table 1-4. Examples of cell free in vitro assays 
 
The Springer handbook of Nanotechnology (129) enumerates how G protein coupled 
receptors can be used as a biosensor in cell free assays. The miniaturization of cell free 
assays is only limited by the sensitivity of the reporter being assayed for. Cell free 
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fluorescence based assays are discussed in more detail in section 1.5, table 1-7. Virtual 
screening can also be used prior to testing in cell based assays to identify or narrow down 
targets from a known library of compounds. It has been successfully used in a variety of 
ligand screens such as identification of inhibitors of lipoxygenase activity (130). 
 
1.4.2 Cell based assays  
Cell free assays do not always reflect how a drug interacts with a target molecule within the 
complex environment of an intact cell. It has therefore been proposed that increased reliance 
on cell based validation early in the discovery process will prove economically 
advantageous (131). 
An important advantage of a cell based assay comes from the following considerations. The 
probability of identifying a selective interaction between a compound and a biological target 
increases with the number of compound-target pairs assayed. This is the basic concept of 
empirical high throughput screening (HTS). Consequently, with respect to a single 
compound the number of biological targets available for screening determines the success. A 
cell is a complex biological system containing a huge number of target molecules that are all 
functionally connected: a high content bio-assay system. The cell reacts to the action of the 
compound by developing a distinct phenotype which is the assay read-out. Thus, cell based 
phenotypic screening is particularly effective in the search for bioactive compounds, 
although the target is not immediately apparent and needs to be identified subsequently. 
This approach became feasible through the combination of high-throughput cellular assays 
and diverse libraries of compounds. The ability to perform genetic screens in cellular assays 
vastly increases the throughput – traditionally a key limitation when studying higher 
organisms. It also allows the separation of effects in somatic cells from those in 
development. This thus requires continued advances in combinatorial chemistry, protein 
biochemistry, miniaturization, automation, and global profiling technology. Trends in 
screening technologies include miniaturization (µHTS) to functional assays (cell based 
assays, CBA) to high content screening where the amount of data collected per well is much 
larger. Cell based assays have become indispensable to screen for targets that cannot be 
biochemically purified such as G-protein coupled receptors and ion channels.  
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1.4.2.1 Cell based assay: cell lines 
In the transition from a simplified solution binding assay to in vivo testing, cell based testing 
has proven to be a valuable stepping-stone to quickly weed out toxic and non-functional 
compounds. The low cost and high speed of testing compounds in cell culture, and the 
obvious advantages of using intact cells as the most expedient first representation of the 
living patient, has made cell based testing a key component of drug discovery programs. 
Cell based testing is well established in drug discovery research with well-described cell 
lines and models such as the ones listed in the table below. The same physiological or 
disease conditions can be studied using cell lines from different organisms as can be seen in 
the table below.  
 
Physiology/ 
Disease 
studied 
Cell line Target molecule/ Pathway References 
Alzheimer’s Drosophila S2 cells Beta Secretase (132) 
 Rat primary cortical neurons 
Beta Amyloid peptide (1-
42) 
(133) 
 
Human Embryonic Kidney 
HEK293 cells 
Gamma Secretase (134) 
Cancer Yeast KCT120a cells Histone deacetylase (135) 
 
Rat Chondrosarcoma (RCS) 
cells 
Erk MAPK pathway (136) 
 
Human ovarian carcinoma 
A2780 cells 
MLH1 mismatch repair 
gene 
(137) 
Diabetes 
Rat Hepatoma 
H4IIE cells 
Glycogen Synthase Kinase 
3 (GSK3) 
(138) 
 
Chinese Hamster Ovary 
CHO- K1 cells 
Beta catenin & GSK3 (139) 
 
Human Hepatoma  
HepG2 cells 
Protein Tyrosine 
Phosphatase 1B 
(140) 
Intestinal 
Absorption 
Human Intestinal Epithelial 
cells Caco2 
Bile pigments (141) 
 Human Mast cells HMC-1 Peptidoglycan (142) 
Viral 
Replication 
Monkey Kidney Epithelial 
Vero E6 cells 
SARS virus replication (143) 
 
Human Hepatoma 
HepAD38 
Regulated replication of 
HBV  
(144) 
 
Table 1-5. Cell lines from different organisms used to study human diseases and physiology along 
with the molecule or pathway at which the cell based assays are targeted are listed. 
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1.4.2.2 Cell based assays: growth surface  
A crucial parameter for cells growing attached to a surface is the surface itself which serves 
as a micro-environment. Hence while choosing a platform suitable for cell growth, it is 
essential to look at surface properties such as hydrophobicity and roughness and also 
possible cell surface interactions. Cellular attachment and spreading to display cellular 
morphology is also vital. Choice of an appropriate cell line to investigate and reproduce 
observed cellular phenotypes also plays a key role while deciding on surface suitability. The 
simple addition of serum to fibroblasts activates a genetic program that unfolds a complex 
tapestry of functional gene clusters activated in time (145). This program resembles, in part, 
that of the wound healing response, presumably because fibroblasts see serum in vivo only 
in the context of a wound. Growth surfaces such as polyamines may induce cellular 
differentiation of fibroblast-like cells. Polyamine coated growth surfaces facilitate primary 
neuron adhesion and differentiation.  
Cell spreading and intercellular contact are the two physical cues that provide distinct 
inputs to regulate cell proliferation (146; 147). Using a specialised set of semiconductor 
manufacturing tools, cell culture substrates are micro-patterned with micrometer-scale 
islands coated with extracellular matrix ligands surrounded by non-adhesive regions. 
Culturing endothelial cells or hepatocytes on such substrates, single cells were made to 
attach on each island such that cells spread to the size and shape of the engineered islands. 
Cell spreading itself, in the absence of cell–cell contact and in constant growth factor 
concentrations, can thus switch cells between quiescence and proliferative states (148; 149). If 
pairs of cells are placed on such islands, such that cell–cell contact is introduced without 
changing cell spreading, contact induces proliferation (150). 
Anderson et al. describe a method of hit arrays to identify the appropriate bio-polymer 
which could be used for biomaterial based therapies. These biomaterial microarrays were 
tested for their effects on human embryonic stem cells as well as their differentiation (151). 
The polymers were arrayed onto normal epoxy glass slides coated with poly hydroxy 
methacrylate (pHEMA) known to inhibit cell growth. This prevented the growth of cells in 
between the arrayed polymer spots. The microarrays they developed thus enabled both the 
rapid synthesis and cell based screening of biomaterial libraries. Bailey et al. developed a 
novel method of presenting small molecules impregnated in a biodegradable polymer 
(poly-(D),(L)-lactide glycolide copolymer, PLGA) to form small molecule microarrays, 
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which could be presented to cell based screening (152). Using this method they were able to 
screen for distinct p53 mediated cellular responses with respect to apoptosis.  
 
1.4.2.3 Cell based assays: advantages 
Cell based assays have a distinct advantage over protein or DNA based screening as this 
approach enables the screening of a complex cascade of events that result from signal 
transduction in a cell. CBA can exploit easy read-outs like phenotypic characteristics of the 
cells. Studies related to cancer usually focus on cell motility, proliferation and migration as 
important parameters on which to base the cell based assays. Cell death including apoptosis 
and necrosis are other parameters generally used as readout for such assays. Several 
optimised kits from companies such as Promega and Roche enable these assays to be carried 
out in almost any lab setting. Also, the cells used for these assays may be transformed, 
immortalised, or have certain genes knocked out or overexpressed in them. Breakthrough 
technologies such as Antisense and RNA interference make the applications of cell based 
assays endless. The ability to tag the cells with reporters for proteins also increases the types 
of parameters that can be assayed for and quantified.  
Further specialised cell lines can be developed for specific tasks such as the HEK293/GFP2 
beta arrestin cell line developed for quantification of G-Protein coupled receptors (GPCR) 
assays (153). Similarly Cytoblots are whole-cell immunodetection based assays that enable 
the monitoring of biosynthetic processes such as DNA synthesis and post- translational 
modifications (154). More specialised assays such as those for ion channels, associated with 
several neurological and muscular diseases (reviewed in (155)), require the use of modified 
cell lines such as clonal rat pituitary cell line GH4C1, possessing L-type voltage-operated 
calcium channels and Chinese hamster ovary cell line, stably expressing Kv1.3 potassium 
channel (156; 157). Similarly, the life span of fibroblast-like synoviocytes can be extended by 
transducing genes such as telomerase to facilitate the use of this cell line for CBA to study 
rheumatoid arthritis (158).  
Another advantage of cell based assays is the construction of specific reporter cell lines that 
express the target protein of interest as a fluorescent or luminescent molecule that can be 
used for intensity based and phenotypic readouts. Changes in protein structure by events 
such as phosphorylation or cleavage lead to the change in its intracellular localization which 
Introduction 25 
 
 
can be studied using fluorescent microscopes and is high throughput compatible using high 
content screening technology. Plasmids constructed with the protein and reporter of interest 
can be transfected into cells either chemically using readily available reagents such as 
Fugene or using electroporation. Table 1-6 lists examples of reporter cell lines constructed to 
enable studies related to specific proteins of interest.  
 
Reporter Assay  Cell line used References 
Chloramphenicol 
acetyl transferase 
Viral versus mammalian 
promoter use in cell 
based assays, tissue 
specific regulation of 
insulin receptor gene 
breast cell lines T47D 
and MCF-7, HepG2 
and rat liver cells 
(159; 160) 
Beta 
Galactosidase 
Detection of nuclear 
translocation of the 
glucocorticoid receptor 
Chinese hamster ovary 
K1 cells 
(161) 
Secreted 
Alkaline 
phosphatase 
human telomerase 
reverse transcriptase 
(hTERT) gene expression 
Lung carcinoma cells 
H1299 and human 
foreskin fibroblasts 
hTERT-BJ1 cells 
(162) 
Human growth 
hormone 
Secreted growth 
hormone levels  
Mouse fibroblast A31 
cells 
(163) 
Luciferase Hypoxia response 
element VEGF 
Human endothelial 
EAhy926 cells able to 
express luciferase in 
hypoxic conditions 
(164) 
Green 
fluorescent 
protein 
Detect osteogenic 
differentiation upon 
stimulation 
rat type I collagen 
promoter based 
construct Col1a1GFP 
stably transfected pre-
osteoblastic MC3T3E1 
cells  
(165) 
 
Table 1-6. Reporter cell lines used in cell based assays 
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1.5 Fluorescence reporter technologies 
Assay volumes and the concomitant decrease in the use of biological reagents are perceived 
as key factors for the high throughput screening process. However, assay miniaturization is 
dependent on multiple factors, including the need for homogeneous assays, the ability to 
handle ultra-low volumes of liquids and the demand for sensitive readouts. Although, 
radiometric and absorbance-based techniques have been the traditional methods, there are 
clear limitations with respect to miniaturization. By contrast, the inherent efficiency of 
fluorescence readouts overcomes these boundaries, as a consequence of the multiple 
(typically many thousands) of excitation and emission cycles that each fluorophores 
molecule undergoes before photobleaching. Intrinsic scalability enables seamless 
miniaturization with fluorescence-based methods, right down to the single-molecule level. 
Fluorescence assays can deliver the same results, whether applied in 100 µl or 5 µl because 
readouts are, theoretically, volume-independent, although, in practice, the geometry of 
microtiter plates and detection equipment, such as imaging systems, restricts 
miniaturization for macroscopic measurements. In many cases, however, miniaturization 
using fluorescence readouts is only restricted by liquid handling, absorption or evaporation 
effects. 
Green Fluorescent Protein (GFP) is a fluorescent molecule found in the jellyfish Aequorea 
victoria. Isolated in 1961 (166) and cloned in 1992 (167), it has become a popular reporter 
molecule for gene expression in biological systems. It exists as a 238-amino-acid protein; its 
crystal structure illustrates its conformation as a rigid β can, enclosing a helical region that 
contains the chromophore (168; 169). The chromophore itself is a cyclic tripeptide (Ser65-
Tyr66- Gly67), and this region is required for fluorescence. Because of its compact structure, 
and because the chromophore is protected from the external environment inside the β can, 
GFP is extremely stable and resistant to bases, mild denaturing and reducing agents and 
high temperatures, and it is capable of renaturing after exposure to harsh conditions.  
Several modifications of GFP have given rise to reporter molecules with superior monitoring 
capabilities compared to luciferase or colourimetric detection systems based on Horse radish 
Peroxidase (HRP) or Alkaline Phosphatase (AP). Wild type GFP is maximally excited in the 
near UV range 395 nm; with a minor excitation peak at 470 nm and emits green light at a 509 
nm maximum with a shoulder at 540 nm. To improve detection in mammalian systems, 
several research groups have modified the sequence of GFP. One common variant, enhanced 
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green fluorescent protein (EGFP), contains two mutations in the chromophore region – 
Phe64 to Leu and Ser65 to Thr – that red-shift the spectral excitation peak to 489 nm. Red-
shifted GFPs, such as EGFP, can be excited using the 488 nm argon-ion laser and can be 
detected using standard fluorescein (fluorescein isothiocyanate, FITC) filter sets used in both 
fluorescence microscopy and flow cytometry. Since the creation of red-shifted GFPs, further 
amino acid manipulations within the chromophore region have successfully produced 
colour shifts into the yellow and blue regions of the visible spectrum. The various variants of 
GFP and their applications have been reviewed in (170).  
The different fluorescence-based methods used in cell free and cell based assays are as listed 
in table 1-7. These methods each exploit different aspects of fluorescence and present distinct 
advantages and disadvantages, particularly in terms of their sensitivity, robustness and 
susceptibility to artifacts. The underlying physical principles and applications of 
fluorescence in bioassays have been reviewed in more detail in (171-173). Fluorescent 
methods used in this thesis include GFP tagged recombinant proteins and Fluorescence 
Resonance Energy Transfer. Table 1-7 lists fluorescent technologies in use today in cell free 
and cell based systems. The various diverse fluorescence methods available provide 
diversity to the kinds of cell based assays that can be performed to achieve a more sensitive 
and reliable readout in high throughput assays.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 28 
 
 
Fluorescence 
Technology 
Detection of  Use/ Advantage References  
Macroscopic fluorescence methods 
 
FP  
(fluorescence 
polarization) 
rotation of single bio-
molecules or their complexes 
in relation to their mass 
Detection of cAMP 
in living cells 
(174) 
FLINT  
(fluorescence 
intensity) 
Fluoro-substrate turnover Direct enzyme 
assays 
(175) 
FRET  
(fluorescence 
resonance energy 
transfer) 
 
Resonance energy transfer 
from a donor fluorescent 
molecule to an acceptor 
fluorescent molecule 
Receptor activation, 
Identification of 
inhibitors 
(176-178) 
Single molecule fluorescence detection techniques 
 
FCS  
(Fluorescence 
correlation 
spectroscopy) 
detection of single 
fluorescently labeled 
molecules in solution based 
on mass 
Diagnosis of prion 
diseases  
(179) 
FLIM  
(Fluorescence 
lifetime imaging 
microscopy) 
Imaging technique where 
lifetimes rather than intensity 
of signal is measured 
Receptor inhibitor 
binding,  
dimer formation 
(180; 181) 
TRF 
(time-resolved 
fluorescence) 
measuring fluorescent events 
usually from fluorophores 
with long lived signals, can 
be applied with FRET, FP etc 
Inhibitor screening, 
measure interferon 
activity on human 
cells 
(182; 183) 
Single molecule 
FRET 
Resonance energy transfer 
from a donor to an acceptor 
molecule both attached to the 
same biological molecule  
Folding and 
unfolding of 
proteins 
(184; 185) 
FIDA  
(1D and 2D 
fluorescence 
intensity 
distribution 
analysis 
Single molecule detection 
(based on mass as well as 
fluorescence intensity) 
Screen for 
activators of p53, 
quantification of 
protein aggregates 
(186; 187) 
 
Table 1-7. Different fluorescence based screening methods applied to cell free and cell based 
systems 
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1.6 High throughput screening – limitations and advantages 
The laborious target validation step usually presents the real bottleneck in high throughput 
screening; thereby reducing the pace with which new drugs are discovered today. The 
selective ligand-binding interaction validates the target, and inversely the binding to the 
target confirms the biological activity of the ligand. Inhibition of candidate gene function 
might not, in all instances, result in an obvious phenotypic change and, therefore, it might be 
relevant to first identify the proper biological context (with respect to specific signalling 
pathway the particular gene of interest functions). Recent developments have substantially 
improved the level of assay sensitivity and assay throughput, for studying gene function in 
cell based assays. Cell based assays will help elucidate the molecular changes that occur 
over time and that lead to the manifestation of a pathological phenotype.  
A successful cell based assay relies on factors such as availability of large amounts of the 
same cell line, testing of cell lines from different tissues and organs, thereby introducing the 
feature of scalability and flexibility of the assay in question. Along with this aspect is raised 
the issue of standardisation of every aspect of the assay from cell maintenance to the quality 
of tissue culture or detection plates to the hardware used for HTS and the software used for 
data analysis, mining and storage. Moreover, assays relying on phenotypic analysis of cells 
can be largely influenced by changes in batches of cell culture media or reagents. The 
availability of these from reliable sources eases the HTS assay, making cell supply and 
recognition of this no longer a limiting factor. These are however expensive and so are the 
systems for detecting, analysing and documenting cell based assays, thereby generating the 
need for cost effective cell based assay options. The availability of kits and ready-made 
reagents for routine cell based assays based on cytotoxicity and proliferation not only 
increase the probability of cell based assays being used for preliminary screens but also 
appeal to labs where the focus of research may not be drug discovery.  
The logistics of developing a high-throughput screen, delivering hundreds of thousands of 
compounds to the screen, screening the plates and producing possibly thousands of follow-
up samples, requires an extensive infrastructure and involved planning, as well as time. 
Though the parameters of a successful HTS are now well established, one of the key factors 
remains miniaturization to 96, 384, 1536 well plates or even smaller formats without 
affecting the reproducibility, statistical significance of the results or robustness of the assay. 
The evolution of sensitive luminescent and fluorescent detection systems makes 
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miniaturization possible. Also the development of liquid handling robots makes it possible 
to screen for thousands of compounds at a time.  
The parallel advances in biological tools to identify, mutate, express, characterise and purify 
proteins have also led to rapid identification of novel targets associated with disease 
processes. However, with this rapid progress another limitation has emerged in early phases 
of drug research: the need for processing large numbers of potential drug candidates and 
identifying those that have a high probability of becoming marketable products as early as 
possible. Screening a small molecule library in binding assays is usually the approach 
adopted by companies towards to identify possible lead drugs. Introduction of databases 
such as the ChemMine, Cell Wall Mining and AgBase aid in centralising the structure of 
compounds and information of their activity from a growing number of public providers 
and vendors of chemical screening libraries (188-190). Web accessible databases such as 
PubChem, an open, centralised database of small molecules serve as a chemical gateway to 
biomedical databases such as PubMed. More specialised databases such as TarFisDock 
identify targets with docking approaches (191). The PDBbind, BindingDB and AffinDB 
focus on the binding affinities between target and molecules (192-194).  
 
1.7 The experimental concept 
The various steps involved in generating an assay have been discussed in the previous 
section. The goal of this thesis is to develop a platform where cell based assays can be 
carried out on the same surface used for small molecule synthesis. This project aims at 
establishing a cell based assay to screen for the cleavage of human La protein. The "La"-
assay will be screened against peptides and small molecules generated using the SPOT 
method explained in more detail in section 1.7.1. The basis of synthesis of small molecule 
compounds has already been discussed previously (section 1.2). The structure and function 
of the La protein, its interaction with the Hepatitis B Virus and current strategies against 
Hepatitis are reviewed below in sections 1.7.2 to 1.7.4. 
 
1.7.1 SPOT synthesis technique 
Arrays for screening the La protein will be generated with the SPOT-synthesis technique. 
This method belongs to a family of positional addressable solid phase methods that allows 
for the simultaneous parallel chemical synthesis on membrane supports (95). In principle, 
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dispensing of a small droplet of liquid on a planar surface of a porous membrane results in 
its absorption and formation of a circular spot. The SPOT synthesis technique relies on the 
formation of open reactors for chemical conversions where the reactive functions are 
anchored to the membrane support as in conventional solid phase synthesis (51). This 
method was first described by Dr. Ronald Frank and termed as SPOT synthesis (54; 95).  
The SPOT technique is especially widely used for the generation of large repertoires of 
peptide fragments in a high density array format. In this case, low volatility solutions of N-
terminally and side chain protected amino acids are distributed by manual or automated 
pipetting to defined positions on a modified cellulose membrane and are coupled in situ to 
the previously functionalised solid support. The basic concept came from observations made 
previously with combinatorial oligonucleotide (195) and peptide synthesis on separate, 
labelled membrane (cellulose) disks, indicating that chemical reactions can proceed to 
completion, when only enough reagent solution is used as can be taken up by the support 
material itself. This observation suggested that individual amino acid coupling reactions in a 
multiple parallel synthesis scheme could be carried out simultaneously on distinct areas of a 
continuous membrane sheet (95). 
To prepare the membrane supports for chemical peptide synthesis, the entire cellulose 
membranes were originally modified by esterification with β-alanine (Fmoc-β-Ala) followed 
by the removal of the Fmoc protection group. Specially modified membranes for the 
preparation of either immobilised or solution phase peptides are available commercially. 
Special safety catch linkers have been developed that cleave also C-terminally unmodified 
peptide acids or amides directly into neutral aqueous buffer for direct use in bioassays. 
Fmoc-β-Ala is initially distributed on previously defined positions on the membrane 
generating sites for peptide synthesis. The remaining amino groups on the membrane are 
acetylated and therefore no longer accessible for further reactions. Elongation of the peptide 
sequence is an iterative process employing several washing steps as well as steps of de-
protection, coupling and acetylation of amino acids. This is described in more detail in the 
Materials and Methods section 2.2.15.  
The N-terminal protection groups are removed before distribution of different activated 
amino acids to different peptide sites. After the coupling reaction is completed, the 
remaining free amino groups are deactivated by acetylation. In the next step, the terminal 
protecting groups of the coupled amino acids are removed and the entire cycle can be 
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repeated. After coupling the last amino acid, all peptides are N-terminally acetylated to 
mimic the backbone of proteins. Although several steps during the SPOT peptide synthesis 
must be carried out manually, the delivery of the activated amino acids to the corresponding 
reaction sites has been automated using the SPOT synthesiser developed at ABIMED 
Analysen Technik GmbH (Langenfeld, Germany). The process automation helps to reduce 
the size of spots and thus increase the number of spots per area considerably. Currently, 
2500 spots can be generated on a micro-titer plate sized sheet.  
The SPOT-synthesis method opened up countless opportunities to synthesise and 
subsequently screen large numbers of synthetic peptides as well as other organic 
compounds arrayed on a planar cellulose support (95). They have become a very important 
tool for studying the protein-protein or protein-peptide interactions. Although SPOT-
synthesis is not as impressively miniaturized as, e.g. the Affymax photolithographic 
technique (196), it fulfils similar demands with the advantage of a reliable and easy 
experimental procedure, inexpensive equipment needs and a highly flexible array and 
library formatting (94). The method permits rapid and highly parallel synthesis of huge 
numbers of peptides and peptide mixtures (pools) including a large variety of unnatural 
building blocks, as well as a growing range of other organic compounds. Further advantages 
are related to the easy adaptability to a wide range of assay and screening methods such as 
binding, enzymatic and cellular assays, which allow in situ screening of chemical libraries 
due to the special properties of the membrane supports. Therefore, peptide arrays prepared 
by the SPOT technique became quite popular tools for studying numerous aspects of 
molecular recognition, particularly in the field of molecular immunology. Much wider scope 
of their applications is reviewed in (197). Several examples of the application of the SPOT 
technology are as shown in table 1-8.  
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Application Example 
Identification of linear epitopes Reviewed in (198) 
Identification of paratopes HIV antiviral activity (199) 
Discontinuous epitope mapping IL-10 (200) 
Bovine prion protein antibody mAb 15B3 (201) 
Peptide antibody interaction Transformation of L-peptide epitopes to D-peptide 
epitopes (202) 
Protein - protein interactions Characterisation of the proline rich binding motifs of 
the EVH1 domains in the Ena-VASP family (203) 
Activity of cleaved solution phase 
peptides 
Mapping T Cell epitopes (204; 205) 
Enzyme substrate recognition Protein kinase substrate specificity (206) 
Animal immunization (207) 
 
Table 1-8. Applications of the SPOT technique 
 
1.7.2 Introduction to the model La protein 
An important attribute of the immune system is the ability to distinguish self from non self. 
When the immune system fails, an immune response is generated against cells and tissues of 
an individual’s own body known as an auto-immune reaction. The ensuing auto immune 
tissue damage may be cell mediated as in Multiple Sclerosis or mainly mediated by the 
humoral immune response via autoreactive antibodies as is the case in Systemic Lupus 
Erythematosus or in Sjögren’s syndrome. The La protein was first discovered as an 
autoantigen in Sjögren’s syndrome (208; 209). Patients with Sjögren’s syndrome, a systemic 
autoimmune rheumatic disease, frequently present autoantibodies to both organ- and non-
organ-specific autoantigens. The most commonly detected autoantibodies are those directed 
against the ribonucleoproteins Ro/SSA and La/SSB. The presence of the antibodies in 
Sjögren’s syndrome is associated with early disease onset, longer disease duration, parotid 
gland enlargement, higher frequency of extraglandular manifestations and more intense 
lymphocytic infiltration of the minor salivary glands.  
Over the past several years, the structure and function of these autoantigens have been 
extensively studied. The human La protein is a 47 kDa nuclear phospho-protein known to be 
associated with all newly synthesised RNA polymerase III transcripts. It is ubiquitously 
expressed and there are about 2 x 107 molecules of the La protein per cell which is about 50 
nM, making it as highly abundant in the cell as ribosomal protein (210; 211). The name La is 
derived from the name of the patient in which the antibody was detected, and SS-B refers to 
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the prevalence of the antibodies in Sjögren’s syndrome. Although La was first characterised 
as a human protein, homologs have been identified in many eukaryotes ranging from yeasts 
and Drosophila to Xenopus (212-218). Within the nucleus, La is found to be both 
nucleoplasmic and nucleolar (219-222). However certain conditions such as apoptosis in 
mammalian cells may cause it to become cytoplasmic (223; 224). 
 
1.7.2.1 The La Protein Function 
The La protein belongs to a family of RNA binding proteins and is characterised by the 
presence of one or more RNA recognitions motifs (RRMs). La is associated with a very large 
number of nascent RNAs as well as viral encoded RNAs as listed below (Table 1-9). RNA 
chaperone activity is defined as an activity that either prevents RNAs from misfolding or 
that helps to open up RNA structures without ATP consumption (225; 226). The major role 
of La is to act as a molecular chaperone of newly synthesised RNAs by stabilising them from 
exonuclease digestion leading to either their nuclear retention or export and hence 
determining their correct fate (216; 227-231). In viruses, the La protein is required for viral 
replication and controls translation.  
 
 Type of RNA interacting with 
the La protein 
Function of the La 
protein in the 
interaction 
Reference 
Viral RNAs 
1 leader RNAs of several negative-
strand viruses 
Required for replication 
of viruses 
(232; 233) 
2 Adenovirus-encoded VA RNAI 
and VA RNAII 
Formation of a 
ribonucleoprotein (RNP) 
particle 
(234; 235) 
3 Dengue Virus RNA Chaperon to facilitate 
replication 
(236) 
4 the Epstein-Barr virus–encoded 
EBER 1 and EBER 2 RNAs 
Chaperone activity (237; 238) 
5 Hepatitis B Virus RNA Stabilization (239) 
6 Hepatitis C Virus RNA Translational control (240) 
7 Herpes simplex virus type 1 facilitates viral 
replication in transfected 
mouse 3T3 cells 
(241) 
8 HIV type I virus Translational control (242) 
9 Norwalk Virus RNA Translation/ Replication (243) 
10 Polio virus m RNA Translational control (244) 
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Other RNAs 
1 Bip RNA Translational control (245) 
2 Histone RNA Stabilization (246) 
3 pre-5sRNAs Maturation of pre-
5sRNAs 
(247) 
4 pre-tRNAs maturation and efficient 
folding of pre tRNAs 
(248-251) 
5 Telomerase RNA Chaperone for 
Telomerase RNP binding 
(252) 
 
6 TOP mRNA Translation (253) 
7 RNAs transcribed by RNA 
polymerase II such as U1, U2, U4, 
and U5 pre-snRNAs 
La interaction protects 
against exonuclease 
digestion 
(254; 255) 
8 U6 small nuclear RNAs Binds to precursors of U6 
snRNAs and aids in their 
maturation 
(256) 
9 Vault RNA Chaperone for the vault 
RNA 
(257) 
10 Y RNAs La binding contributes to 
nuclear retention 
(258) 
 
Table 1-9. Interaction of the La protein with different RNAs 
 
1.7.2.2 The La Protein Structure 
The N terminus of La is well conserved from yeast to humans, whereas the human La 
protein gained an additional C-terminal domain absent in the yeast Lhp1p. The N terminus 
of all known La proteins contains the 60–amino acid La motif [previously called the La 
domain], a highly conserved sequence that is also present in a number of otherwise 
unrelated proteins. Recent structural data revealed that the N-terminal La motif does not 
adopt an RRM structure but folds into a winged helix motif (WHM), whereas the central 
and C-terminal RRMs (RRMs 1 and 2, respectively) resemble RNA recognition motifs 
(RRM). The ribonucleoprotein RNP2 signature of the RRM1 is known to be of general 
importance for RNA binding.  
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Figure 1-3. Schematic diagram depicting the various motifs in the La protein.  
The human La protein contains a winged helix La motif, central and C terminal RNA recognition 
Motifs (RRM) with internal conserved ribonucleoprotein (RNP) signatures, nuclear localisation (NLS), 
nucleolar localisation (NoLS) and nuclear retention signals (NRE). A dimerization/multimerization 
signal and a Walker A motif are also present along with the Ser 366 phosphorylation site essential for 
RNA interactions.  
 
The C-terminal domain is the least conserved part of the La protein, varying in both size 
and sequence between species. This portion of the La protein (defined as being C-terminal to 
the central RRM), usually contains between 40% and 50% charged residues. The C-terminal 
region is quite variable in length, ranging from 70 amino acids in the yeasts S. cerevisiae and 
S. pombe to more than 220 amino acids in humans and Xenopus laevis. The lower degree of 
conservation of the C-terminal portion is emphasised by the finding that almost all 
differences between the human and mouse proteins are found in the C terminus. At least 
some of the additional size of vertebrate La proteins comes from a potential atypical RRM in 
this region. A possible Walker A motif, a nucleoside triphosphate–binding sequence found 
in many ATP-binding proteins, has also been noted in the C terminus of vertebrate La 
proteins. Trafficking signals in the human La include a nuclear localization signal (NLS), a 
nuclear retention element (NRE) and a nucleolar localization signal. In addition, human La 
autoantigen (hLa) also contains a dimerization domain as well as a conserved basic region. 
Phosphorylation events, in particular those responsible for communication signals, are 
among the most common post-translational protein modifications that are necessary for cell 
functions. In human cells, most La is phosphorylated on serine-366 by protein kinase CK2, 
resides in the nucleoplasm, and is associated with nascent pre-tRNAs. Non-phosphorylated 
La is mostly concentrated in the nucleolus and was independently found at tRNA and other 
RNA polymerase III-transcribed genes, but it also resides in the cytoplasm associated with 5’ 
TOP mRNAs that encode ribosomal proteins and translation factors.  
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1.7.3 The HBV RNA and its interaction with the La protein 
HBV is a noncytopathic, enveloped, double-stranded DNA virus that causes acute and 
chronic hepatitis and hepatocellular carcinoma (HCC). It replicates through a RNA 
intermediate and encodes four unspliced, overlapping messages that terminate at a common 
polyadenylation signal. HBV is transmitted sexually and from mother to infant at birth like 
the human immunodeficiency virus (HIV). More than 2 billion people alive today have been 
infected by HBV, and more than 350 million people are chronically infected (259). The 
chronic infection may lead to liver cirrhosis and liver cancer. Accordingly, HBV causes 
approximately 1 million deaths each year worldwide.  
Viral hepatitis is initiated by an antigen-specific antiviral cellular immune response. 
Although clearance of most virus infections is widely thought to reflect the killing of 
infected cells by virus specific T cells, recent data also suggest that non-cytolytic intracellular 
viral inactivation by certain inflammatory cytokines released by activated lympho-
mononuclear cells may play an important role in the clearance of at least some of these 
viruses from the infected cell (260). This is also true for HBV. Inflammatory cytokines, such 
as gamma interferon (IFN-γ) and tumour necrosis factor alpha (TNF-α), can abolish hepatic 
HBV gene expression and replication in the livers of these animals where HBV-specific 
cytotoxic T lymphocytes (CTLs) are transferred. The cytokines destabilise HBV mRNA 
thereby suppress HBV gene expression by a posttranscriptional mechanism.  
In HBV transgenic mice injected with CTLs and infected with lymphocytic choriomeningitis 
virus and murine cytomegalovirus, the liver nuclear extracts contain three proteins (p45, p39 
and p26) that bind a 91-nucleotide (nt) in vitro transcript of HBV. All the three proteins p45, 
p39, and p26 are recognised by anti- La antibodies and bind HBV RNA in a 
phosphorylation-dependent manner. The La autoantigen (p45) and La fragments (p39 and 
p26) are HBV RNA-binding proteins, which bind to a predicted stem-loop structure located 
between nucleotides 1243 and 1333 of HBV RNA (numbering according Galibert et al.). A 
tight correlation was observed among the downregulation of HBV RNA, the disappearance 
of p45, and the appearance of p26, suggesting that these proteins might contribute to the 
regulation of HBV mRNA stability by the cytokines.  
The La protein, especially p45, may be part of a complex mechanism that controls HBV RNA 
stability, constitutively and in response to inflammatory cytokines (261). The La protein 
interacts with a small cis-acting element located within the viral RNA between nt 1275 and 
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1291. The tight temporal correlation between the cytokine-mediated downregulation of HBV 
RNA and the cytokine-induced fragmentation of full-length La led to the assumption that 
full-length La stabilises HBV RNA by interacting with the cis-acting element. HBV RNA is 
more accessible to endoribonucleolytic cleavage after the disappearance of full-length La 
protein. The presence of full length La protein correlated directly with the presence of HBV 
RNA, detectable when the viral RNA was abundant and disappearing when the RNA 
degradation was post transcriptionally induced in response to IFN-γ and TNF-α.  
Figure 1-4A shows the presence and binding of full length La protein in control saline 
conditions to HBV RNA and its disappearance on CTL injection. Figure 1-4B shows the 
predicted region of the HBV RNA that binds to the La protein (HBV RNA.B). 
 
 
Figure 1-4. HBV RNA-binding proteins p45 and p39 are detectable in liver nuclear extracts from 
NaCl-injected mice, while p39 and p26 are detectable in CTL-injected mice. (adapted from (261)) 
(A) Northern blotting and UV cross-linking analysis of 20 mg of total liver RNA or 5 mg of liver 
nuclear extract prepared from the same liver were performed. Sex and serum HBsAg-matched mice 
(lineage 1.3.32) were intravenously injected with 107 CTLs or with saline and sacrificed on day 5 after 
CTL administration. The upper panel shows the Northern blot analysis, and the lower panel shows 
the UV cross-linking analysis of nuclear extracts.  
(B) Predicted secondary structure of HBV in vitro transcript RNA.B used in this study. The secondary 
structure was calculated with the program MFOLD version 3 by Zuker and Turner available on the 
MFOLD server. Arrows indicate the 39 ends of in vitro transcripts RNA.C and RNA.D and of an 
oligoribonucleotide, RNA.E. The positions for all RNAs are shown according to the HBV ayw subtype 
sequence. 
 
 
1.7.4 Drug Strategies against Hepatitis 
Hepatitis B vaccines are of two types, plasma derived and recombinant. Recombinant 
vaccines are produced by cloning the gene encoding HBsAg into yeast cells and are 
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increasingly replacing plasma derived vaccines. Infection with hepatitis B virus (HBV) can 
be prevented by vaccination with the major HBV surface antigen (HBsAg) (262; 263). 
However, HBV mutants are able to escape immune responses against hepatitis B vaccines 
and to establish chronic infection in a liver transplant recipient. These HBV mutants carry 
multiple amino acid substitutions around and within the HBsAg thereby exhibiting a 
reduced reactivity to a panel of anti-HBs antibodies (264). Three drugs—interferon alfa, 
lamivudine, and adefovir—are approved in several countries for use in chronic hepatitis B 
(265). Of these, interferon has both antiviral and immunomodulatory activity; lamivudine 
and adefovir are primarily antiviral. Emtricitabine, entecavir, telbuvidine and clevudine are 
currently under investigation.  
Interferon alfa, a host cytokine produced in response to any viral invasion, has 
immunomodulatory, antiviral, and anti-fibrotic properties. It was first used in the 1980s and 
was the first drug to be found useful in the treatment of chronic hepatitis B. However, 
interferon has many adverse effects. Lamivudine, a synthetic nucleoside (cytosine) analogue 
available since 1998, undergoes intracellular phosphorylation to its active metabolite 
lamivudine triphosphate and inhibits viral reverse transcriptase, causing premature chain 
termination during viral DNA synthesis. Adefovir dipivoxil, a nucleotide analogue of 
deoxyadenosine monophosphate, inhibits viral reverse transcriptase activity in hepatitis B 
virus. However, some mutants of hepatitis B virus also show Adefovir resistance. Hence, 
there is a need for newer approaches to hepatitis vaccines as well as drugs available for 
hepatitis B. The use of RNA interference in the treatment of viral hepatitis is an emerging 
strategy in the treatment of this disease (266). RNA interference (RNAi) is a mechanism of 
gene regulation in plants, invertebrates and, more recently, in mammalian cells in which 
target mRNAs are degraded in a sequence-specific manner. RNAi strategies against HBV 
have been targeted against viral RNA replication in cells (267; 268) as well as in mice (269; 
270). There is thus still a need for newer strategies against HBV and this is the exploited in 
this thesis. 
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1.8 Aims of this thesis  
AIM 1: To develop a platform where small molecule synthesis and cell based assays can 
be carried out on the same surface. 
The main goal of this thesis is to establish a novel chemical platform that is suitable for cell 
based assays. Several platforms from membranes to slides have been discussed in section 
1.3. In this thesis the aim is to develop a platform where cell based assays can be carried out 
on the same surface after chemical synthesis. The patches used for the cell based assays are 
shown in figure 1-5. Optimization of the polypropylene surface for a) cell growth and 
viability b) cell morphology, phenotypes and c) chemical manipulation of phenotypes will 
be carried out. 
 
 
 
Figure 1-5. Poly-propylene foils used in cell based screening 
The above panels depict the PP foils (Patches) used in the cell based screenings done in this thesis. 
Panel a depicts the array of patches on the PP foil. The black arrow depicts the side of each a patch 
square having dimensions of 2mm. Panel b represents organic medium spots pipetted onto the 
individual patches. In case of cell based assays, cells in cell culture media were pipetted onto patches 
with modified surface chemistry. 
 
For this, cell lines will first be grown on polypropylene foils with chemical modifications in 
order to test their ability to sustain cell growth. Once this has been established, the patches 
will be tested for replication of simple cellular phenotypes such as cytokinesis. Further, 
chemical modification of cellular phenotypes in response to small molecules synthesised on 
the surface will also be tested. With the establishment of such a platform it will be possible 
to screen for libraries synthesised on the platform using cell based assays with the model La 
protein. 
Introduction 41 
 
 
 
AIM 2: Development of a cell based assay to be applied to the new screening platform in 
order to screen for small molecule compounds which induce intracellular cleavage of the 
La protein. 
Simultaneously for a more functional assay, the model La protein whose proteolytic 
cleavage can be targeted as a drug strategy against Hepatitis, will be used to develop cell 
based screens that can be applied to the patches. It is known that inhibition of the human La 
protein by RNA interference down regulates hepatitis B virus mRNA in 2.2.15 cells (271). 
Also, HBV RNA is more accessible to endoribonucleolytic cleavage after the disappearance 
of full-length La protein. The presence of full length La protein correlated directly with the 
presence of HBV RNA, detectable when the viral RNA was abundant and disappearing 
when the RNA degradation was post transcriptionally induced in response to IFN-γ and 
TNF-α. 
Peptide or small molecule libraries can thus be screened using cell based assays based on La 
protein binding/cleavage strategy. For this a FRET La molecule will be developed by the 
group of Dr. Tilman Heise at the HPI in Hamburg. 
 
 
 
Figure 1-6. Schematic representation of the development of cell based assays using a human FRET-
La protein. 
In the mouse model, inflammatory cytokines, such as gamma interferon (IFN-γ) and tumour necrosis 
factor alpha (TNF-α) are known to abolish hepatic HBV gene expression and replication in the livers 
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of mice where HBV-specific cytotoxic T lymphocytes (CTLs) are transferred. The cytokines destabilise 
HBV mRNA thereby suppress HBV gene expression by a posttranscriptional mechanism. The 
presence of full length La protein correlated directly with the presence of HBV RNA, detectable when 
the viral RNA was abundant and disappearing when the RNA degradation was post transcriptionally 
induced in response to IFN-γ and TNF-α. This has been schematically illustrated in the left panel. In 
the cell based model, the FRET La construct on being transfected into cells such as HepG2 can be used 
to screen for peptides and other small molecules that can activate protease that can cleave the La 
protein. This screening for small molecule compounds would be based on the disappearance of the 
FRET signal from the FRET La construct.  
 
AIM 3: Screen random SPOT libraries to identify peptides that can bind to the Wildtype 
La protein.  
In order to validate the assay concept and cellular constructs, a positive control would be 
highly desirable. Therefore SPOT peptide libraries will be screened for the identification of 
random peptides that can bind to the wildtype La protein that could be used to 
competitively inhibit the binding of the La protein to the HBV RNA. In 2002, Horke et al. 
published several mutants of the La protein, one of which does not bind to the HBV RNA. 
This mutant (Δ2) could be used to screen for peptides that bind specifically to the wildtype 
La protein but not to the mutant La protein as is illustrated in the diagram below  
(Figure 1-7). 
  
Figure 1-7. Wildtype La and Mutant La (Δ2) used for screening SPOT peptide libraries.  
(A)Standard gel retardation assay to show that the interaction between hLa and HBV RNA.B strongly 
depends on the RNP-2 signature of RRM-1. Wild type recombinant hLa (WT, lane 2) and recombinant 
hLa-Δ2 (lane 3) with a deleted hLa RNP-2 signature (Δ2, aa 113–119) of RRM-1. was analyzed for 
HBV RNA.B binding. Lane 1, reaction without hLa. (from (272-274), published data).  
(B)Schematic representation depicting the region and six amino acid sequence of the RNP2 of RRM1 
that is deleted in the hLa Δ2 mutant. For a more detailed description of the wildtype La protein 
domains, refer to figure 1-3. 
 
Introduction 43 
 
 
For this a radioactive strategy will be used as depicted schematically in the figure 1-7. An in 
vitro transcription/translation system will be used to synthesise radioactive recombinant 
wildtype and mutant (Δ2) La proteins to screen for peptides by carrying out affinity binding 
assays with random peptide libraries. Those peptides that bind to Wildtype La and not to 
Mutant La will be further validated in the cell based assay of AIM 2. The peptide libraries 
for screening will be presented as high density arrays on membrane supports manufactured 
by SPOT synthesis. Hexa- and octapeptide libraries in the form of arrays of XX12XX and 
XXX12XXX pools (X = random position occupied by all 20 amino acid residues; 1,2 defined 
position occupied by only one amino acid residue) will be applied. 
As outlined in the schematic figure 1-8, the wildtype La binds to 2 peptide spots (green) that 
are not bound by the mutant La protein using the same peptide library, thus yielding two 
potential peptides based on which the next set of libraries can be synthesised.  
 
 
 
Figure 1-8. Schematic representation of in vitro SPOT library binding assays using recombinant 
wildtype La or mutant La proteins.  
Binding assays with in vitro synthesised radioactive wildtype or mutant La protein will yield spots 
that can bind with the wildtype La protein but not the mutant La protein. Since the only difference 
between the two proteins is their ability to bind to the HBV RNA, screenings of such peptide libraries 
will allow the identification of peptides that require the HBV RNA binding site to bind to the 
wildtype La protein.  
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2 Materials and Methods 
 
2.1 Materials 
  
2.1.1 Chemicals 
All chemicals used during the course of this work were of analytical grade. All buffers 
containing water were made with autoclaved Millipore water. All the chemicals not 
mentioned here were from Merck, Roche, Carl Roth or Fluka.  
 
Acrylamide/Bisacrylamide (40,29:1)   Carl Roth 
Agarose     Peqlab  
Bacto tryptone     BD Biosciences 
Bacto yeast Extract    BD Biosciences 
Bovine Serum Albumin   Sigma 
DEPC       Sigma 
DMEM     Gibco 
DMSO      Sigma  
EDTA      Sigma 
Ethidium bromide     Sigma 
FBS      Gibco 
Glutaraldehyde    Sigma 
Glycerol Ultrapure    Invitrogen 
Gylcine     Sigma 
Igepal CA630     Sigma  
Imidazole     Sigma 
IPTG      Carl Roth 
K3FeCN6     Merck 
L-Arginine     Sigma 
Methanol     Mallinckrodt Baker 
Mineral oil      Carl Zeiss  
Mowiol      Calbiochem  
NaCl      Carl Roth 
Sodium dodecyl sulphate (SDS)   Carl Roth 
NaH2PO4      Calbiochem, Merck 
Ni-NTA-Agarose     Qiagen  
NP-40      Sigma 
n-propyl gallate    Sigma 
Nuclease free water    MBI Fermentas  
Paraformaldehyde    Fluka & Riedel 
Poly-L-Lysine     Sigma  
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Protease Inhibitor Cocktail   Roche  
SDS 10% solution    Sigma  
Silver Nitrate     Merck 
Skim Milk     Difco  
TEMED     Roth  
Trizma base      Sigma  
Triton X-100      Roche  
Tween-20      Sigma  
Xylencyanol     Fluka & Riedel 
 
 
2.1.2 General buffers and solutions: 
Cell Freezing Medium: 
Cell culture Media plus 10% DMSO  
 
La protein binding buffer: 
10 mM Tris HCL pH 7.4, 150 mM NaCl, 3 mM MgCl2, 0.5 mM EDTA, 1 mM DTT, 0.5 % NP-
40 
 
PBS buffer (10X): 
80 g NaCl, 2 g KCl, 14.4 g Na2HPO4.2H2O, 2.4 g KH2PO4, H20 to 1L, pH 7.4 with 1 M HCl 
and autoclave 
 
Complete Protease-Inhibitor (100X, Roche):  
2 tablets in 1 ml nuclease free sterile water 
 
TBS (10X): 
30 g Tris base, 80 g NaCl, 2 g KCl, H2O to 1L, pH 7.4 with 1 M HCl and autoclave 
 
TBST Buffer:   
1X TBS plus 0.05% (v/v) Tween 20 
 
 
2.1.3 DNA/protein markers, restriction enzymes, buffers, proteases and inhibitors 
Alkaline Phosphatase    Roche  
Alkaline Phosphatase, 10x buffer  Roche  
Chymotrypsin     Sigma 
Complete protease inhibitor   Roche 
100 bp DNA Ladder, 100-1517 bp  New England Biolabs 
1 kb DNA Ladder, 500-10.000 bp  New England Biolabs  
Smart Ladder, 200-10,000 bp   Eurogentec  
DNase, RNase-free    Promega  
dNTPs      Promega  
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Elastase     Sigma 
Lysozyme      Serva  
Proteinase K     Sigma 
Prestained broad-range Marker   New England Biolabs  
Restrictions enzyme EcoR I    New England Biolabs 
Restrictions enzyme Hind III    New England Biolabs 
Restriction enzyme Xho I    New England Biolabs  
dNTPs      Promega  
Shrimp-alkaline Phosphatase   Roche  
Shrimp-alkaline Phosphatase, 10X buffer Roche  
T4 Polynucleotide Kinase    Roche  
T4 Polynucleotide Kinase, 10X buffer  Roche  
Taq-DNA-Polymerase    Invitrogen  
Taq-DNA-Polymerase, 10X buffer   Invitrogen 
Thrombin     Sigma 
 
Antibiotics and radioactivity 
Kanamycin     Sigma 
Stock: 10 mg/ml stock in water, 
 sterile filtered, working conc. 50 µg/ml 
Ampicillin     Sigma 
Stock: 50 mg/ml in water 
sterile filtered, working conc. 60 µg/ml 
 
Radioactivity: 
S35 Methionine    Amersham Biosciences 
(GE Healthcare Europe GmbH) 
 
2.1.4 Materials 
Amicon-YM10 Concentrators   Millipore 
Dialysis membranes:  
- Spectra/ Por MWCO 6,000-8,000  Spectrum Europe BV  
 - Zellu Trans MWCO 12,000 to 14, 000 Carl Roth 
Eppendorf tubes     Eppendorf  
G25-spin columns     Amersham Biosciences  
      (GE Healthcare Europe GmbH) 
GF/C-round filter     Whatman  
Ni-NTA spin columns   Qiagen  
Nitro-cellulose membranes    Amersham Biosciences 
(GE Healthcare Europe GmbH) 
X-Ray-Film      Kodak BioMax XAR Film 
Whatman Paper, 3mm    Whatman  
Cell culture Dishes and flasks  Greiner bio-one 
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2.1.5 Kits and ready to use reagents 
Amido black staining solution   Sigma 
In vitro protein transcription 
& translation     Promega 
Bradford protein assay reagent  Bio-Rad 
DNA purification Maxi/-Mini kits  Qiagen 
FuGene-6 transfection reagent   Roche  
Ni-NTA spin columns and reagents  Qiagen 
QIAquick Gel extraction kit    Qiagen  
QIAquick PCR purification kit  Qiagen  
Rapid DNA ligation kit    Roche 
Red Alert western blot stain   Novagen  
Enhanced Chemiluminescence Western 
Blotting detection reagents   Amersham Biosciences 
      (GE Healthcare Europe GmbH) 
 
 
2.1.6 Instruments 
Agarose gel tanks 
Agagel Mini, Agagel G45   Biometra 
Agagel Maxi     Biometra 
 
Power Supply 
High Voltage Power pack P30  Biometra 
Minicell Power pack    Biometra 
 
Gel documentation 
CCD Camera UVT-20  and EASY  Herolab 
UV Transilluminator 
 
Protein Gel tank 
Mini -Protean 3 cell    Biorad 
 
Western Blotting Apparatus 
Semi-dry Fast blot apparatus B 33  Biometra 
 
Centrifuges 
Sorvall centrifuge    Kendro Laboratory Products 
Sorvall rotors: SS-34, SLA-1500, SLA-3000 
Cell culture centrifuge   Eppendorf  
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Photometers 
GeneQuant II, RNA/DNA calculator  Pharmacia Biotech Europe GmbH 
Ultrospec 2000 (for bacteria) 
UV/Visible Spectrophotometer   Pharmacia Biotech Europe GmbH 
 
Microscopes 
Confocal fluorescence microscope  Zeiss Axiovert, Carl Zeiss 
Laser scanning fluorescence microscope LSM 510 meta, with meta detector, Carl Zeiss 
 
Lenses  
Plan Neo 40X      Carl Zeiss 
Plan ApoChr 33    Carl Zeiss 
Achroplan LD 40X, 20X    Carl Zeiss 
 
Other equipments 
UV Crosslinker, Stratalinker 1800  Stratagene 
pH meter, CG 840    Schott-Geräte GmbH 
Thermomixer, 54 36    Eppendorf 
Incubator, Multitron    Infros HT GmbH 
Shakers, Rotomax120, Duomax120  Heidolph Instruments GmbH 
Weighing balance, TE 1535 and R160P Sartorius 
Phosphor imager Fujifilm BAS 2500  Fuji Photo Film (Europe) GmbH, 
Agfa Curix 60 film developer   Agfa-Gevaert Group 
 
 
2.1.7 Biological materials 
Genotype of bacterial strains used from Invitrogen 
Escherichia Coli DH5 α 
F-φ80dlacZΔM15 Δ (lacZYA-argF)U169 deoR, recA1 endA1 hsdR17 (rk- mk+ phoA supE44 λ- 
thi-1 gyrA96 relA1 
 
Escherichia Coli BL 21 (DE3) 
F - ompT hsdSB (rB - mB - ) gal dcm rne131 (DE3) 
 
Mammalian Cell Lines used in this thesis and their sources 
3Y1:   Rat embryonic fibroblasts  from Dr. K. Rottner, GBF 
A431:  Human epidermoid cancer cells from Dr. F. Sasse, GBF 
A498:   Human kidney cells   from Dr. F. Sasse, GBF 
A549:  Lung carcinoma cells   from Dr. F. Sasse, GBF 
HeLa:   Human cervical carcinoma cells from Dr. T. Heise, HPI Hamburg 
Huh7:  Human Hepatoma cells  from Dr. T. Heise, HPI Hamburg 
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HepG2: Human Hepatocellular carcinoma from Dr. T. Heise, HPI Hamburg 
L929:   Mouse fibroblasts   from Dr. F. Sasse, GBF 
PC3:   Human prostate cancer cells  from Dr. F. Sasse, GBF 
PtK2:   Rat kangaroo kidney epithelium from Dr. F. Sasse, GBF 
SKOV3:  Ovarian carcinoma cells  from Dr. F. Sasse, GBF 
 
Vectors and engineered plasmids used in this thesis 
1. pET 28b(+) human La –WT (pET -huLa -WT) described in Horke S. et al. in 2002 (272).  
2. pET 28b(+) human La –Mut ∆2 (pET -huLa -Mut∆2) described in Horke S. et al. in 2002 
(272).   
3. pEGFP -La -WT described in Horke et al. in 2004 (273). 
4. pEGFP -La -WT rev2xNES(+) constructed from the pEGFP -La -WT plasmid by adding a 
Nuclear Export Signal (NES). 
5. pcDNA 3.1 (-)-La-Cygnet-2 (Cygnet La) constructed from the Cygnet plasmid as 
described in Honda et al. in 2001 (275) and insertion of the WT hLa gene in place of the PKG 
gene 
6. pEYFP-C1 vector from Clontech 
7. pECFP-C1 vector from Clontech 
 
Antibodies 
Anti -La antibody in mouse, 4B6     from HPI, Hamburg 
Anti -GFP antibody, A. V. MAb JL -8    BD Biosciences 
HRP conjugated secondary antibody goat anti-mouse Dianova 
Anti-tubulin antibody     Sigma 
 
Primers for cloning of pEGFP -La -WT NES (+): 
NES of the Protein kinase inhibitor (PKI), judged as a fast NES (5±10min) 
PKI-S:  
5’-T CGA GCT CAA TTA GCC TTG AAA TTA GCA GGT CTT GAT ATC AAC TC-3’ 
PKI-AS: 
3’- CGA GTT AAT CGG AAC TTT AAT CGT CCA GAA CTA TAG TTG AGA GCT-5’  
 
NES of HIV-1 Rev, judged as a medium type 1 NES (10±20min) 
REV-S:  
5’-T CGA GCT CAA CTT CAG CTA CCA CCG CTT GAG AGA CTT ACT CTT TC-3’ 
REV-AS: 
3’- CGA GTT GAA GTC GAT GGT GGC GAA CTC TCT GAA TGA GAA AGA GCT-5’ 
 
NES of Adenovirus type 5 E1B-55K, judged as a slow NES (30±60min) 
E1B-S:  
5’-T CGA GCT CAA CTG TAT CCA GAA CTG AGA CGC ATT TTG ACA ATT TC-3’ 
E1B-AS: 
3’- CGA GTT GAC ATA GGT CTT GAC TCT GCG TAA AAC TGT TAA AGA GCT-5’ 
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2.1.8 Software 
CCD Camera     EASY Image 3.16 software 
Confocal fluorescence microscope  IP Lab spectrum, version 3.2 
Image processing software   Adobe photoshop, version 7 
LSM 510 meta     LSM 510 software, version 3.2.SP2   
Protein estimation    TECAN Magellan, versions 2 and 3 
Fluorometer, FLUOROMAX 3  Instrument Control Center, version 2.2.12 B  
Zeiss Microscope    Axiovision, version 3.1 and 3.0 
Image Reader LAS 1000   Image Reader LAS 1000 Pro, version 2.5 
Phosphor imager Fujifilm BAS 2500  AIDA version 3.51 
Spot binding assays analysis   AIDA version 3.51 
 
2.1.9 Providers 
Abimed Analysen Technik   Langenfeld, Germany 
Agfa-Gevaert Group    Cologne, Germany 
Amersham Biosciences/ 
GE Healthcare Europe GmbH  Munich, Germany 
BD Biosciences    Heidelberg, Germany    
Biochrom Ltd.     Cambridge, UK 
Biometra Biomedizinische Analytik GmbH  Göttingen, Germany 
Biorad Laboratories GmbH   Munich, Germany 
Calbiochem     Merck KGaA, Darmstadt, Germany 
Carl Roth GmbH    Karlsruhe, Germany 
Carl Zeiss MicroImaging GmbH  Goettingen, Germany 
Dianova     Hamburg, Germany 
Difco      OttoNordwald KG, Hamburg, Germany 
Eppendorf     Hamburg, Germany 
Eurogentec GmbH    Köln, Germany 
Fluka & Reidel    Sigma, Steinheim, Germany 
Fuji Photo Film (Europe) GmbH  Duesseldorf, Germany 
Grenier bio-one    Frickenhausen, Germany   
Heidolph Instruments GmbH & Co. KG Schwabach, Germany 
Herolab     Wiesloch, Germany 
Infros HT GmbH    Einsbach, Germany 
Invitrogen     Karlsruhe, Germany 
Kendro Lab Products    Bad Homburg, Germany 
Mallinckrodt Baker, Deutschland  Griesheim, Germany 
Merck KGaA     Darmstadt, Germany 
MBI Fermentas    St. Leon-Rot, Germany 
Millipore     Eschborn, Germany 
New England Biolabs    Frankfurt am Main, Germany 
Novagen     Merck KgaA, Darmstadt, Germany 
Pharmacia Biotech Europe GmbH  Freiburg, Germany 
peqLab Biotechnologie GmbH  Erlangen, Germany 
Promega GmbH    Mannheim, Germany 
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Qiagen     Hilden, Germany 
Roche Diagnostics GmbH   Mannheim, Germany 
Schott-Geräte GmbH    Hofheim, Germany  
Sigma      Steinheim, Germany 
Spectrum Europe BV    Breda, the Netherlands 
Stratagene     La Jolla, CA, USA 
Whatman GmbH    Dassel, Germany 
 
 
2.2 Methods 
2.2.1 Growth of bacteria: transformation 
LB medium:  
For 1 L Bacto tryptone 10 g, Yeast extract 5 g, NaCl 10 g, pH 7.0 with 5 N NaOH 
LB agar: 
For 1 L Bacto tryptone 10 g, Yeast extract 5 g, NaCl 10 g, Bacto agar 15 g 
SOB- medium:  
Bacto tryptone 2%, Yeast Extract 0.5%, NaCl 0.05%, KCl 2.5 mM, MgCl2 10 mM 
SOC- medium:  
SOB medium, 20 mM Glucose  
 
Transformation is the genetic alteration of a cell resulting from the uptake and expression of 
foreign genetic material. Bacteria are made artificially competent by passively making cells 
permeable for foreign DNA using methods that do not normally occur in nature. The 
plasmid being used for transformation should contain an origin of replication for 
independent replication and a selectivity marker that differentiates transformed cells from 
non transformed cells. Max efficiency DH5α competent cells from Invitrogen were thawed 
completely on ice and gently mixed. 1 ng to 10 ng plasmid DNA was pipetted to 100 µl of 
competent cells. These cells were then incubated on ice for 30 min followed by a heat shock 
treatment at 42°C in a water bath for 45 sec. The micro-centrifuge tubes were then placed on 
ice for 2 min and 900 µl of SOC medium was added. The bacteria were allowed to grow with 
shaking at 150 rpm for one hour at 37°C after which they were spread onto LB agar plates 
with the respective selection marker expressed from the transformed plasmid and grown 
overnight. Individual colonies were inoculated for culturing bacteria for plasmid isolation or 
protein purification.  
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2.2.2 Growth of bacteria: plasmid isolation 
Bacterial colonies were streaked on LB agar plates. Individual colonies were inoculated in 5 
ml culture and were used as preculture. This was inoculated at 1:100 dilutions in larger 
culture volumes. The strain of bacteria used for plasmid isolation was DH5α and the 
plasmids were isolated from this culture according to the manufacturer’s (Qiagen) protocols 
using Qiagen Mini prep or Maxi prep kits.  
 
2.2.3 Storage of bacteria 
The exponential (or log) phase of growth is a pattern of balanced growth wherein all the 
cells are dividing regularly by binary fission, and are growing by geometric progression. 
This is measured by reading the optical density (OD) of the cultures at a wavelength of 600 
nm. For storage of transformed bacteria, pelleted fresh log phase cultures were mixed with 
sterile glycerol (final concentration 20%) and stored at –80°C.  
 
2.2.4 Agarose gel electrophoresis 
TAE-buffer:  
50 mM Tris pH 7.4, 20 mM Na-Acetate, 2 mM EDTA  
TBE-buffer:  
40x 1.8 M Tris-HCl, pH 8,5, 1,8 M Borate, 0.04 M ETDA  
DNA Loading Buffer and dye: 
1x TAE-buffer, 0.01% Bromphenol blue, 40% Glycerine  
 
Agarose gel electrophoresis is a powerful analytical method for the separation of 
biomolecules. DNA is composed of a negatively charged phosphate group. The gel-
electrophoresis apparatus uses a positively and a negatively charged pole generated by 
electrical currents. In the presence of charge, larger molecules move slower than smaller 
molecules, therefore the DNA molecules separate based on their respective sizes. The DNA 
is loaded in wells present on the negatively charged pole and allowed to pass through the 
gel towards the positive pole. DNA samples were prepared with 6X agarose gel loading 
buffer. These were loaded on 1% agarose gels in TAE or TBE buffer with 5% ethidium 
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bromide. The gels were run at 120 V until the dye reached half the length of the gel. The gel 
was then observed on a UV trans-illuminator and photographed. The DNA samples were 
loaded along with a DNA marker to determine the size of the bands observed. 
 
2.2.5 Restriction enzyme digestion of the pET -huLa -WT and pET -huLa -Mut∆2 
plasmids 
Restriction enzymes cut DNA at a specific target nucleotide sequence thereby generating a 
reproducible set of fragments. The pET -huLa -WT and pET -huLa -Mut∆2 plasmids were 
digested with EcoR I in order to linearise the plasmids. 0.1 units of the enzyme EcoR I was 
added to 100 ng of DNA along with 3 µl of the reaction buffer supplied from New England 
Biolabs and the volume was made up to 20 µl. The reaction was carried out O/N at 37°C. 
This reaction was loaded on an agarose gel to observe the lengths of the fragments 
generated. 
 
2.2.6 DNA concentration 
The concentration of the DNA samples was quantified using GeneQuant II RNA/DNA 
calculator (Pharmacia Biotech Europe GmbH) in 10 µl Hellma quartz suprasil glass cuvettes 
(10 mm). Milli Q water or the buffer in which the respective DNA was eluted was used for 
calibration of the photometer. 5 µl were added to the cuvette and the concentration 
measured by UV absorption at 260 nm. A260 and A280 are the optical spectrometer 
measurement of absorbance at the wavelengths of 260 nm and 280 nm respectively. A260 is 
frequently used to measure DNA/RNA concentration and A280 is used to measure protein 
concentration. A ratio of A260/A280 > 1.8 suggests little protein contamination in a DNA 
/RNA sample. When the DNA samples were too concentrated, they were further diluted 1:5 
or 1:10 times before they were measured and then the concentration was calculated.  
 
DNA concentrations were calculated using the equation: 
Concentration = A260 nm x dilution factor x 50 mg/ml (1 A260 nm unit of ds DNA = 50 
mg/ml) 
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Determining the OD ratio (A280 nm/A260 nm) approximated DNA purity. A ratio value of 
1.8 was considered to indicate DNA purity, with lower and higher values indicating RNA- 
and protein contamination, respectively accordingly (276).  
 
2.2.7 WT La/Mut La protein production in vivo from recombinant bacteria 
Lysis Buffer:  
50 mM NaH2PO4 pH 8.0, 10 mM imidazole, 300 mM NaCl, 4% protease -inhibitor Complete 
Wash Buffer: 
50 mM NaH2PO4 pH 8.0, 42.5 mM imidazole, 1 M NaCl, 0.11% Triton-X100, 1% protease -
inhibitor Complete 
Elution Buffer:  
50 mM NaH2PO4 pH 8.0, 300 mM imidazole, 300 mM NaCl, 1% protease -inhibitor Complete  
Dialysis Buffer:  
10 mM Tris-HCl pH 7.4, 3 mM MgCl2, 100 mM NaCl, 0.5 mM EDTA, 5% Glycerine 
 
BL21 bacterial colonies transformed with the respective plasmids (pET -huLa -WT and pET -
huLa -Mut ∆2) were streaked on LB Agar plates and from these individual colonies were 
inoculated in 5 ml culture and were used as preculture. This was inoculated at 1:100 
dilutions in larger culture volumes. The strain of bacteria used for plasmid isolation was 
BL21. Absorbance was measured at 600 nm (A600). 
The pET hLa plasmids (pET -huLa -WT and pET -huLa -Mut ∆2) used have a His tag that 
allows for the purification of the proteins expressed in E.coli using Qiagen’s Ni-NTA 
(Nickel-nitrilotriacetic acid) metal affinity chromatography matrices for biomolecules having 
6 consecutive histidine (6xHis) residues as an affinity tag. The 6xHis tag facilitates binding to 
the Ni-NTA agarose. Imidazole at higher concentrations facilitates the elution of the His 
tagged protein. The lysis buffer contains 10 mM imidazole to minimise binding of untagged 
contaminating proteins and increase purity with fewer wash steps. The wash buffer also 
contains imidazole at lower concentrations in order to stringently wash out any endogenous 
proteins with histidine residues.  
IPTG was added to a final concentration of 1 mM in culture when the A600 (at 37°C with 
shaking of 200 rpm overnight) reached 0.5. IPTG is a non fermentable analog of lactose and 
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induces expression of genes under the control of a promoter based on the lac operon in 
bacteria that utilise lactose and can inactivate the lac repressor. After this the culture was 
shaken for 4-5 hours at 37°C, during which time the desired protein was expressed. The 
bacterial culture was then centrifuged and the pellet was resuspended in chilled lysis buffer 
(50 mM NaH2PO4, 10 mM imidazole and 300 mM NaCl) with 4% protease inhibitor and 
sonicated 3 times for 10 sec each to lyse the bacterial cell membranes. The supernatant of this 
lysate was then maintained on ice for all further steps of Ni-NTA agarose gel based batch 
purification or spin column purification. The wash buffer used contained 50 mM NaH2PO4, 
42.5 mM imidazole, 1 mM NaCl and 0.11% Triton X 100. The column or agarose (in the batch 
process) was washed 2 times after which elution buffer (50 mM NaH2PO4, 300 mM 
imidazole and 1 mM NaCl) was used to elute the protein bound to the column. The total 
volumes of the buffers used for each method are as listed below: 
    Spin columns  Batch process 
Volume of culture used 5 ml   500 ml 
Volume of agarose used 2 columns  2 ml 
Volume of lysis buffer (10X) 0.5 ml   50 ml 
Volume of wash buffer 600 µl   8 ml 
Volume of elution buffer 300 µl   4 ml 
 
This eluate was then dialyzed overnight at 4°C and concentrated with Amicon concentrators 
from Millipore as per the manufacturer’s instructions. Protein concentration estimation was 
made by Biorad protein assay method (as described in section 2.2.8) and evaluated after 
Western blot analysis. 
 
2.2.8  Protein concentration estimation 
The Bradford method was used to measure protein concentration. This method is used to 
measure solubilised protein. Bovine Serum Albumin (BSA) was used as standard and 5X 
Bradford reagent from Bio-Rad was used for protein estimation. This reagent is acidic, 
containing Coomassie brilliant blue dye that changes colour corresponding to the 
concentration of the protein present and this colour change can be read on a 
spectrophotometer or a microplate reader at 595 nm. This reagent was prepared by diluting 
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it to 1X before it was added to samples. All steps were done according to the manufacturers 
instructions. Standards were made from 1 to 5 µg/ml BSA protein as 5 dilutions. Samples 
were diluted further if needed (when the blue colour arising after the sample was added to 
the Bradford reagents, was visibly more than the 5 µg/ml BSA standard). This was then 
incubated for 30 min at RT and 200 µl were transferred into a well of a 96 well microtiter 
plate. Using a microtiter plate reader (SLT spectra III plate reader from SLT Lab 
Instruments), the protein concentration was measured at 595 nm and the Magellan 3 
software was used to calculate the concentrations. The protein concentrations were 
calculated using the BSA standard curve. 
 
2.2.9 SDS Polyacrylamide Gel Electrophoresis (SDS PAGE) 
SDS PAGE protein loading dye 4X:  
0.4 M Tris-HCl pH 6.8, 10 mM EDTA, 0.1 M β -mercapto ethanol, 20% Glycerine, 8% SDS, 
0.06 g Bromophenol blue for 10 ml dye 
Running Gel buffer:  
250 mM Tris (pH 8.8), 19.2 mM Glycine, 0.35 mM SDS  
Spacer Gel Buffer: 
0.5 M Tris, 0.4% SDS, pH adjusted to 6.76 with conc. HCl (37%) 
Running gel buffer: 
1.5 M Tris (pH 6.8), 0.4% SDS, pH adjusted to 8.8 with conc. HCl (37%) 
 
The SDS PAGE method separates proteins according to their molecular weights (277). The 
electrophoretic mobility of proteins in gels will depend on both the size as well as the 
charge-to-mass ratio. Therefore, to separate proteins according to size it is necessary to give 
them to same charge-to-mass ratio. This can be accomplished by denaturing the protein in 
SDS (sodium dodecyl sulfate, shown below). The SDS binds to proteins in a uniform manner 
giving all proteins the same charge-to-mass ratio. SDS also denatures the proteins and β-
mercaptoethanol cleaves disulphide linkages.  
The protein samples to be analyzed were prepared with protein loading dye with 0.5% β-
mercaptoethanol and were heated at 95°C for 3 minutes. The samples and appropriate 
markers were loaded onto 10% or 12.5% SDS PAGE gels and run at 125 V in the spacer gel 
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and 180 V in the running gels. The gels with radioactive protein were run until before the 
dye phase ran out of the gel and the non radioactive protein gels were run until the 
fragment of interest was well separated on the gel.  
If the gels had to be blotted as was the case for Western blot analysis, they were done so at 
this stage (see section 2.2.10). Depending on the amount of protein in the gel, it was either 
stained using the Coomassie blue staining procedure or Silver staining. The gels were dried 
in moist thin foils overnight at room temperature.  
  
2.2.10 Immunodetection (Western Blot) 
TBS (10X): 
30 g Tris base, 80 g NaCl, 2 g KCl, H2O to 1 L, pH 7.4 with 1 M HCl and autoclave 
TBST Buffer:   
1X TBS plus 0.05% (v/v), Tween 20 
Western-Blot Transfer buffer: 
48 mM Tris-HCl , 139 mM Glycine, 20% Methanol, 0.05% SDS 
Transfer Buffer: 
48 mM Tris, 20% Methanol, 39 mM Glycine, 0.05% SDS 
 
Western blotting was done on the semi-dry blotting apparatus at 180 V for 20 minutes. The 
nitrocellulose membrane (Hybond-ECL) from Amersham Biosciences was used for blotting 
and was prepared according to the manufacturers instructions. The gel was placed on the 
membrane and these lay in between a sandwich of 8 Whatman papers (4 on each side) 
soaked in transfer buffer. After blotting, the transfer of proteins on the membrane was 
judged either using Amido Black or Ponceau-S staining (reversible) as described below. The 
gels were stained using Coomassie staining or silver staining as described in sections 3.2.11.  
 
Amido Black staining solution: 
2X concentrate from Sigma 
Amido Black destaining solution: 
Aqueous solution containing 25% isopropanol, 10% Acetic Acid 
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Ponceau-S Staining solution: 
 0.5% (w/v) Ponceau-S, 1% Acetic Acid  
 
The blotted membranes were stained with Amido black or with Ponceau-S (reversible 
staining) in order to control the amount of protein transferred. This was done according to 
the manufacturer’s instructions. Usually Ponceau-S was used when the membranes were 
further used for Western blot analysis. This step confirmed blotting of the proteins from the 
gel to the membranes. 
 
2.2.11 Antibody binding and Chemiluminescence reactions: 
The nitrocellulose membrane obtained after Western blotting was blocked with 5% milk in 
TBST for an hour and then the blot was incubated in primary antibody (anti-La 4B6) at a 
dilution of 1:500 in blocking buffer overnight at 4°C. Washes were carried out twice with 
TBST before the secondary antibody HRP-conjugate goat anti-mouse was added in blocking 
buffer at a dilution of 1:5000. Similar washes were carried out. The membrane was detected 
using ECL kit from Amersham. The Enhanced Chemiluminescence (ECL) reagent from 
Amersham Biosciences is a light emitting non-radioactive method for detection of 
immobilised specific antigens, directly or indirectly with Horseradish Peroxidase (HRP) 
labelled antibodies. HRP catalyzes the oxidation of luminol in alkaline conditions and this is 
the principle used in ECL where this reaction is done in the presence of chemical enhancers 
such as phenols resulting in increasing both the intensity as well as the time of light 
emission. This light produced at a wavelength of 428 nm is detected by a short exposure to 
blue light sensitive autoradiography film. Equal amounts of solution 1 and solution 2 were 
added to the membrane, enough to cover it completely and incubation times varied between 
a few seconds and 10 min depending on the amount of protein on the membrane. These 
membranes were then exposed to Kodak Biomax XAR films, which were developed using 
the Agfa Curix 60 machine. 
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2.2.12 Staining of protein gels  
2.2.12.1 Staining of gels with Coomassie blue staining 
Coomassie staining solution: 
0.2% Coomassie R-250, 20% Methanol, 5% glacial acetic acid, water up to 2.25 L and filtered. 
Coomassie destaining solution: 
5% Methanol, 7.5% Acetic Acid 
 
Proteins on the gels were stained using coomassie blue staining. Coomassie stain was added 
to the gels, enough to cover them completely and staining was allowed for 20 minutes, after 
which the solution was decanted and destaining solution was added or the gels were 
allowed to destain in water overnight.  
 
2.2.12.2 Silver Staining of protein gels 
Silver Staining: Fixer: 
45% (v/v) Methanol and 10% (v/v) glacial acetic acid 
Silver Staining: Farmer’s reducer: 
0.03 M K3 Fe(CN)6 and 0.032 M Na2S2O3.5H2O 
Silver Staining: Developer: 
2.5% (w/v) Na2CO3 and 0.09% (v/v) Formaldehyde 
Silver Staining: Stop solution: 
10% glacial acetic acid in water 
 
Silver staining was used as a more sensitive alternative to Coomassie staining of 
polyacrylamide gels. The protocol is a modified protocol (278). The gel was fixed with fixing 
solution for half an hour and then farmer’s reagent was added to the gels for 1 minute. The 
gel was then washed with water until the yellow colour was completely removed from the 
gels and then the gels were incubated for 15 min in Silver nitrate solution. They were then 
developed with 2.5% Na2CO3 and 0.09% formaldehyde until the protein bands could be 
observed. The reaction was stopped with stop solution containing 10% acetic acid.  
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2.2.13 WT La/Mut La protein production in vitro 
Single tube in vitro protein production was made using the TNT Quick coupled transcription 
& translation system with T7 promoter from Promega. The TNT Quick coupled transcription 
& translation system combines RNA Polymerase, nucleotides, salts, and RNasin 
ribonuclease inhibitor to form a single quick master mix. 1 µg of DNA was added to the 
TNT master mix. In addition to 2 µl of plasmid DNA (0.5 µg/µl) to be transcribed, 5 µl of S35 
methionine from Amersham was added the reaction was filled up to 100 µl using nuclease 
free water. The reaction was allowed to proceed for 60 min at 30°C. These reaction mixes 
were either used immediately or frozen at -20°C until they were used or evaluated. The 
control used was the reaction mixture without DNA, as recommended according to the 
manufacturer’s protocol. The results of translation were analyzed by SDS PAGE and 
Western blot analysis.  
 
2.2.14 Detection of radioactive protein on gels 
The dried gels were exposed to X-ray film directly or else onto Phosphor Imager screens. 
The X ray films were developed in an Agfa Curix 60 machine. The phosphor imager screens 
were subjected a FUJI FILM BAS 2500 reader and analysed by AIDA software. The exposure 
of gels to films lasted from a few seconds to a few minutes, the exposure to phosphor imager 
screens was normally done overnight. The used phosphor imager screens were erased using 
the Ray test eraser and the types of screens used were usually M type.  
 
2.2.15 Peptide Synthesis on cellulose membrane library using the SPOT synthesis 
technique 
Spot synthesis was the method used to synthesise peptides on cellulose membranes and 
these libraries were screened using mutant and wildtype La in order to find possible peptide 
binding partners. The syntheses for these libraries were carried out on the Abimed ASP222 
Automated SPOT Robot (95). An amino-PEG cellulose membrane was used having a 
loading of 0.4 mMol /cm2. 425 spots can be synthesised on a 8x12 cm membrane. Arrays of 
spots providing suitable anchor functions for peptide assembly on cellulose membranes are 
most easily generated by a two-step procedure. The first step involves preparation of the 
amino paper through esterification of an αN-Fmoc-protected amino acid to make available 
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the hydroxyl functions on the cellulose fibres of the whole sheet, followed by Fmoc cleavage. 
For this, the cellulose sheet is soaked in a solution containing 0.2 M Fmoc-β-alanine, 0.3 M 
DIC and 0.3 M NMI in dry NMP for 1-4 hours. The cellulose sheet is first washed in the 
reaction trough twice and left overnight with acetylation mix (capping mix). The sheet is 
then washed three times using 20 ml DMF, then incubated in 20% piperidine/DMF for 20 
min to cleave the Fmoc protecting groups and then again in 20 ml DMF four times, with 20 
ml alcohol three times and then dried in a desiccator overnight. Finally it is stored at -20°C. 
For long term storage, the Fmoc protecting groups should be left. The treatment with 20% 
piperidine/DMF is then carried out before the second step.   
The second step involves spot-wise coupling of a suitable anchor compound (such as βAla-
βAla-anchor) or another Fmoc amino acid which generates the array of spot reactors. All 
residual amino functions between spots are blocked by acetylation (2% acetic anhydride in 
DMF). 0.2 M of the second anchor compound (such as Fmoc-βAla-OH), 0.3 M HOBt and  
0.3 M DIC in NMP was prepared (for this step only 0.1 µl was spotted). BPB was added and 
left for 30 min. Active ester between the HOBt and the βAla is formed to attack the free 
amino functions on the cellulose paper. Aliquots of this solution were spotted to all 
positions of the array and this reaction was allowed to be carried out for 30 min. Washes 
were done with 20 ml of acetylation mix for 30 sec and then 2 min and finally the sheet was 
left overnight in the acetylation mix (cap all amino functions between every spot, only till 
the second βAla step). This was again followed by washes with 20 ml DMF three times, 
incubation for 5 min with 20 ml of 20% piperidine/DMF. This was followed by further 
washes with DMF four times and incubation with 20 ml BPB (1% BPB v/v from 10 mg/ml 
stock in DMF) until the spots stain light blue. This is followed by a 20 ml alcohol wash (done 
twice). The sheet is dried with cold air from a hair dryer and can be used immediately or can 
be stored in a sealed plastic bag at -20°C. 
The amino acids for building up the peptide chain are dissolved at 0.2 M ratio in NMP 
containing 0.3M HOBt and are stored at -70°C (this is the amino acid stock solution). 
Activation of the amino acids was done using 4 µl DIC (0.4 M DIC) per 100 µl amino acid 
stock solution at room temperature for 30 min. Vials containing activated amino acids were 
placed in a synthesiser rack and a spotting protocol was initiated. 0.2 µl of the amino acid 
solution was dispensed up to 3 times on a single spot for every spotting step. Capping of the 
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amino acids was done using 2% acetic anhydride in DMF for 30 sec and then 10 min in fresh 
acetylation mix. This was followed by 3x10 min washes in 20 ml DMF. The next step in the 
synthesis was deprotection of the amino functions by the cleavage of Fmoc by 20% 
piperidine in DMF for 5 minutes followed by 4x10 min washes with DMF. At this stage, a 
bromophenol blue (BPB) reaction was done in order to detect free amino groups. This was 
followed by washes with ethanol 3 times. The sheet was then dried with cold air from a hair 
dryer after every step.  
The next elongation cycle of peptide synthesis, which consisted of activation of amino acids, 
spotting, capping, Fmoc deprotection, washing and drying were repeated in order to couple 
the next amino acid. 
In the last step of SPOT technique based peptide synthesis, deprotection of the Fmoc group 
was done without prior capping, followed by the BPB reaction. This served as an indicator 
of synthesis as well as an indicator of the next capping step (2% acetylation mix, 2x15min) 
because the amino functions were blocked until the blue colour from the BPB reaction 
disappeared. This is followed by washing steps, 3x10 min DMF, 3x10 min ethanol and then 
the membranes are dried. After the last cycle, the side chain deprotection was done for two 
times one hour each using 50% TFA, 3% TIBS, 45% DCM, 2% H2O (20 ml of deprotection 
mix) with gentle agitation. After deprotection, the membrane was washed for 4x10 min with 
DCM, 3x10 min with DMF, 3x10 min with ethanol, 3x10 min with 1M Acetic Acid (in water) 
and finally for 3x10 min with ethanol. Membranes were air-dried and stored at -20°C. These 
membranes could now be used for biological assays such as ligand/antibody binding. 
  
2.2.16 Binding assays on cellulose membranes with WT and Mut La proteins 
2.2.16.1  Radioactive WT and Mut La proteins used as probes (made using the pET -huLa 
-WT and pET -huLa -Mut∆2 plasmids)  
La protein binding buffer: 
10 mM Tris HCl pH 7.4, 150 mM NaCl, 3 mM MgCl2, 0.5 mM EDTA, 1 mM DTT, 0.5% NP-40 
Stripping buffer: 
0.06 M Tris HCl pH 6.8, 0.1 mM Beta mercapto ethanol , 2% SDS 
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The cellulose membranes were washed 2 times in 70% Ethanol and 2 times with the La 
protein binding buffer. They were then blocked overnight in 5% skim milk. 100 µl 
radioactive Mut ∆2 La probe made using the TNT kit was added to these membranes and 
binding was allowed for 4 h. This membrane was then washed four times for 10 minutes 
each in La protein binding buffer and then exposed to a phosphor imager screen overnight. 
The screen was read in the phosphor imager and signals were analysed using the AIDA 
software. Later the membrane was stripped using stripping buffer and the binding assay 
was repeated for WT hLa probe from the TNT kits. Based on the binding signals observed, 
further membranes were synthesised and binding assays were done with them in the same 
manner. 
 
2.2.16.2 Non radioactive WT and Mut La proteins used as probes (made using the pET -
huLa -WT and pET -huLa –Mut ∆2 plasmids) 
La protein binding buffer: 
10 mM Tris HCL pH 7.4, 150 mM NaCl, 3 mM MgCl2, 0.5 mM EDTA, 1mM DTT, 0.5% NP-40 
Stripping buffer: 
0.06 M Tris HCl pH 6.8, 0.1 mM Beta mercapto ethanol , 2% SDS 
 
The cellulose membranes were treated as above and blocked in a similar way. Non 
radioactive recombinant Mut ∆2 La protein made in E. coli BL21 was added to these 
membranes and binding was allowed for 4 h in La protein binding buffer. The membrane 
was then washed with La protein binding buffer four times for 10 minutes each and after 
incubation with Amersham’s ECL kit were exposed to Fuji X ray film. Later the membrane 
was stripped using the stripping buffer and the binding assay was repeated in the same way 
for recombinant wild type La protein. 
  
2.2.17 Peptide synthesis on polypropylene foils 
The amino functions necessary for peptide synthesis on the foils were produced by 
derivatisation of a native polypropylene foil of hydroxyl functions. On these amino 
functions, were carried out the peptide SPOT synthesis as on the cellulose membranes (as 
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described in sections 2.2.15) with minor differences. Briefly, the amino acids to be used for 
spotting were dissolved in HOBt containing DMF in the case of PP foils (instead of NMP as 
in the case of cellulose sheets) and are stored at -20°C. Activation of the amino acids was 
done using DIC at room temperature for 30 min. BPB was not added to the amino acid 
spotting solution. Spotting was done manually per each patch. The spotting volume was 
between 0.5 µl and 1 µl per patch. All the capping steps are done using acetic anhydride for 
1x30 sec and 1x2 min and finally for 1x10 min (unlike the first capping step in cellulose 
sheets which is overnight). This is followed by Fmoc deprotection of the amino acids and 
continuation with the next cycle of peptide synthesis (which consisted of repeating the 
previous steps). All the washing steps are reduced to 3 min for each step (unlike 10 minutes 
in the cellulose sheets). In the last step of SPOT technique based peptide synthesis, 
deprotection of the Fmoc group was done without prior capping (same as cellulose) and 
using the side chain deprotection mix which consisted of 82% TFA, 3% TIBS, 10% DCM and 
5% water. The washing steps after side chain deprotection have the same times as on 
cellulose membranes. The patches are dried in air and can then be used.  
Apart from this different chemistries for the cell based assays were used. The βAla support 
was used for the peptide synthesis on foils.  
 
Derivatisation of polypropylene foils: 
A commercial available polypropylene foil of 0.27 mm thickness has been derivatised to 
create different functional groups and surfaces in order to perform cell based assays. The 
dimensions of the hydrophilic patches used for the assays were between 2x2 and 3x3 mm2.  
Starting with the native polypropylene foil a mask, plotted with paint was applied to the 
foils before they were subjected to ozone treatment. At the non-painted areas this created a 
number of reactive species such as peroxides and hydroxyl functions and made this so 
called patches more hydrophilic than the with paint covered areas which are left 
hydrophobic. These hydrophobic areas are building the borders between the patches.  
This foil with hydrophilic patches and hydrophobic barriers was the starting material for all 
following derivatisations and reactions. The reactions were done on the hydrophilic patches 
only, the hydrophobic barriers did not undergo the reactions. For the order of the reactions 
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to create the different surfaces see table 2-1. The operations carried out for derivatisation are 
specified below.  
 
Ozonolysis: 
A mask was plotted with paint onto the polypropylene foil surface. Ozone treatment was 
done for 4 to 8 hours. The mask was washed off with 3x3 min ethanol.  
 
Reduction with boran dimethyl sulphide complex: 
The foil was treated overnight with a 1 M solution of boran dimethyl sulphide complex in 
methyl tert.-butyl ether (MTBE). After washing with 1x for 5 min with MTBE the foil was 
incubated with a 1:1:1 (v/v/v) solution of 3 N NaOH, water and 30% H2O2 for 1 hour. This 
was followed by washing steps, each for 5 min with 1x1 N NaOH, 1x1 N HCl, 1x water, 2x 
DMF and 2x DCM and drying. 
 
Polymerization: 
For the polymerization a monomer or a monomer mixture were solved as a 7% solution in 
DMSO containing 0.5 mM copper-(II) acetate as catalyst to initiate the radical 
polymerization. To start the reaction the foil were placed in a closed reaction vessel, the 
polymerization solution were added and a nitrogen stream were applied in to the 
polymerization solution to remove all oxygen out of the solution and the vessel which 
otherwise would avoid the radical polymerization. Then the reaction vessel were placed at 
80°C in an oven and left for 24 h. After removing the foil out of the polymerization solution 
it was washed with each 3x3 min with 1 N NaOH, 1 N HCl, water and ethanol. The foils 
were air dried.  
 
Polymers used: 
DMA   N,N-dimethyl acryl amide 
APMAA   N-(3-aminopropyl) methacrylamide hydrochloride 
ThMAA  N-[Tris(hydroxymethyl)-methyl]acrylamide 
For the mixture of monomers the ratios were for ThMAA/DMA 1:3 and for APMAA/ DMA 
1:2. 
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CDI activation: 
To make the hydroxyl functions of ThMAA accessible for further reactions the foils were for 
4 to 6 hours treated with a 0.5 M solution of carbonyldiimidazole (CDI) in DMF.  
 
Amine reaction: 
The CDI activated foils were placed in a trough and overnight treated with a 60% solution of 
the desired amine in DMF. Only for the treatment with glucosamine hydrochloride were 
solved as a 0.5M solution in water and 1N NaOH adjusted to pH 7.5. After washing with 3x3 
min with DMF and 3x3 min with ethanol the foils were air-dried. 
 
The amines used were: 
DACH   trans-1,4-diaminocyclohexane  
Jeffamin 130   O-(2-Aminopropyl)-O'-(2-methoxyethyl)polypropylene 130 
Jeffamin 500  O-(2-Aminopropyl)-O'-(2-methoxyethyl)polypropylene 500 
Glucosamine  D(+)-glucosamine hydrochloride 
 
A foil, derivatised according to the point# 9 in the table 2-1 was used to perform the peptide 
synthesis according to section 2.2.15. 
 
Coating with Poly Lysine: 
The foils were treated overnight with a 1:20 dilution of a poly lysine solution (100 µg/µl) in 
0.1 M PBS, pH 7.4. After washing with 3x3 min water and 3x3 min ethanol the foil were air-
dried.  
 
Per Iodine cleavage: 
Sodium metaperiodate, NaIO4, is 3.3 M solved in a 20% solution of acetic acid in water. With 
this solution the glucosamine foil was treated for 10min, followed by washing with 3x3 min 
with water and 3x3 min with ethanol and then air-dried.  
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1. 
Ozonolysis 
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Hydroxyl 
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x      
2. Ozonolysis + 
Reduction with  
Boran dimethyl 
sulphide complex 
Hydroxyl 
functions 
x x     
3. Polymerization 
with DMA 
Methyl 
groups 
x  DMA     
4. Polymerization 
with 
APMAA/DMA 
Amino 
functions 
x  APMAA/DMA    
5. Polymerization 
with 
ThMAA/DMA 
Hydroxyl 
functions 
x  ThMAA/DMA    
6. Polymerization 
with 
ThMAA/DMA + 
CDI activation 
CDI 
preactivate
d surface 
x  ThMAA/DMA x   
7. Polymerization 
with 
ThMAA/DMA + 
Diaminocyclohexa
ne (DACH) 
Amino 
functions 
x  ThMAA/DMA x DACH  
8. Polymerization 
with 
ThMAA/DMA + 
Jeffamine (130) 
Amino 
functions 
x  ThMAA/DMA  Jeffamine 
130 
 
9. Polymerization 
with 
ThMAA/DMA + 
Jeffamine (500) 
Amino 
functions 
x  ThMAA/DMA x Jeffamine 
500 
 
10. Polymerization 
with 
ThMAA/DMA + 
Jeffamine (500) + 
Poly Lysine coat 
Poly –L -
Lysine 
x  ThMAA/DMA x Jeffamine 
500 
Poly-
Lysine 
coating 
11. Polymerization 
with 
ThMAA/DMA + 
Jeffamine (500) + β 
Alanine spots 
β Alanine  
x  ThMAA/DMA x Jeffamine 
500 
ßAlanine 
Spots 
12. Polymerization 
with 
ThMAA/DMA + 
Jeffamine (500) + 
Lysine 
x  ThMAA/DMA x Jeffamine 
500 
Lysine 
Spots 
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Table 2-1. The type of surface chemistry done on the foils and the respective functional groups 
obtained are listed. 
 
2.2.18 DT-2 peptide synthesis on polypropylene foils with cleavable linker 
Foils with amino functions and the Jeffamine 130 spacer were used for the DT-2 peptide 
synthesis (279). The coupling was of a carboxy-Frank-Linker DHCA (2-(1-t-
Butyloxycarbonyl-4-methyl-imidazol-5-yl)-2-hydroxy-acetic acid dicyclohexylamine). The 
linker was used as a 0.2 M solution in DMF, 2 equivalents HOBt and 1.5 equivalents DIC 
were used for preactivation for 20 min. Spotting of the linker solution was done twice onto 
the foil, working up as after normal peptide synthesis cycle. On this linker-foil the DT-2 
peptide was coupled, starting again with the esterification of histidine as first step. Peptide 
synthesis and also the side chain deprotection with TFA was then carried out like in section 
2.2.15 and 2.2.17.  These were then used for cell based assays. The DT-2 peptide was released 
into media by using a solution with neutral pH such as cell culture media. This was due to 
the characteristic of the linker which has the property to be cleaved in neutral pH. 
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2.2.19 Cell Based Assays on polypropylene foils with hydrophilic patches 
The different cell lines were grown in their respective media (Table 2-2) and after counting 
on a haemocytometer the final concentration was adjusted to 500,000 cells/ml.  
The cells were counted on a Neubauer chamber according to the following equation: 
 
Cells/ml = (average count /square) x (dilution factor) x 104 [chamber conversion factor] 
 
Cell line Medium Serum 
Number 
of 
passages 
per week 
Proportion 
inoculated  
for next passages 
Method to 
de–adhere cells 
from the surface 
L929 DME FBS/NCS 1x 1:20 Scrapped 
PtK2 MEM+ FBS 1x 1:10 Scrapped 
A498 MEM+ FBS 1x 1:10 Scrapped 
PC-3 F12K FBS 1x 1:10 Scrapped 
SKOV-3 Mc Coy FBS 1x 1:10 Scrapped 
A431 RPMI FBS 1x 1:20 trypsinised 
Hela DMEM FCS 1x 1:20 trypsinised 
3Y1 DMEM FCS 1x 1:10 trypsinised 
HepG2 DMEM FCS 1x 1:10 trypsinised 
Huh7 DMEM FCS 1x 1:10 trypsinised 
A549 DMEM FCS 1x 1:20 trypsinised 
 
Table 2-2. Mammalian cell lines used and their respective cell culture requirements 
 
2.2.20 Freezing of mammalian cells: 
Cell Freezing Medium: 
Cell culture media plus 10% DMSO  
 
In order to preserve the cells used for the various experiments done here, they were grown 
on tissue culture plates and were trypsinised or scrapped and resuspended in cell culture 
medium. After this the cells were centrifuged at 1000 g for 3 min at 4°C. The cell pellet was 
resuspended in ice-cold cell freezing medium at a concentration of 0.5 x 107 cells/ml and then 
slowly brought from 4°C to liquid nitrogen. A frozen vial of cells was thawed after a certain 
number of passages for the each cell line.  
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2.2.21 Growth of cells on patches 
The desired number of patches was selectively cut from the polypropylene foils (usually 6 to 
8 depending on size of patch). This foil was then washed 2 times with 70% ethanol and 3 
times with PBS (5 min for each washing step). 5 µl of media having 500,000 cells/ml were 
added per patch on all the patches on a foil. These were then put in 3.5 cm diameter culture 
plates and 3 such plates were put in a 10 cm petriplate that is filled with water to facilitate 
humidity in the plate and prevent the evaporation of media from the individual drops over 
time. The cells were incubated at 37°C with 5% CO2 and grown over 2 days and then 
analysed and documented with photographs from the individual patches in order to study 
characteristics such as cell growth, adherence to the patch, clustering, monolayer forming 
ability and cell viability. The microscope used for this study was the Olympus SZX 12. 
 
2.2.22 Monitoring parameters of normal cell growth using Trypan Blue 
One of the simplest ways to monitor normal cell growth is using Trypan Blue. It is a 
biological stain/viable dye that stains dead cells blue and is excluded by cells having an 
intact cell membrane. Trypan Blue is a tetrasulfonated anionic dye and has widely been used 
as a vital stain since the early 20th century. This dye has a wide variety of other applications 
and can be used to stain collagen, amyloid, as a quenching agent to suppress auto-
fluorescence in tissue section, in flow cytometry as a fluorescent tracker of cell populations 
and also has several uses in biomedicine. 1 µl of dye was added to each of the patches. After 
an incubation time of 3 min, the liquid was gently pipetted off the patch and PBS was added 
to observe the cells for their viability on patches. Cell growth was compared on patches at 
various steps of peptide synthesis, in order to standardise the kind of linker to be used as 
well as to observe the effects of surface chemistry of the patches on the cells. 
 
2.2.23 Repeating cellular phenotypes on patches 
2.2.23.1 Lamellipodia induction in 3Y1 cells grown on PLL 
Solutions and Buffers: 
Stock of Poly L Lysine (PLL)   10 mg/ml in water  
PLL –A     150,000 to 300,000 Da Molecular weight 
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PLL –B     30,000 to 70, 000 Da Molecular weight 
Working solution of PLL   100 µg/µl 
 
The poly L lysine (PLL) stock of 2 mg/ml was diluted 1:20 to obtain a working stock of 100 
µg/ml. 100 µl of this was used per coverslip and 500 µl per piece of PP foil. Drops of PLL 
were first pipetted onto parafilm and placed in a humid chamber. The coverslips or foils 
were then laid with the cell growing surface facing the parafilm and in this way were 
incubated with PLL for 30 min. They were then thoroughly washed with PBS by dipping 
into beakers containing PBS. These steps were done fast in order to remove uncoated excess 
lysine. The coverslips and foils were placed right side up (cell growing surface) and stored at 
room temperature. Prior to use they were UV sterilised for 10 min.  
The PP foils that were treated with PLL in the above method were categorised as PLL coated 
(not covalently linked) foils where van der Waals forces are the binding force of PLL to the 
PP surfaces. In order to covalently link PLL to the surface of these foils, a solution of 0.1 M 
PBS, 5% of the PLL stock and 0.1% of tween 20 were poured onto a square petriplate and the 
PP foils were carefully placed on this with the patch side facing the surface of the petriplate. 
These were then placed on a rocking table overnight and were subsequently washed with 
PBS, 70% ethanol and then 100% ethanol for 5 min, 3 times each. The foils were then dried 
and sealed in plastic sheets. The foils used for growing cells were cut so that each foil would 
have 6-8 patches each where cells could be grown. These foils were designated as activated 
covalently linked foils.  
3Y1 cells were grown in cell culture plates and prior to plating on the activated foils, were 
trypsinated, counted and further diluted to obtain 5 x 105 cells/ml. 5 µl of the suspension was 
pipetted onto each patch. As coverslip controls, 500 µl of these diluted cells were further 
diluted in 2 ml media per 6 cm plate having 3 coverslips at its bottom. Cell growth was 
allowed for 2 days (280).  
The cells were fixed with 4% PFA/0.25% gluteraldehyde for 20 min at 37°C. They were then 
twice washed with PBS and the cell membranes perforated for antibodies using pre-warmed 
4% PFA/0.1% Triton X 100 in PBS for 30 sec. The coverslips or membranes were then 
incubated on a drop of 30-50 µl of Alexa 488 Phalloidin for 45 min at RT in a humid chamber 
followed by washes in PBS. These were then mounted using Mowiol and n-propyl gallate 
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(npg) as anti-fade reagent on slides. These were stored at 4°C until photographed and 
analyzed using the Axiovert Microscope from Zeiss. IPLab spectrum was the software used 
for taking photographs and analyzing the pictures taken.  
 
2.2.23.2 Inhibition of cytokinesis in PtK2 cells grown on foils with DT2 peptide 
synthesised 
DT-2 peptide with the sequence YGRKKRRQRRRPPLRKKKKKH (Mol Wt. 2800) (281) was 
synthesised on the patches as described in section 2.2.18. These patches were washed with 
ethanol and PBS pH 6.5. 5 µl of PtK2 cells were added to each patch. These cells were 
allowed to grow on the patches for 2 days at 37°C. After this, the patches with cells were 
washed with PBS and fixed with 37% formaldehyde for 10 min. After 3 washes in PBS, the 
patches were incubated with 0.05% triton X-100 in PBS. This step accounts for the 
permeability of cells to antibodies.  
Following 2 washes with PBS, the patches were incubated with primary anti-tubulin 
antibody at a dilution of 1:500 for one hour (dilutions were done in 10% NCS and PBS). Later 
they were incubated for an hour with the fluorescein conjugated secondary goat anti-mouse 
antibody at a dilution of 1:200. These patches were then incubated with DAPI (final 
concentration 1 µg/ml) for 5 minutes and then mounted in anti-fade on glass slides. These 
were then observed with a confocal microscope having the respective filters and double-
labelled images were taken with the Axioviosion software.  
A basic peptide, pep1 (highly basic sequence -Ac-KETWWETWWTEWSQPKKKRKVC(SH)- 
amide, was used as a negative control on patches. It was given externally to the patches to 
the cells at a concentration of 10 µg/ml. DT2 peptide was also externally added to the 
patches with cells at the same concentration as the positive control. All experiments 
consisted of coverslip controls with the same conditions.  
 
2.2.24 Transfection into mammalian cells 
Fugene 6 was the transfection reagent used to transfect mammalian cells with the respective 
plasmids. FuGENE® 6 transfection reagent, a proprietary blend of lipids and other 
components supplied in 80% ethanol, forms a complex with DNA and then transports it into 
Materials and Methods 73 
 
 
 
animal cells. Cells were plated to 70% confluency. Medium was changed 3 to 4 hours before 
transfection. The ratio of transfection reagent used to the µg of DNA was 3:1. This ratio was 
found to be optimum for transfection efficiencies between 8 to 18 percent. These transfected 
cells were grown for at least 48 hours before they were used in further experiments. 
 
 
2.2.25 GFP La nuclear export signal (NES) construct 
In the GFP-C1-La-WT plasmid, C1 indicates the pEFGP vector (clonetech). La was cloned via 
SacI and HindIII. La sequence between nt 1354 and 2641 (La nt 91-1378). The three 
oligonucleotides for cloning the NES were chosen based on the speed at which they move 
cargo out of the nucleus. (282) 
 
 
NES of the Protein kinase inhibitor (PKI), judged as fast NES (5 ± 10min) 
        XhoI                     EcoRV     XhoI  
PKI-S: 5’-T CGA GCT CAA TTA GCC TTG AAA TTA GCA GGT CTT GAT ATC AAC TC-3’ 
PKI-AS:3’-   CGA GTT AAT CGG AAC TTT AAT CGT CCA GAA CTA TAG TTG AGA GCT5’ 
             L  A  L  K  L  A  G  L  D  I  N  
 
 
NES of HIV-1 Rev medium type 1 (10 ± 20min) 
 
       XhoI                             XhoI 
REV-S: 5’-T CGA GCT CAA CTT CAG CTA CCA CCG CTT GAG AGA CTT ACT CTT TC-3’ 
REV-AS:3’-   CGA GTT GAA GTC GAT GGT GGC GAA CTC TCT GAA TGA GAA AGA GCT5’ 
             L  Q  L  P  P  L  E  R  L  T  L 
 
NES of Adenovirus type 5 E1B-55K slow (30 ± 60min) 
       XhoI                            XhoI  
E1B-S: 5’-T CGA GCT CAA CTG TAT CCA GAA CTG AGA CGC ATT TTG ACA ATT TC-3’ 
E1B-AS:3’-   CGA GTT GAC ATA GGT CTT GAC TCT GCG TAA AAC TGT TAA AGA GCT5’ 
             L  Y  P  E  L  R  R  I  L  T  I 
 
1 µl of the oligonucleotides at a concentration of 0.05 µM were annealed in annealing buffer 
at 95°C for 4 min. The vector was XhoI digested and purified by gel extraction and then 
dephosphorylated. The annealed oligos were phosphorylated and ligated with the 
dephosphorylated vector using the rapid DNA ligation kit. The ligated mixture was 
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transformed into competent cells. Mini preps were performed and plasmids isolated. All the 
cloning was done in the lab of Dr. T. Heise.  
 
2.2.26 Induction of apoptosis in transfected cells 
On apoptosis induction, it would be expected that the WT hLa protein which is 
predominantly in the nucleus should be translocated into the cytoplasm (223). Apoptosis 
induces cleavage of the La protein and the aim was to reproduce the cleavage of La on 
apoptosis induction using known apoptosis inducers such as UV or chemical compounds 
like epothilone.  
 
2.2.26.1 Induction using UV 
HeLa cells were transfected with the GFP La plasmid and were allowed to grow for 48 hours 
before they were exposed to 100 J of UV light. Therefore, all media was aspirated to allow 
for proper apoptosis induction of the cells by placing the culture dish in a Stratagene linker 
and irradiating with UV. Then fresh medium was added to the cells and they were observed 
at different time points for cellular translocation of the La protein from cell nucleus to the 
cell cytoplasm. The cells were fixed in 3.7% formaldehyde for 10 min and washed with PBS. 
Then the coverslips were mounted in Mowiol containing npg and observed using 
fluorescence microscopy. The controls were transfected cells without UV treatment. 
 
2.2.26.2 Induction of apoptosis using chemicals 
A549 (lung carcinoma cells) were transfected with the pEGFP WT La and pEGFP NES WT 
La plasmids and were grown for 48 hours before they were treated with epothilone which 
induces apoptosis at a concentration of 50 ng/ml (283). The cells were fixed with 3.7% 
formaldehyde for 10 min and washed with PBS. The coverslips were mounted in mowiol 
containing npg, observed by fluorescence microscopy and photographed. The controls were 
transfected cells without epothilone treatment. 
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2.2.27 Cygnet La construct 
The pcDNA 3.1 (-) -Cygnet-2 vector was kindly provided by Dr. Dostmann (275), University 
of Vermont, U.S.A. This vector has a fluorophore on either end, the ECFP at the C terminal 
end and the EYFP at the N terminal end. The other plasmids used for this cloning were 
pEGFP-La WT and pQe9. The Cygnet vector was digested with EcoR I/Xho I to remove the 
ECFP-PKG-EYFP cassette. The products after the digestion were cygnet EcoR I/Xho I vector 
(about 5400 nt) and ECFP-PKG-EYFP cassette (about 3225 nt). The pQe9 was digested with 
EcoR I/Xho I resulting in fragments with 90 nt and 3350 nt. Ligation of the ECFP-PKG-EYFP 
cassette into the pQe9-EcoR I/Xho I digest resulted in a pQe9-ECFP-PKG-EYFP fragment. 
This was then digested with Sac I and Sph I enzymes and the PKG fragment was removed. 
The elution resulted in a pQe9-ECFP-SphI-SacI-EYFP fragment. 
A La fragment was raised by PCR using oligonucleotides 54AS/53S containing restriction 
sites for SphI and SacI. The PCR amplified La fragment was cleaved with Sph I and Sac I, gel 
eluated and ligated into the pQe9-ECFP-Sph I-Sac I-EYFP, leading to a ECFP-La-EYFP 
fusion cDNA. This part was removed by EcoR I/XhoI digestion from pQe9-ECFP -La-EYFP 
and ligated with cygnet EcoR I/Xho I cleaved vector resulting in the pcDNA 3.1 (-)-La-
Cygnet-2 vector. The La borders were then sequenced to confirm in-frame ligation. All the 
cloning was done in the lab of Dr. T. Heise. 
 
2.2.27.1  Fluorescence activated cell sorting (FACS) 
HeLa cells transfected with the Cygnet La plasmid were sorted in a Mo Flo cell sorter (Dako, 
formerly Cytomation). The sorting was done based on the YFP fluorophore. The cells were 
sorted twice to have about 90% or more positively transfected cells. The sorting could also 
be done using the ECFP fluorophore. However it was found that EYFP, which gave a much 
stronger signal, was easier to sort. The software used to obtain graphs and follow the entire 
sorting procedure was Summit (version 3.1). The sorted cells were then lysed as described in 
the next section. 
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2.2.27.2  Lysis of transfected cells 
Mammalian Cell Lysis Buffer:  
150 mM NaCl pH 7.4, 10 mM Tris HCl pH 7.4, 0.5% NP40, 1X protease inhibitor 
 
The cells obtained after sorting were centrifuged at 1000 rpm for 3 min and resuspended in 2 
times (the volume of the cells) as much mammalian lysis buffer, according to a published 
protocol (284; 284). These cells were lysed for 10 min at 4°C. Later this lysate was centrifuged 
at 9300 rpm (10,000 g) for 10 min and the supernatant was carefully transferred into another 
eppendorf tube. This was then stored at -20°C and used for all further experiments. 
According to this lysis procedure, the supernatant contains the cytoplasmic contents of the 
cells and the pellet contains the unlysed nuclear fractions.  
 
2.2.28 FRET in vivo measurements 
HeLa cells were grown in chambers having a coverslip bottom. Transfection of the cells was 
done on these chambers using Fugene 6 transfection reagent. The ratio of transfection 
reagent used to the µg of DNA was 3:1. The cells were excited with light of wavelength 458 
nm and emission spectra were recorded from 467 to 628 nm. The lens used was Plan Neo 
Fluar 100X Oil with a NA of 1.3. Then a certain defined region in a transfected cell was 
selected for photobleaching. This area was bleached for up to 8 min with 514 nm laser light 
that excites and bleaches the acceptor (EYFP). Hence this method of photobleaching is called 
acceptor photobleaching. After this, emission spectra were again recorded for the defined 
region as well as for the whole cell. The detector used in this case was a Meta detector and 
the software used for analysis was LSM 510 version 3.2.SP2. The filters used for imaging 
were with a band pass (BP) of 475 nm to 525 nm for ECFP and 530 nm to 560 nm for EYFP.  
 
2.2.29 FRET in vitro measurements 
2.2.29.1  Lysis of transfected cells 
HeLa cells were transfected with the cygnet La plasmid and allowed to express the protein 
for about 36 to 48 h before they were sorted. Sorting was done on the basis of the EYFP 
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fluorophore. The sorted cells were lysed in cell lysis buffer containing 150 mM NaCl, 10 mM 
Tris-HCl pH 7.4, 0.5% NP-40 and 1% protease inhibitor (according to the protocol from E. 
Chan et al.). The lysate was centrifuged at 10,000 rpm for 10 min at 4°C. The supernatant 
was used for all further experiments with protease digestion or FRET measurements in vitro.  
 
2.2.29.2   FRET measurement 
Emission spectra were recorded in quartz suprasil cuvettes for 400 µl of lysed cell samples 
(at 1 µg/µl) at excitation 430 nm for ECFP in the Fluoromax 3 fluorometer. The emission 
spectra were read from 480 nm to 560 nm, which is the expected range for EYFP emission. 
The spectra were exported from Instrument Control Center software and plotted in EXCEL 
for further comparative analysis.  
 
2.2.29.3   Protease digestion of cygnet La transfected Hela cell lysate 
Protease digestion buffer:  
200 mM Tris-HCl pH 6.9, 2 mM EDTA 
 
Protease digestion of wildtype La was carried out with Proteinase K (at 0.6 µg/ml, 1.8 µg/ml 
& 5.4 µg/ml), Chymotrypsin (25 µg/ml and 50 µg/ml) and Elastase (5 µg/ml and 90 µg/ml) 
(284). 1.5 µg of protein was digested in each case for 1 min, 10 min and 30 min and the 
reaction in each case was stopped by adding sample loading buffer and heating the sample 
for 3 min at 90°C. In case of Cygnet La, 50 µg of total cell lysate (cygnet La transfected HeLa 
cells) were digested with the same concentrations of restriction enzymes. And for the FRET 
spectrum measurement, 500 µl of sorted cell lysate at a concentration of 1 µg/ml were 
digested and used to read spectra. 20 µl of the digested sample was stored at -20°C after 
stopping the reactions with an appropriate amount of loading buffer, until it was loaded on 
an SDS page, blotted (western blotting) and bound to primary anti-La antibody 4B6. ECL 
detection was carried out after binding with HRP conjugated Goat anti-mouse secondary 
antibody.  
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3 Results and Discussion 
 
3.1 Cell based assays on a novel platform for chemical synthesis 
3.1.1 Comparison of the growth of different mammalian cell lines in response to patch 
surface chemistry 
The main aim of this study was to establish a platform where cell based assays could be 
carried out on the same polypropylene (PP) plastic surfaces (referred to as PP foils or 
patches) having small molecules synthesised on them. On standardization, these assays 
would serve as a platform to screen libraries of small molecules against cells transfected 
with the La protein in order to identify compounds or peptides that would activate a 
protease that can target the La protein. The patches used for the cell based assays are shown 
in figure 1-5. 
 
 
Figure 3-1. Steps involved in preparing the PP foils for synthesising small molecule compounds on 
the patches.  
A mask was printed or plotted on the hydrophobic foil followed by ozone treatment. The mask was 
then removed and the foil is ready for graft polymerisation creating hydroxyl groups on the 
individual patches. Derivatisation creates amino groups on which further synthesis was carried out. 
These foils are UV sterilised before they can be used to grow cells. 
 
Hydrophilic patches were created on PP foils by subjecting pre-masked foils to ozonolysis 
(see figure 3-1). Further chemical reactions were possible by polymerisation of different 
monomers (as described in section 2.2.17). Once the foils were ready, they were UV sterilised 
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for cell growth. Cell lines were tested for their suitability for growth on the patches. They 
were pipetted on to individual hydrophilic patches in their respective media requirements 
(as listed in section 2.2.18). A total of ten commonly used cell lines were tested on the 
patches.  
 
3.1.2 Response of cells to the functional groups present on the patch surfaces 
Cell lines were tested for their response to the surface chemistry used on the foils. Different 
functional groups were generated and cell behaviour towards these groups was observed. 
These behavioural assays were performed in order to be able to decide which surfaces and 
spacers could be used for the synthesis of compounds. From the ten cell lines tested on the 
different surface chemical modifications (see appendix 6.1), HepG2, Huh7 and Hela were of 
importance for this project as these most closely resembled human liver cells. At first, the 
reactions to simple surface chemical modifications (patches 1, 9, 10, 11, 13, & 15 as can be 
seen in the appendix 6.1) such as surfaces with hydroxyl and aldehyde functions were 
observed. Later a series of patches were synthesised with more complex surface chemical 
modifications including methyl and amino functions (patches V1 to V14), which could 
eventually be involved in synthesizing the different compounds on the patches. In each case 
a cell viability staining using trypan blue was done on the patches after cell growth in order 
to observe cell death on the individual patches. Based on cell growth, cell death and cell 
adherence, the suitability of the patch surfaces for cells was decided (see figure 3-2 for 
examples of how patches were graded based on cell behaviour). 
Surface modifications with hydroxyl functions on ozonolysis gave the best results where 
cells grew as they did on coverslips. Amino functions were in comparison not as good, 
however they were rather important since they would form the basis for peptide synthesis 
on patches. Hence an effort was made to optimise cell growth on these. Examples of cell 
behaviour to patches can be seen in figures from appendix 6.1 and based on the gradation 
scheme used are summarised in table 6-1. 
In this study Jeffamine has been used as a spacer. The JEFFAMINE® polyoxyalkyleneamines 
are a part of an ever-expanding family of polyether compound products. They contain 
primary amino groups attached to the terminus of a polyether backbone. They are thus 
"polyether amines” (poly(propylene glycol)bis 2-(aminopropyl) ether). The polyether 
backbone is based either on propylene oxide (PO), ethylene oxide (EO), or mixed EO/PO. 
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Newer products may contain other backbone segments and varied reactivity provided by 
hindering the primary amine or through secondary amine functionality. The basic 
JEFFAMINE® product family consists of monoamines, diamines, and triamines, which are 
available in a variety of molecular weights, ranging up to 5,000. The wide range of molecular 
weights, amine functionality, and oxide type and distribution provides flexibility in 
synthetic design of compounds made from JEFFAMINE® products.  
The 130er and 500er Jeffamine (J130 and J500 respectively) have been used in this study as 
short and long spacers. Jeffamine spacers have been employed to tether antibodies to silicon 
wafer surfaces for the purpose of improving the orientation of antibody as well as reducing 
the steric hindrance (285). Other biological applications of Jeffamine include its use in 
reducing the calcification of bio-prostheses such as heart valve tissues in rat models (286; 
287) 
 
 
Figure 3-2. Examples of cell behaviour towards patch chemistry 
The functionalisation methods used to obtain the different functional groups are listed. Also listed is 
the status conferred on each of the individual patches which depict whether the patch was considered 
acceptable or unfavourable based on a system of grading the growth of cells and viability on the 
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patches, Grade 1 (being the least acceptable growth) to Grade 5 (being excellent growth comparable to 
cell growth on glass coverslips). Since a quick screen was done visually based on which the suitability 
of the patches was determined, examples have been given of favourable patches for cell growth and 
less favourable ones. The examples given are of Hela cells grown on the respective patches, depicting 
conditions necessary for a patch to be considered acceptable. The cells depicted in each view are HeLa 
cells grown on 4 patches with different surface modifications. Panels (a) and (b) depict patches where 
cell growth was excellent (Grade 5) and good (Grade 3) respectively hence leading to these patches 
being classified as favourable for cell growth. Panels (c) and (d) depict cell growth on less favourable 
patches. These criteria determine which steps can be used during the chemical modification 
favourably for cell growth. The chemistry on the patches was intended to depict the various stages of 
small molecule synthesis. This would form the basis for the chemical modification steps which would 
ultimately be chosen to give rise to full length peptides. (Magnification: 90X, DMA: N, N-
Dimethylacetamide, ThMAA: 2-N-(Acryloyloxyethyl)-N-methyl 1 thiophenecarboxamide). 
 
It was observed that in general, cells preferred patches with amino groups on a shorter 
spacer as compared to the same groups on a longer spacer. This thus led to testing of 
patches with variable linker length (J130 and J500) and surface charge of the individual 
compounds, in this case completely synthesised peptides (section 3.1.3).  
 
3.1.3 Response of cells to the property of an individual peptide and the length of 
spacers used 
The responses of different cell lines to the charges of compounds synthesised on the surface 
as well as the effect of length of a linker were studied (figure 3-3 and appendix 6.2). The 
130er and 500er Jeffamine (J130 and J500 respectively) have been used in this study as short 
and long spacers. Peptides that were highly basic (KKKK), acidic (DEDE), non polar 
hydrophobic (AVAV) and polar uncharged (GQGQ) were used to test the four extreme 
conditions of surface charge. It was observed that the cell lines were sensitive to surface 
charge as well as to length of the linkers used. The effect of charged surfaces was tested in 5 
different cell lines (see appendix). Cells grown on patches with shorter spacer showed better 
growth and less cell death on trypan blue staining as compared to cells grown on patches 
with a long linker having the same peptide sequences as can be clearly observed in the 
figure 3-3. Also, in both cases, the patches with basic peptides (KKKK) showed better results 
as compared to the patches with non polar hydrophobic (AVAV). The acidic (DEDE) peptide 
and the polar uncharged peptides (GQGQ) resulted in a lot of cell death upon trypan blue 
staining. These are overall generalizations since the individual cell lines showed some 
variations. The length of the spacer or the charge of the peptides did not seem to affect the 
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HepG2 cells and PtK2 cells. However, the effect of the length of the spacer was profound in 
HeLa cells and Huh7 cells (appendix section 6.2).  
This thus led to the conclusion that the type of surface chemistry on the patches influences 
the behaviour of the cells. Also, this varied from cell line to cell line. As with all high 
throughput techniques, the use of these patches would need some optimization especially 
for more sensitive cell lines as compared to the more robust ones. Also, it is important to 
note that in this case the tests have been made with peptides that were highly charged 
whereby the extreme results observed, can thus be justified. The results obtained from the 
experiments in this section enabled the further testing of the patches for full length peptides. 
 
 
Figure 3-3. Comparing cells grown on PP foils synthesised with highly charged peptides  
Behaviour of HepG2 cells towards the surface charge of patches as well as the effect of the length of 
these linkers used to link these peptides to the surface of the PP foils can be observed. (Magnification: 
90X, AVAV: non polar hydrophobic, DEDE: acidic, GQGQ: polar uncharged, KKKK: basic, PEG: poly 
ethylene glycol 
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3.2 Reproduction of morphological phenotypes on polypropylene foils 
 
Lamellipodia induction observed in 3Y1 cells plated on PLL coated patches 
In order to check for the reproduction of morphological phenotypes on the PP foils, it was 
essential to check the foils for the duplication of a simple cellular phenotype such as cell 
shape. The shape of a cell in a differentiated tissue is dependent on its interactions with its 
neighbours and the extracellular matrix. Acquisition of cell form during development 
requires cytoskeletal reorganisation which is closely coordinated with the establishment of 
junctional structures that couple the cytoskeleton to extracellular ligands through 
transmembrane interactions. The actin cytoskeleton plays a major role in shape 
determination but its own reorganisation is subject to modulation by extracellular 
interactions and by microtubule-dependent activities. It is an integrated array of 
interconnected filament-assemblies, each with a defined architectural organization. 
The most-cited assemblies of actin in cultured cells are stress fibres, lamellipodia and 
filopodia. Actin filaments are assembled into networks in lamellipodia and into radial 
bundles in filopodia. Lamellipodia are thin veil-like extensions of the cell periphery and 
comprise of a planar meshwork of unipolar actin filaments whose fast-growing plus ends 
are oriented outwards. Depending on cell type and condition, the lamellipodium can vary in 
breadth from ~1 µm to 5 µm and can exhibit highly variable numbers of radiating bundles 
0.1–0.2 µm in diameter and many micrometers long. 
The lamellipodium tip engages protein complexes to drive actin polymerisation (288). 
Fibroblastic cells attached to a substrate extend lamellipodia and filopodia in the direction of 
cell locomotion. Although much of what is known about the dynamics of the actin 
cytoskeleton in vertebrate cell shape development comes from studies of cells spreading, 
moving and associating in tissue culture — an essentially artificial environment, yet it is 
expected that the general principles in culture are also be applicable in vivo. Cell migration 
is modulated by a variety of factors such as regulatory peptides, metabolic substrates, 
cytokines, integrins, the extracellular matrix and polyamines. Cell culture is dependent on 
proper anchorage of cells to the growth surface. Poly-L-lysine is commonly used as adhesive 
molecule. Other biological molecules used to coat surfaces on which cells grow include 
fibronectin, laminin and other polyamines. Alternatives to these molecules such as 
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electropolymerization of different polymers (289) or growth on polyacrylamide films (290) 
has also being tested. 
Spreading of fibroblastic cell types like Swiss 3T3 has been studied on PLL coated surfaces in 
order to elucidate the molecular mechanisms of how different patterns of actin cytoskeletons 
are determined (291). Migration and invasion assay platforms are well established and 
readily available through companies such as BD Biosciences and Chemicon. These assay 
platforms help study chemotaxis in cells and factors that affect cell motility. 
In 2001, Nakagawa et al. showed that lamellipodia were induced in 3Y1 cells by culturing 
these rat fibroblasts on poly-L-lysine substrates (280). This led to the loss of the characteristic 
fibroblastic morphology and acquisition of a round phenotype of the 3Y1 cells on PLL 
treated coverslips. Similar results were obtained in studies done using other cell types such 
as transformed NIH3T3 cells grown on poly-D-lysine (292). Hence, this phenotype was 
chosen in order to test whether the surface of PP foils allowed cells to react to the chemicals 
coated on its surface. 
 
 
 
Figure 3-4. Repetition of cellular phenotypes on polypropylene surfaces 
Morphology of 3Y1 cells grown on coverslips (b) as compared to those grown on patches (d) coated 
with poly-L-lysine (PLL). Panels (a) and(c) serve as the respective untreated controls. Single cells are 
photographed at a magnification of 630X with oil. 
  
The 3Y1 cells seeded on to the patches treated with poly-L lysine depicted the characteristic 
round morphology as shown by Nakagawa et al. in 2001 (as seen in figure 3-4, see section 
2.2.23.1 for detailed procedure). This required some optimisation with respect to the 
molecular weight of PLL, time for coating the patches and time point of observation of cells. 
According to Nakagawa et al., the coverslips were coated for 30 min and the lamellipodia 
formed were observed after plating the 3Y1 cells on the coverslips as early as after 1 h. For 
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the patches, it was observed that 3 h of coating with PLL and overnight growth of the cells 
on the patches gave the best results. Molecular weight of PLL used was 150,000 to 300,000.  
As in the case of all surfaces, with a little optimisation the PP foils can be used quite well for 
cell based assays. Nevertheless, the reproducibility of this phenotype on PP surfaces proved 
that this surface allows the cells to show special phenotypes as seen on glass (coverslip) 
surface. And hence, these foils were further tested for the reproducibility of phenotypes in 
patches with fully synthesised peptides.  
 
 
3.3 Inhibition of cytokinesis by the DT -2 peptide 
 
Another fairly easy to observe cellular event that has been extensively studied is cytokinesis. 
Cytokinesis is the final event of the cell cycle and is the process that divides one cell into two 
daughter cells. Anti-mitotic compounds such as Disorazol A1 have the ability to inhibit 
tubulin polymerisation and thus have cytostatic activities (293).  Anti-mitotic therapies that 
target tubulin are known to be effective and widely used to treat cancer. Anti-mitotic drugs 
such as Docetaxel and Paclitaxel act by stabilizing tubulin whereas others such as 
Vinblastulin act by de-stabilizing tubulin (294). In this study, peptides that inhibit 
cytokinesis were examined. These would be synthesised on the patches and presented to 
cells grown on the patches. 
The sequence LRK5H, was identified by iterative deconvolution of every amino acid as a 
peptide sequence with the highest binding affinity for cGMP–dependent protein kinase Iα 
(cGPK). This sequence when fused to the membrane translocation signals from HIV-1 tat 
protein forms the DT -2 peptide (YGRKKRRQRRRPP–LRK5H) providing an efficient 
method for intracellular delivery (281; 295). The DT -2 peptide decreased NO-induced 
dilation in pressurised cerebral arteries. This peptide was also checked in proliferative cells 
(unpublished results Dostmann W. R. G., Sasse F. and Tegge W.) and was found to inhibit 
cytokinesis. A simple yet prominent morphological phenotype induced by peptides was 
required to test for cell growth on full length peptides. Hence, this peptide was used to test 
whether the compounds that were synthesised on the patches could induce the same 
morphological phenotypes they were expected to as when they were added externally to 
mammalian cells.  
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PtK2 cells (Rat kangaroo kidney epithelial cells) were tested on PP foils synthesised with the 
DT -2 peptide (synthesis done by U. Beutling). The DT -2 peptide is a highly charged 
peptide. Therefore, the Pep-1 peptide having the sequence Ac-
KETWWETWWTEWSQPKKKRKVC(SH)- amide (also highly basic) was chosen as a 
negative control. The Pep -1 peptide mediates protein import of β –Gal (296). Both the D and 
L amino acid forms of the DT -2 peptide were externally added to the cells growing on non –
synthesised patches as positive controls. The synthesised DT2 peptide was designed to 
release into cell culture media because of the ability of the carboxy-Frank-linker used here to 
be cleaved by solutions having neutral pH (see section 2.2.18). PP foils with amino functions 
and Jeffamine 130 were coupled with the linker preactivated with HOBt and DIC. After 
spotting of the linker solution on the foil, the DT-2 peptides were coupled and peptide 
synthesis was as done in section 2.2.17. The foils with the DT-2 peptide synthesised on them 
were used for cell based assays. These foils were first washed with ethanol and PBS pH 6.5. 
PtK2 cells were added to each patch and were allowed to grow on the patches for 2 days at 
37°C. Thus the DT-2 peptide was available to the cells grown on the patches on the addition 
of cell culture media (DMEM). After this, the patches with cells were washed with PBS and 
fixed with 37% formaldehyde for 10 min. The cells on the patches were stained using anti-
tubulin antibody and detected using a fluorescence microscope.  
The cells were treated with the DT -2 peptide for 2 days and then observed. Treatment with 
the DT-2 peptide (both synthesised as well as externally added) resulted in cells where the 
inhibition of cytokinesis caused cells to have more than one nucleus (predominantly 2 nuclei 
but at times up to 4 nuclei in cells). This effect was also observed in both the externally 
added D- and L- DT -2 peptides. In each case, the cells were compared to cells growing on 
coverslips. The cells treated with Pep -1 peptide did not show any inhibition of cytokinesis 
(figure 3-5a). These cells were similar to untreated cells grown on coverslips and patches. 
 The foils were thus successfully used for the synthesis of small molecules; in this case 
peptides. In addition, the loading of the peptides on the patches was sufficient to see a 
phenotypic effect of these on cells. Hence, these conditions can be used as initial conditions 
for optimising any further assays performed with either random or directed screening of 
compound libraries synthesised on these patches.  
Further optimisation of delivery of peptides in general presented to cells in this manner is 
possible by synthesising peptides that are capable of penetrating the cell membrane. Such 
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peptides are called protein transduction domains (PTD) or cell permeable peptides (CPP). 
They are derived from naturally occurring proteins such as anti-DNA mouse 
immunoglobulin (297; 298), DNA binding domain (homeodomain) of Drosophila 
transcription factor Antennapedia (299), the HSV-1 structural protein VP22 (300) and the Tat 
protein of human immunodeficiency virus type 1 (HIV-1) (301; 302) or artificially designed 
peptides (303). Such modifications can be incorporated into the synthesised peptides for a 
more efficient delivery into cell based assays. 
 
Figure 3-5. Effect of the DT -2 peptide on PtK2 cells.  
The panel to the left shows PtK2 cells grown on the patches (a,c,e,g) and on the coverslip(b,d,f,h)s 
which were treated with externally added peptides. The panel to the right (i,j,k,l) shows patches with 
the DT2 peptide synthesised on which PtK2 cells have been grown. Cells grown with the Pep 1 
control peptide externally added to patches and coverslips (a,b) showed no effect and were similar to 
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those that were untreated (g,h). On the patches synthesised the DT2 peptide is present as both D and 
L amino acids externally added. In the control (a,bg,h) all the cells have a single nucleus. In the cells 
grown on patches with the DT2 peptide or the patches or coverslips where the DT2 peptide is 
externally added, the presence of cells with two or more nuclei is observed, as pointed out with the 
red arrowheads. Magnification: a to j are 400X and k,l are 1000X (oil). 
 
 
3.4 Fluorescence based readouts for cell based assays based on La 
 
In order to test for the cleavage of the La protein inside a cell, a sensitive yet efficient method 
was required. The La protein was cloned into a cygnet vector based on fluorescence 
resonance energy transfer with the aim to exploit changes in FRET signal by the intended 
induction of La cleavage. This would enable the rapid screening of compounds using 
changes in emission spectra of cells transfected with the cygnet La protein.  
Fluorescence resonance energy transfer (FRET) is a non-radiative process where energy from 
a donor is transferred to an acceptor when they have overlapping emission/ absorption 
spectra with a suitable orientation and distance (in the range of 10–100 A˚). FRET was 
described about 60 years ago (304) and enables the study of molecular interactions with an 
optical microscope well beyond the resolution limit of light microscopy. This phenomenon 
occurs when the proximity of a suitable pair of spectrally distinct fluorescent molecules is 
sufficiently close (between 1 and 10 nm) for a radiationless transfer of energy via a dipole-
dipole interaction from the excited fluorophore (donor) to the second fluorophore (acceptor). 
Since transfer efficiency is dependent upon distance between the acceptor and donor, this 
technique is inherently sensitive to small physical changes in proximity. Förster distance, 
defined as the distance between the donor and acceptor where the average efficiency of 
energy transfer is 50%, is used when estimates of intramolecular distances between 
molecules are desired. The principles of FRET have been reviewed in detail by Pollok and 
Heim (305). 
Green fluorescent protein (GFP) is a spontaneously fluorescent protein which has been 
commonly adopted as an excellent reporter module of the fusion proteins (306). An 
important feature of GFP is that variants of GFP have showed distinguished spectral 
properties which can be used as donors and acceptors of FRET (307; 308). The original pair 
of fluorescent proteins was a blue fluorescent protein (BFP) donor and a GFP acceptor with 
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relatively low quantum yield, easy bleaching, and high autofluorescence background (308). 
To overcome these drawbacks, a pair of GFP mutants with longer wavelengths, namely cyan 
fluorescent protein (CFP) and yellow fluorescent protein (YFP), has been reported with 
improved FRET efficiency (307; 309-311). 
It is possible to study both intramolecular FRET or intermolecular FRET by fusing two 
spectrally overlapping GFP variants to two different regions of the same protein or to two 
different proteins facillitating the study of protein-protein interactions or protein 
conformation changes (312). Commonly, FRET is employed to visualise protein-protein 
interactions by targeting the desired cellular constituents with fluorescent dyes, fluorescent 
antibodies and/or fluorescent proteins. A cellular target is labeled with a donor fluorophore 
while another is labeled with an acceptor fluorophore. If the fluorophore labeled proteins 
are intimately associated (Fig. 3-6), excitation of the donor molecule will produce an 
emission at the acceptor wavelength. (Periasamy and Day, 1999; Sekar and Periasamy, 2003).  
 
 
 
Figure 3-6. FRET schematic using CFP and YFP fusion proteins. 
No energy transfer: Excitation of a donor fluorophore (D) sufficiently separated from its acceptor 
fluorophore (A) will result in only donor emission. 
FRET energy transfer: Excitation of a donor fluorophore (D) within approximately 10nm of its 
acceptor fluorophore (A) will result in acceptor emission and quenched donor emission. 
 
The development and use of sensors based on the genetically encoded variants of green-
fluorescent proteins has facilitated the observation of 'live' biochemistry on a microscopic 
level, with the advantage of preserving the cellular context of biochemical connectivity, 
compartmentalization and spatial organization. Protein activities and interactions can be 
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imaged and localised within a single cell, allowing correlation with phenomena such as the 
cell cycle, migration and morphogenesis (313; 314). Although new GFP variants are being 
created to act as better FRET pairs (170; 315; 316), CFP and YFP have been used commonly 
as FRET pairs in a variety of studies as can be seen in the table below.  
 
 Application FRET pair used Reference 
Kinases cAMP indicator in 
cardiac myocytes and 
transgenic fruit flies 
CFP- YFP (317; 318) 
 Calmodulin based Ca2+ 
binding 
ECFP -EYFP (319; 320) 
 GMP related neural 
studies 
BFP- GFP (321) 
 Protein phosphorylation CFP- YFP (322) 
 Signal transduction 
pathways 
CFP - YFP (323) 
Cell based Cell motility  CFP- YFP (324) 
 Cell membrane lipid rafts CFP- Fast DiI (325) 
 Nuclear transport 
 
Vesicle transport 
ECFP- EYFP 
 
CFP- YFP 
(326) 
(327) 
 Hormonal studies 
Growth factors 
UCP-oyester 556 
fluorescein/rhodamine 
and Cy3/Cy5 
(328) 
(329) 
Immunological 
responses 
Study structures of 
biomolecules involved in 
malignancy of tumours 
CFP-YFP 
Alexa Fluor 594 
hydrazide & Alexa 
Fluor 488-SE 
(330) 
(331) 
 Viral/pathological studies EBFP- GFP 
ECFP-EYFP 
(332) 
(333) 
Cancer Tumour diagnosis 7-aminoactinomycin D 
Hoechst 33258 
(334) 
 Apoptotic signalling CFP- YFP 
CFP-YFP-mRFP 
(335) 
(336) 
Diseases Alzheimers CFP- YFP (337) 
 
Table 3-1. Examples of biological studies based on FRET 
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3.4.1 FRET spectra in vitro 
3.4.1.1 Sorting of cygnet La transfected HeLa cells  
The cloning of the wildtype La in to the cygnet vector was as described in section 2.2.27. This 
vector was kindly provided by Dr. W. Dostmann from the University of Burlington, 
Vermont, USA (275). Cloning was done in the lab of Dr. Tilman Heise at the HPI in 
Hamburg.   
HeLa cells transfected with the cygnet La plasmid were sorted in order to separate the 
transfected cells from the non-transfected cells. This was done based on the parameters for 
the YFP fluorophore. The excitation laser used was 488 nm. The cells were sorted twice for 
enrichment and purification respectively. The transfection efficiency attained was between 
8% to 18% and the samples contained about 80% transfected cells after sorting. In the figure 
3-7 below, region R3 represented the transfection efficiency. If needed, depending on the 
transfection efficiency, the cells were also subjected to an extra step of enrichment prior to 
the purification step. 
These sorted cells could not be maintained for more than three days in culture as they gave 
up the Cygnet La plasmid and became non-fluorescent cells in culture. On sorting, they 
were lysed and used for in vitro FRET studies in order to confirm that the Cygnet La protein 
on protease treatment displayed no FRET.  
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Figure 3-7. Sorting of Cygnet La transfected HeLa cells  
(A-C) FACS sorted untransfected control Hela cells, (D-H) FACS sorted Hela cells transfected with 
the Cygnet La plasmid. Region R1 (in A and D) represent the number of live cells. Region R2 (in B 
and E) represents the number of single cells. R3 and R4 represent the YFP positive and YFP negative 
cells respectively. G and H represent cells from the second sort. The transfection efficiency in this 
experiment is 7.9% (region R3 in F). A total of 3.78 x 105 cells are obtained for further in vitro FRET 
experiments after this FACS sorting.  
 
3.4.1.2 Protease mediated cleavage of the Cygnet La protein 
La is predominantly a nuclear protein. On transfection into mammalian cells, cygnet La is 
retained in the cytoplasm. This is most likely due to the cloning of the GFP molecule at the C 
terminus of the La protein. Cygnet La is probably not localised into the nucleus because the 
GFP masks the nuclear localisation signal (NLS). Despite this, the La protein obtained after 
transfection was fully functional and gave FRET readings in vitro. FACS sorting aided in 
further concentrating the cell lysate, since owing to the absence of a purification tag in this 
vector it was not possible to purify the La protein using affinity binding.  
Also, it was critical to mimic the conditions inside the cell where the La protein may be acted 
upon by proteases to trigger cleavage of the protein. One way to initiate this kind of 
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cleavage is through the induction of apoptosis, known to trigger the intracellular 
translocation of the La protein.  
In this study, this was reproduced in vitro using proteases to cleave the La protein (284). 
Treatment with Chymotrypsin (CT) yielded 3 fragments that were visible on the gel after 
silver staining but were no longer recognised by the anti–La antibody 4B6. Elastase and 
Proteinase K (PK) cleaved the WT La into smaller fragments with at least one fragment still 
recognised by the primary antibody 4B6 (figure 3-8).  
This was then repeated in Cygnet La using Elastase at 5 µg/ml and 90 µg/ml. These reactions 
were then stopped at 10 min and 30 min respectively in order to find the right conditions for 
Cygnet La cleavage (figure 3-9). Digestion with Elastase at 10 min did not show significant 
digestion at 5 µg/ml and 90 µg/ml, however cleavage was observed at 30 min. 
 
 
 
Figure 3-8. Controlled protease digestion of wildtype La protein to check for the cleavage pattern 
Lane 1: Chymotrypsin 25µg/ml, lane 2: Chymotrypsin 50 µg/ml, lane 3: Elastase 5 µg/ml, lane 4: 
Elastase 90 µg/ml, lane 5: Proteinase K 0.6 µg/ml, lane 6: Proteinase K 5.4 µg/ml, lane 7: Proteinase K 
1.8 µg/ml, lane 8: wildtype La 1.5 µg. Digestion with proteases was done for 30 min. a) Silver staining 
of 10% SDS PAGE Gel. b) ECL after binding the blotted membrane with primary antibody 4B6 and 
secondary antibody G anti-mouse conjugates with HRP. 
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Figure 3-9. Elastase digestion of the Cygnet La protein  
Elastase digestion of the Cygnet La protein to check for the cleavage pattern in 10 min and 30 min 
lane 1: Ladder, lane 2: Elastase digestion done at 5µg/ml at 10 min, lane 3: Elastase digestion done at 
90µg/ml at 10 min, lane 4: Elastase digestion done at 5µg/ml at 30 min, lane 5: Elastase digestion done 
at 90µg/ml at 30 min, Lane 6: Cygnet La protein undigested.  
  
Further, to check for possible cleavage sites in the individual fluorophores for Elastase, a 
time dependent cleavage was carried out and the blots after Western blotting were bound 
with anti-GFP antibody and detected by ECL. In order to check that the protease did not 
cleave the fluorophores, a time dependent protease cleavage of the cell lysate obtained from 
EYFP and ECFP vectors was done (from clonetech). Lysate from Hela cells transfected with 
either of these plasmids was subjected to Elastase digestion without cell sorting. Further 
experiments were done as in the case of the Cygnet La transfected HeLa cell lysates. It was 
observed that the fluorophores did not get cleaved over time with Elastase while the Cygnet 
La protein did. This can be seen in the following figures. The primary antibody used in this 
case was the anti-GFP antibody to detect for cleavage of the fluorophores.  
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Figure 3-10a. Elastase digestion of the ECFP protein 
ECL on binding with anti-GFP antibody after ECFP Elastase (ELS) digestion  
Lane 1: Ladder, ECFP ELS digestion at time points lane 2: 0 min, lane 3: 1 min, lane 4: 2 min, lane 5: 5 
min, lane 6: 10 min, lane 7: 15 min, lane 8: 30 min, lane 9: 60 min.  
The band in lane 1 is the 50 KDa band from the chemichrome western control ladder from Sigma. 
 
 
 
Figure 3-10b. Elastase digestion of the EYFP protein  
ECL on binding with anti-GFP antibody after EYFP ELS digestion  
Lane 1: Ladder, EYFP ELS digestion at time points lane 2: 0 min, lane 3: 1 min, lane 4: 2 min, lane 5: 5 
min, lane 6: 10 min, lane 7: 15 min, lane 8: 30 min, lane 9: 60 min.  
The band in lane 1 is the 50 KDa band from the chemichrome western control ladder from Sigma. 
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Figure 3-10c. Elastase digestion of the Cygnet La protein 
ECL reaction after Cygnet La digestion with ELS 
Lane 1: Ladder, Cygnet La ELS digestion at time points lane 2: 0 min, lane 3: 1 min, lane 4: 2 min, lane 
5: 5 min, lane 6: 10 min, lane 7: 15 min, lane 8: 30 min, lane 9: 60 min.  
The band in lane 1 is the 50 KDa band from the chemichrome western control ladder from Sigma.  
 
 
 
Figure 3-10d. Later time points of Elastase digestion of ECFP, EYFP and the Cygnet La protein 
ECL on binding with anti-GFP antibody after ECFP ELS digestion (lanes 2 to 4)  
EYFP ELS digestion (lanes 5 to 7) and Cygnet La digestion (lanes 8-10) 
Time points 120 min, 240 min, overnight in each case 
The band in lane 1 is the 50 KDa band from the chemichrome western control ladder from Sigma. 
 
These studies thus indicate that the Cygnet La protein is digested using the protease Elastase 
which does not digest the ECFP or the EYFP fluorophores themselves. Thus we were able to 
mimic the in vivo cleavage of the La protein by proteases. 
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3.4.1.3 Spectra from the digested Cygnet La lysates  
The lysate from the sorted HeLa cells (transfected with the cygnet La plasmid) was read in a 
spectrofluorimeter and the sample was excited with 430 nm for ECFP. Emission spectra 
were recorded in quartz suprasil cuvettes for 400 µl of lysed cell samples at excitation 430 
nm for ECFP in the Fluoromax 3 fluorometer. The emission spectra were read from 460 nm 
to 560 nm, which would cover the range for ECFP and EYFP emission. The first peak 
obtained at around 470 nm is the emission from the ECFP fluorophore and the peak at 
around 530 nm is from the energy transfer mediated excitation of the EYFP fluorophore. The 
spectra were exported from the Instrument Control Center software and plotted in EXCEL 
for further comparative analysis. 
 
 
Figure 3-11. Spectra obtained before and after treatment of Cygnet La in HeLa cell lysates with 
proteases  
Spectra obtained on excitation of the Cygnet La at 430 nm. The first peak obtained at around 470 nm 
is the emission from the ECFP fluorophore and the peak at around 530 nm is from the energy transfer 
mediated excitation of the EYFP fluorophore. The spectra in green are from the undigested Cygnet La 
from lysed transfected Hela cells. The spectra obtained after both Proteinase K digestion (in blue) and 
Elastase digestion (in red) 
  
The cygnet La lysate was also digested with Elastase and Proteinase K and the spectra were 
recorded again. The peak at 530 nm that could be observed in the undigested sample 
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disappeared after controlled protease digestion. These results are in accordance with the 
expected results on the cleavage of cygnet La.  
 
3.4.2 FRET spectra in vivo 
One of the techniques for measuring FRET is acceptor photobleaching: the increase in donor 
fluorescence after complete acceptor photobleaching is a measure of the FRET efficiency. It is 
often used as a relatively straightforward approach for determining FRET with conventional 
and confocal microscopy (338; 339). When FRET pairs are in close proximity, the donor 
energy is transferred to the acceptor molecule. Bleaching of the acceptor fluorophore will 
dequench the donor and result in increased donor emission (as depicted in figure 3-12).  
 
 
 
Figure 3-12. Simplified schematic of how acceptor photobleaching works.  
Quenched Donor (FRET): Excitation of a donor fluorophore that is (D) within 10 nm of its acceptor 
fluorophore (A) will result in acceptor emission and quenched donor emission.  
Acceptor Photobleach: Sufficient excitation to irreversibly photobleach the acceptor fluorophore (A) 
eliminates the potential for the acceptor to participate in energy transfer.  
Dequenched Donor: Excitation of the donor fluorophore (D) following acceptor photobleaching (A) 
will result in dequenched donor emission.  
 
When energy transfer occurs, the donor emission will be quenched because of the direct 
transfer of excitation energy to the acceptor. If the acceptor fluorophore is destroyed, FRET 
will be eliminated and the donor signal will be de-quenched. The increase in the donor 
signal resulting from de-quenching is a direct measure of the efficiency of FRET. The 
technique of acceptor photobleaching FRET (apFRET) exploits this characteristic, and 
measures the de-quenching of the donor signal in the regions of the cell where FRET had 
occurred. The apFRET method requires the selective bleaching of the acceptor, because any 
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bleaching of the donor fluorophore will lead to an underestimation of the de-quenching. 
Further, bleaching of the acceptor should be as close to completion as possible, since any 
remaining acceptor will still be available for FRET, again resulting in an underestimation of 
the donor de-quenching. One of the many advantages of FRET is that it is robust yet 
sensitive enough and can be miniaturised to be applied for high through-put based drug 
screening.  
Cygnet La transfected HeLa cells were excited with light of wavelength 458 nm and 
emission spectra were recorded from 467 to 628 nm in order to look for FRET. Acceptor 
photobleaching with the 514 nm laser resulted in bleaching of the EYFP molecules. This can 
be clearly seen by comparing figure 3-13.  
In figure 3-13b, the second peak at 530 nm is reduced due to photobleaching of the 
fluorophore. However, the control cell, where there is no photobleaching shows the same 
amount of EYFP intensity both before and after photobleaching, thereby serving as an 
internal control also against possible leakage of photobleaching or carrying over to the next 
cell. Emission spectra were again recorded for the defined region as well as for the whole 
cell (R3 and R2 respectively). At the same time, there is a visible increase in intensity of the 
ECFP after photobleaching depicting dequenching of the donor. The regions R2 and R3 both 
show an increase in the ECFP signal after photobleaching in figure 3-11. However the 
increase in the donor emission after photobleaching is still weak. This is proof of a weak 
FRET signal.  
Hence, FRET can be used in vivo as a method to screen for compounds that cleave the La 
protein. However, the cygnet La construct should be optimised further for a stronger FRET 
readout. This would be essential for high throughput screening assays where the intensity of 
the FRET signal could be a deciding factor for accuracy of the various automation steps. The 
length of the adjoining fragments between the La protein and the fluorophores should be 
modified to start with. Further quantification based on acceptor photobleaching can be done 
by calculating the FRET efficiency (339). Though this assay needs further optimisation on the 
patches for random library screening, these initial steps confirm that the cygnet La vector is 
functional and can be adapted for high through put screening.  
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Figure 3-13. In vivo FRET changes observed in HeLa cells on acceptor photobleaching  
Two Hela cells transfected with the Cgynet La plasmid are depicted in right panels. The left panels 
depict the spectra obtained from regions of interest within these cells. 
(a) Region ROI 1 depicts the entire cell 1 used as a control cell in this experiment. It is not subjected to 
acceptor photobleaching. Spectra from this region are in red. They remain unchanged both in panels a 
and b. 
(b) Region ROI 2 is drawn to include the entire experimental cell 2 (as shown in panel b). Acceptor 
photobleaching is done in ROI 3 in this cell. Spectra from ROI 2 (entire cell) are non green and spectra 
from the photobleached region ROI 3 are in blue. Both these spectra are increased in the emission 
range of the donor and reduced in panel after acceptor photobleaching in the emission range of the 
acceptor.  
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3.5 Alternative GFP La strategy 
 
3.5.1 Cloning of an NES into GFP-La vector 
The cygnet La FRET strategy for cell based assays for the screening and identification of 
compounds capable of triggering protease activities within a cell to mediate La protein 
cleavage as described in section 3.4 worked well both in vivo as well as in vitro. However, for 
reasons unknown, the cygnet La protein remained localised in the cytoplasm. It has been 
reported that upon induction of apoptosis, the La protein was cleaved by proteases (340). An 
assay that would allow the translocation of the La protein from the nucleus to the cytoplasm 
upon cleavage would enable the simple cellular event of translocation to be used as readout 
for the screening of compound libraries.  
WT La protein had been cloned in the pEGFP-N1 vector in Hamburg. Apoptosis induction 
experiments performed by Dr. Tilman Heise at the HPI in Hamburg didn’t yield the 
expected change in intracellular translocation with this plasmid and so for this project, it 
was essential to clone a nuclear export signal (NES) into this plasmid. The pEGFP -N1 vector 
from Clonetech has a size of 4.7 kb and a Kanamycin resistance marker. The GFP WT La 
plasmid was linearised with Sac I restriction enzyme and the insert was cut using Sac I/Hind 
III double digest. The cloning strategy for the NES WT GFP La has been described in section 
2.2.25. Cloning was attempted for all three nuclear export signals at the Xho I restriction 
enzyme site which lay between the GFP and the La sequences.  
From the 3 NES clonings that were attempted (based on the speed at which they traffic their 
cargo), the REV NES sequence was successfully cloned into the Xho I site between the GFP 
molecule and the La protein DNA and this plasmid was used for the apoptosis induction 
experiments below. The E1 B cloning was not successful and the PKI cloning was less 
effective as compared to the REV NES cloning (data from Dr. Tilman Heise, HPI Hamburg).  
 
3.5.2 Effect on compartmentalisation of the La protein in transfected A549 cells  
Epothilones represent a novel class of anticancer drugs which inhibit the cell cycle and 
strongly influence cell division. The biological activity of epothilones is associated with their 
capacity to bind to the protein tubulin of microtubules and to disturb the dynamic 
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equilibrium between microtubule assembling and disassembling. Consequently, in dividing 
cells, it leads to mitotic arrest and to apoptotic cell death.  
In taxane resistant tumours it is known to induce G2M arrest in many cell types. Exposure of 
human cancer cell lines to epothilone causes aberrant spindle formation during mitosis, 
which results in mitotic arrest at the metaphase/anaphase boundary and eventually 
apoptotic cell death (341). Studies with water soluble epothilone analogues such as BMS 
310705 show that this class of compounds can induce significant apoptosis, decrease 
survival and utilise the mitochochondrial–mediated pathway for apoptosis (283). 
The GFP NES La plasmid was transfected into A549 cells. Along side, the wildtype La 
plasmid was also transfected into A549 cells. The effect of treatment of these cells with 
epothilone on the cellular localisation of the La protein was studied. Epothilone is a known 
apoptosis inducer in mammalian cells (342) and has an IC-50 value of 0.23 ±0.05 nmole for 
net growth inhibition of A549 cells (342). La protein localisation was observed in the 
cytoplasm with cells having non-fluorescent nuclei in the case of treated NES WT La 
transfected cells. It has been shown that the La protein translocates into the cytoplasm on 
apoptosis induction (343). The same effect could be observed through this experiment in 
A549 cells. The GFP NES WT La and the GFP WT La untreated controls did not show this 
effect.  
Ayukawa et al. have reported that the La protein was truncated on apoptosis induction and 
cleaved by caspase-3 or closely related proteases at Asp-374 in the COOH terminus to form a 
43 KDa protein in HL-60 cells (340). In the EpoB induced apoptosis experiments, a complete 
translocation of the La protein from the nucleus to the cytoplasm was observed. Hence, the 
GFP NES WT La has an advantage over the WT La in the development of further screening 
assays using small molecules. With this assay now established, it will be possible to screen 
chemical libraries for compounds that can induce the cleavage of the La protein.  
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Figure 3-14. Effect of the induction of apoptosis on the intracellular localization of the La protein 
GFP NES La transfected A549 cells show translocation of the GFP La protein in the cytoplasm after 
treatment with epothilone (a-f). The GFP NES La control cells (g-i) as well as the GFP La (j-l) 
transfected A549 cells both show the distribution of the La protein predominantly in the nuclei. 
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3.6 Search for small molecule binders of the La protein 
 
3.6.1 Binding assays with radioactively labelled proteins  
Published work suggest that the La protein stabilizes the HBV mRNA by binding to the viral 
RNA. Horke et al. demonstrated that the RRM2 of La is required for binding of La to HBV 
RNA in vitro (272). Hence we postulate that a compound which binds specifically to the 
RRM2 might be able to block the interaction between La and HBV RNA. HBV RNA would 
be less protected and degraded. The aim of the following experiments was to establish a 
screening assays to detect peptides able to bind the La protein via the RRM2. The goal was 
to be able to detect sequences of small molecules that would not bind to the mutant La 
protein (Mut ∆2) but would bind to the wildtype La protein, thereby mimicking the binding 
of the La protein to the HBV RNA. The respective La proteins used for binding assays with 
libraries of small molecules needed to be easily detectable for comparison. One way to 
ensure this was to perform the assays with in vitro synthesised radioactively labelled 
proteins which would allow the quantification of the amount of bound protein. 
 
 
Figure 3-15. Wildtype (WT) La and Mutant (Mut) La plasmids after purification from E. coli DH5α 
Lane 1: Ladder, Lanes 2 and 3: Wildtype La plasmid purified from two different transformed colonies 
(hence labeled WT1, WT2), Lanes 4 and 5: Mutant La plasmid purified from two different 
transformed colonies (hence labeled M1, M2), Lanes 7 and 8: Eco RI digested wildtype La, Lanes 10 
and 11: Eco RI digested mutant La. The wildtype and mutant La plasmids have a size of 6.97 Kb and 
after Ecor RI/XhoI digestion the inserts have a size of 1.6 kb. 
   
The wildtype and mutant La plasmids were cloned in the pET-28 vector having a 
Kanamycin resistant marker for growth in E. coli, a size of 5.37 kb and a T7 promoter. The 
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size of the plasmids which were purified from E. coli DH 5α was confirmed on 1% agarose 
gels. Also these plasmids were digested O/N with EcoR I to linearise the plasmid and with 
EcoR I/Xho I double digest to remove the insert. The inserts had a size of 1.6 kb. The 
undigested plasmids had a size of 7 kb on the gel. The plasmids were purified using the 
Qiagen spin columns according to the manufacturer’s instructions and were further used for 
in vitro transcription & translation kit to produce radioactive proteins.  
 
3.6.1.1 Probe preparation 
The radioactive protein that resulted from the in vitro transcription & translation reactions 
was investigated on the gel. 2.0 µl of the reaction mixture was loaded on the gel. The gel was 
blotted and ECLs were performed for the identification of the La protein bands. Also 
afterwards the gels were exposed to X ray films and the radioactive signals emanating from 
the synthesised protein were investigated (figure 3-16). Thus although the quantities of 
recombinant La proteins produced were not sufficient for detection by ECL, 
autoradiography could detect these effectively.  
 
 
 
Figure 3-16. Radioactive probe for binding assays using SPOT membranes 
Lane 1: Ladder, Lanes 2 and 3: Radioactive Wt La protein and Mut La Δ2 protein obtained from the in 
vitro transcription & translation kit, Lanes 4 and 7: purified recombinant control La proteins (300 ng 
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and 600 ng in Lanes 4 and 7), Lanes 5 and 6: negative and positive controls from the Promega in vitro 
transcription & translation kit. All reactions were performed according to the manufacturer’s 
instructions. It is possible to detect the La proteins produced using the in vitro transcription & 
translation kit (in the autoradiography panel) and compare its size in the gel to the purified 
recombinant control La proteins (300 ng and 600 ng in Lanes 4 and 7 in the ECL panel). 
 
3.6.1.2 Binding assay with RR membranes 
SPOT peptide libraries of both L and D amino acids of hexamer and octamer peptides were 
screened with the La proteins to find possible binding partners. The aim was to find peptidic 
binding partners that could bind to the wildtype La and not with the mutant La. The 
binding assays were thus first done with the radioactive mutant La protein and after 
stripping of the membranes, were repeated with the wildtype La protein. After each 
stripping, the membranes were exposed to the Phosphorimager screens to check for effective 
stripping. The different libraries tried out are as listed below: 
 
Starting Libraries screened Sequence aa residues in spots 
Lib 17 LL  XXX12XXX spot signals with Arginine and Lysine residues 
Mixed 65 LL  XX12XX spot signals with Arginine and Lysine residues 
Lib 18 DL  XX34XX No signals 
Lib 18  DL   XXX45XXX No signals 
Lib 19 DC  XX34XX No signals 
Lib 19 DC  XXX45XXX No signals 
Lib 22  LC different 
mers   
Mutant spots similar to Wildtype spots in 
intensity 
 
Table 3-2. Libraries screened using binding assays with the Mutant and Wildtype La proteins 
The starting libraries screened and their sequences are listed. Also the defined amino acids of the 
spots obtained on binding are listed. 
(DL:D aa linear, LL:L aa linear, DC:D aa cyclic, LC: L aa cyclic) 
 
LL hexamer and octamer SPOT peptide libraries gave signals that had arginine or/and lysine 
in the known positions. However, binding assays with the LL octamer library resulted in 
spots that showed ‘’RR’’ spots lighting up with more intensity as compared to the Mutant La 
binding assays when compared with AIDA and Corel Chart softwares (figure 3-17).  
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Figure 3-17. Comparison of intensities within the Library 17 XXX12XXX after binding assays 
Comparison of intensities within the Library 17 XXX12XXX after binding assays with a) Mutant La 
protein and b) Wild type La protein using the Corel Chart software. Note that the wildtype La protein 
binds with a stronger affinity to “RR” spots and the mutant La protein Δ2 binds to “KK” spots with 
greater affinity.  
 
These were then used to generate the next set of libraries in order to unravel the exact 
sequence of the binding peptides. The next library used was thus Lib 20 LL XX1RR2XX. The 
same procedure was followed as for the earlier assays. These resulted in a series of spots, as 
was expected. 
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Figure 3-18. Comparison of intensities within the Library 20 LL XX1RR2XX 
Comparison of intensities within the Library 20 LL XX1RR2XX after binding assays with a) Mutant La 
protein and b) Wild type La protein using the Corel Chart software. Note the spots such as “SR”, 
“WM” and “WG” bound by the Wildtype La protein with higher intensity than the Mutant La protein 
Δ2. These are also plotted as a graph in the figure 3-19.  
 
Based on Mutant and Wildtype La spot comparisons, 25 spots were selected as listed below 
to make the next library. These were selected based on the intensity of the spots as in the 
earlier case. In this case, too, the positive spots were the ones that showed a higher intensity 
of binding with the Wildtype La as compared to the Mutant La protein binding assays with 
the same library.  
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Figure 3-19. Comparison of spot intensities bound by Wildtype La protein to the Library 20 
(PSL: Photo stimulated)  
 
As can be seen in the figure 3-19, the peptides with the ‘’SRRR’’ (serine, arginine) sequence 
give the highest signal. Also, peptides containing tryptophan (W) gave fairly strong positive 
results. Peptides containing lysine (K) also showed higher intensities. The 20 spots with the 
highest intensities were chosen as positive spots. In addition, 5 sequences were chosen 
which were in comparison, negative for the Wildtype La binding assay and at the same time 
positive for the Mutant La protein. These served as negative controls in the next set of 
libraries (figure 3-19). 
Some trends were further reconfirmed in this set of binding assays. The peptides with the 
structure XXKRRKXX showed higher intensity of binding in the Mutant La binding assay as 
well which was in accordance with the results obtained from the Library 17 results, where 
the lysine sequences showed a comparatively stronger intensity in Mutant La binding 
assays. However the spots with lysine residues such as XXVRRKXX showed a 
comparatively higher signal for Wildtype La binding assays as can be seen in the Corel 
Chart representations below.  
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Figure 3-20. Binding assays with the positive spots chosen from the screening of the Library 20 LL 
XX1RR2XX 
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3.6.2 Binding assay with PNA membranes 
These studies were carried out in an effort to identify PNA sequences that mimic the 
binding between the La protein with the Hepatitis B viral RNA. Peptide Nucleic Acid (PNA) 
libraries with 7 positions for variable nucleotides (a, t, g and c), from which the positions of 3 
for any given spot were known were screened. 
 
Starting libraries screened Sequence PNA residues in spots 
Lib 21 (1)  PNA   LC XBBBBBX Mut spots similar to WT 
Lib 21 (2) PNA   DC XBBBBBX Mut spots similar to WT 
Lib 21 (3)  PNA   LL XBBBBBX ‘’gg’’ spots  
Lib 21 (4)  PNA   DL XBBBBBX Mut spots similar to WT 
 
Table 3-3. PNA Libraries screened using binding assays with the Mutant and Wildtype La proteins 
PNA libraries screened and their sequences are listed. Also defined positions of the identified spots 
that showed binding are also listed. B stands for any of the four PNA bases. For the position X; the 
amino acids can be DL:D aa linear, LL:L aa linear, DC:D aa cyclic, LC: L aa cyclic. 
 
Again, as observed in the case of the Library 17, here too the libraries of PNA with linear 
sequences showed a positive lighting up of spots as compared to the Mutant La. The 
binding assays thus carried out, resulted in the lighting up of spots in the Wildtype La 
binding assays having two guanines in the sequence. However, spots with one or three 
guanines were found to show comparatively weak binding. Based on this, the next set of 
PNAs was synthesised.  
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Figure 3-21. Comparison of intensities within the Library 21 PNA LL XBBBBBX. 
Comparison of intensities within the Library 21 PNA LL XBBBBBX library after binding assays with 
a) mutant La protein and b) wildtype La protein using the Corel chart software. 
 
In this case, 15 positive and 10 negative spots were chosen using similar criteria as were 
used for Library 17. The spot with the sequences XggBBcX and XtgBBgX showed 
comparatively higher signals. However, further assays were not possible with these sets of 
libraries since the Amersham’s TNT kit used to make the radioactive La proteins failed to 
give the right molecular weight of the La protein or in some trials failed to make any at all. 
And hence, the binding assays were repeated with recombinant non-radioactive protein 
made in vitro in E. coli BL21.  
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Figure 3-22. Binding Assays with the positive spots chosen from the screening of the Library 21 
PNA LL XBBBBBX. 
 
At this point in the project, the in vitro transcription & translation kit from Promega yielded 
radioactively labelelled Wildtype and mutant La proteins of several sizes. A similar in vitro 
transcription- translation kit from Ambion was also tried, but this also did not yield 
radioactively labeled proteins of the right size.  
As an alternate, E. coli were transformed with wildtype and mutant La plasmids and the 
respective proteins were purified. Binding assays on SPOT libraries were repeated with the 
non-radioactive mutant and wildtype La proteins. Anti-La antibodies were used to detect 
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the La proteins bound to the cellulose membranes of SPOT libraries. The HRP-conjugated 
secondary antibodies used were detected using the enhanced chemiluminescence system 
from Amersham.  
These assays differed from the radioactive protein assays because they involved several 
steps, which eventually were not as sensitive as radioactive detection of the protein peptide 
interactions and binding. The binding assays gave no spots with the libraries that had to be 
repeated (Lib 17 and Lib 21 PNA). And hence, no further peptide sequences could be 
synthesised and tried. A more sensitive alternative to ECL is needed to repeat these binding 
assays. Some leads to begin with could be ‘’RR’’ spots from L amino acids linear octamer 
libraries or ‘’gg’’ spots from PNA libraries since the earlier binding assays with radioactive 
proteins showed rather promising results. 
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4 Conclusions and Outlook 
 
The main objective of this thesis was to develop a platform where cell based assays could be 
carried out on surfaces where chemical synthesis reactions were previously performed. This 
would enable the platform to be directly used for cell based assays once small molecule 
libraries are synthesised on it without the need to externally add the individual compounds 
to the cells.  
The SPOT libraries used for screening in this study have several advantages. They can be 
screened in-situ and can be reused several times. The need to store large compound libraries 
which rapidly degrade over time is eliminated. There is no need to repetitively check 
compound integrity. Also they require only a small repertoire of chemical building blocks to 
synthesise them. The use of these libraries gave good results for identification of at least 
partial sequences of peptides that could bind to the wildtype La protein. The only limitation 
was of a sensitive detection system.  
Such a platform was developed during the course of this thesis and tested for the growth of 
ten different cell lines commonly used for cell based assays. Cell growth was first analysed 
on polypropylene foils with simple chemical modifications and later fully synthesised acidic 
and basic peptides were also tested. The next step was to repeat known cellular phenotypes 
using this platform. 3Y1 cells grown on PP foils coated with poly L lysine showed the 
characteristic round morphology observed on lamellipodia induction. Also, cytokinesis was 
observed in PtK2 cell based assays using PP patches with DT-2 peptides synthesised on 
them. Thus, a polypropylene patch platform was established where synthesised small 
molecules resulted in observable phenotypes that could be documented using standard 
fluorescence microscopy procedures.  
The next goal was to develop cell based assays using the model La protein that could detect 
the cleavage of the La protein when screened using small molecule libraries. A cygnet La 
vector was developed for this purpose by the group of Dr. Tilman Heise at the HPI in 
Hamburg. The cygnet La protein was tested in in vitro as well as in vivo assays. The in vitro 
results show that on enzymatic cleavage, the cygnet La protein loses its FRET signal which 
can be detected using spectrofluorimetry. Also, in the in vivo assays, cygnet La transfected 
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cells exhibit loss of the FRET signal on acceptor photobleaching. Thus it is now possible to 
use this cygnet La vector to screen small molecule libraries for compounds that can activate 
proteases that can cleave the La protein by screening for loss of the FRET signal in 
transfected cells. For an alternative strategy, a GFP NES La construct was also developed in 
Hamburg to facilitate screenings for translocation of the La protein from the nucleus to the 
cytoplasm in transfected A549 cells on cleavage by small molecule compounds. This was 
tested using a chemical compound, Epothilone which is a known apoptosis inducer in cells.  
Also, recombinant radioactive wildtype and Mutant La proteins were used in binding assays 
with SPOT libraries to obtain peptide sequences that can bind to the Wildtype La protein 
and not to the Mutant La protein. The binding assays yielded partial sequences of peptides 
from LL XX1RR2XX libraries and PNA libraries with “gg” spots. It was not possible to 
obtain complete sequences since the in vitro transcription and translation kit did not yield 
the right size La proteins and repetition using other kits or non-radioactive proteins did not 
yield detectable results. However, the results obtained up to this stage were promising and 
should be further tested to obtain the complete sequences of these peptides. Such peptides 
could then be tested in cell based assays using the GFP NES La vector or the Cygnet La 
vector. Also, cells transfected with either of these two constructs can be used for carrying out 
cell based assays on PP foils synthesised with combinatorial libraries.  
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6 Appendices 
6.1 Behaviour of cells to patch chemistry 
Figure 6-1 to figure 6-10 compare cells grown on PP foils with different chemical functions (see 
Appendix 6.3 for more details).  
The left panels indicate cells grown on patches and the right panels are cells on patches stained with 
Trypan blue.  
 
   
 
Figure 6-1. Behaviour of L929 cells with respect to patch chemistry 
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Figure 6-2. Behaviour of HeLa cells with respect to patch chemistry 
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Figure 6-3. Behaviour of SKOV3 cells with respect to patch chemistry 
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Figure 6-4. Behaviour of Huh7 cells with respect to patch chemistry 
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Figure 6-5. Behaviour of A431 cells with respect to patch chemistry 
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Figure 6-6. Behaviour of A498 cells with respect to patch chemistry 
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Figure 6-7. Behaviour of PC3 cells with respect to patch chemistry 
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Figure 6-8. Behaviour of Ptk2 cells with respect to patch chemistry  
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Figure 6-9. Behaviour of 3Y1 cells with respect to patch chemistry 
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Figure 6-10. Behaviour of HepG2 cells with respect to patch chemistry 
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6.2 Behaviour of cells to patches with peptides synthesised on short and long 
spacers 
 
Figure 6-11 to figure 6-15 compare cells grown on PP foils synthesised with highly charged peptides.  
 
Figure 6-11 shows Hela cells, figure 6-12 shows Huh7 cells, figure 6-13 shows HepG2 cells, figure 6-14 
shows PC3 cells and figure 6-15 shows PtK2 cells.  
 
Behaviour of cells towards the surface charge of patches as well as the effect of the length of the 
spacers used to link these peptides to the surface of the PP foils can be observed.  
 
(Magnification: 90X, AVAV: Non polar hydrophobic, DEDE: acidic, GQGQ: polar uncharged, KKKK: 
Basic, PEG: Poly ethylene glycol 
 
 
Figure 6-11. Behaviour of HeLa cells with respect to surface charge 
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Figure 6-12. Behaviour of Huh7 cells with respect to surface charge  
 
Figure 6-13. Behaviour of HepG2 cells with respect to surface charge 
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Figure 6-14. Behaviour of PC3 cells with respect to surface charge 
 
Figure 6-15. Behaviour of PtK2 cells with respect to surface charge 
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6.3 Comparison of cells to patches 
These readings refer to Appendix 6.1. 
S
td
 
D
e
v
 
0.
00
 
1.
15
 
1.
06
 
1.
35
 
1.
16
 
1.
06
 
1.
27
 
0.
82
 
0.
71
 
1.
36
 
1.
24
 
1.
13
 
1.
24
 
1.
22
 
M
e
a
n
 
5.
00
 
4.
00
 
2.
30
 
2.
60
 
3.
30
 
3.
30
 
3.
50
 
4.
30
 
4.
33
 
2.
89
 
3.
56
 
2.
44
 
2.
44
 
3.
33
 
H
e
p
G
2
 
5 5 3 3 3 4 4 5 5 4 3 4 4 5 
3
Y
1
 
5 4 2 1 4 3 1 3 4 1 2 4 4 2 
P
tk
2
 
5 5 1 1 1 3 2 5 5 2 5 1 1 4 
P
C
3
 
5 2 2 1 2 3 3 4 4 3 4 3 4 5 
A
4
9
8
 
5 5 5 5 5 5 5 5 5 5 5 1 1 4 
A
4
3
1
 
5 4 2 3 4 1 3 4 4 1 2 2 2 3 
H
u
h
7
 5 5 2 3 4 4 4 3 3 4 5 3 2 3 
S
K
O
V
3
 5 4 2 4 4 4 4 5 4 3 3 2 2 2 
H
e
la
 
5 4 2 3 3 3 4 4 5 3 3 2 2 2 
L
9
2
9
 
5 2 2 2 3 3 5 5       
 
 p
la
in
 f
o
il
 
A
ld
eh
y
d
e 
fu
n
ct
io
n
s 
A
ld
eh
y
d
e 
fu
n
ct
io
n
s 
H
y
d
ro
x
y
l 
fu
n
ct
io
n
s 
H
y
d
ro
x
y
l 
fu
n
ct
io
n
s 
H
y
d
ro
x
y
l 
fu
n
ct
io
n
s 
H
y
d
ro
x
y
l 
fu
n
ct
io
n
s 
P
er
o
x
id
es
, H
y
d
ro
x
y
l 
fu
n
ct
io
n
s 
M
et
h
y
l 
G
ro
u
p
s 
A
m
in
o
 F
u
n
ct
io
n
s 
H
y
d
ro
x
y
l 
F
u
n
ct
io
n
s 
C
D
I 
p
re
 a
ct
iv
at
ed
 
su
rf
ac
e 
A
m
in
o
 f
u
n
ct
io
n
s 
 
C
o
v
er
sl
ip
 
P
P
 s
u
rf
ac
e 
G
lu
co
sa
m
in
e 
su
rf
ac
e 
w
it
h
o
u
t 
p
er
 
io
d
in
e 
cl
ea
v
ag
e 
C
H
O
 g
ro
u
p
s 
w
it
h
 G
lu
co
sa
m
in
e 
‘’
T
’’
 2
h
 O
zo
n
e 
+ 
P
o
ly
m
er
is
a
ti
o
n
 
‘’
H
’’
 0
H
- 
g
ro
u
p
s 
d
ir
ec
t 
o
n
 t
h
e 
su
rf
ac
e 
M
at
. ‘
’T
14
0’
’ 
10
h
 O
zo
n
e 
M
at
. ‘
’H
’’
 1
0h
 O
zo
n
e 
O
zo
n
o
ly
si
s 
P
o
ly
m
er
is
at
io
n
 o
n
ly
 w
it
h
 D
M
A
 
P
o
ly
m
er
is
at
io
n
 w
it
h
 A
P
M
A
A
D
M
A
 
P
o
ly
m
er
is
at
io
n
 w
it
h
 T
h
M
A
A
/D
M
A
 
P
o
ly
m
er
is
at
io
n
 w
it
h
 T
h
M
A
A
/D
M
A
 
an
d
 C
D
I-
ac
ti
v
at
io
n
 
P
o
ly
m
er
is
at
io
n
 w
it
h
 T
h
M
A
A
/D
M
A
 
+ 
D
ia
m
in
o
cy
cl
o
h
ex
an
e 
(D
A
C
H
) 
P
a
tc
h
 
N
r 
C
O
V
 
1 9 10
 
11
 
13
 
14
 
15
 
V
1 
V
2 
V
3 
V
4 
V
5 
V
6 
 
Appendix 164 
  
 
 
S
td
 
D
e
v
 
1.
17
 
1.
17
 
1.
17
 
1.
09
 
1.
30
 
1.
33
 
1.
20
 
1.
12
 
  
M
e
a
n
 
3.
89
 
3.
11
 
2.
89
 
2.
78
 
2.
78
 
2.
56
 
2.
78
 
3.
67
 
  
H
e
p
G
2
 
5 4 3 2 3 3 3 4 3.
76
 
0.
91
 
3
Y
1
 
4 3 4 4 1 1 2 2 2.
67
 
1.
31
 
P
tk
2
 
4 1 1 1 4 1 1 5 2.
57
 
1.
78
 
P
C
3
 
5 4 2 3 3 2 2 4 3.
10
 
1.
14
 
A
4
9
8
 
5 5 5 4 5 5 5 5 4.
52
 
1.
18
 
A
4
3
1
 
4 2 2 2 2 2 2 4 2.
62
 
1.
12
 
H
u
h
7
 2 3 3 2 3 2 3 2 3.
10
 
1.
01
 
S
K
O
V
3
 2 3 3 3 1 3 3 4 3.
10
 
1.
05
 
H
e
la
 
4 3 3 4 3 4 4 3 3.
24
 
0.
89
 
L
9
2
9
 
        3.
67
 
1.
41
 
 A
m
in
o
 
F
u
n
ct
io
n
 
A
m
in
o
 
F
u
n
ct
io
n
 
A
m
in
o
 
+ 
h
y
d
ro
x
y
l 
fu
n
ct
io
n
s 
A
ld
eh
y
d
e 
fu
n
ct
io
n
s 
P
o
ly
- 
L
y
si
n
e 
b
et
a 
A
la
n
in
e 
L
y
si
n
e 
H
y
d
ro
x
y
l 
fu
n
ct
io
n
s 
  
 P
o
ly
m
er
is
at
io
n
 
w
it
h
 
T
h
M
A
A
/D
M
A
 
+ 
Je
ff
am
in
 (
13
0e
r)
 
P
o
ly
m
er
is
at
io
n
 
w
it
h
 
T
h
M
A
A
/D
M
A
 
+ 
Je
ff
am
in
 (
50
0e
r)
 
P
o
ly
m
er
is
at
io
n
 
w
it
h
 
T
h
M
A
A
/D
M
A
 
+ 
Je
ff
am
in
 (
13
0e
r)
+ 
G
lu
co
sa
m
in
e 
P
o
ly
m
er
is
at
io
n
 
w
it
h
 
T
h
M
A
A
/D
M
A
 
+ 
Je
ff
am
in
 
(1
30
er
) 
+ 
G
lu
co
sa
m
in
e 
+ 
P
er
 
io
d
in
e 
cl
ea
v
ag
e 
P
o
ly
m
er
is
at
io
n
 
w
it
h
 
T
h
M
A
A
/D
M
A
 
+ 
Je
ff
am
in
 (
50
0e
r)
 +
 P
o
ly
-L
y
si
n
e 
co
at
in
g
 
P
o
ly
m
er
is
at
io
n
 
w
it
h
 
T
h
M
A
A
/D
M
A
 
+ 
Je
ff
am
in
 (
50
0e
r)
 +
 b
A
la
n
in
e 
sp
o
ts
 
P
o
ly
m
er
is
at
io
n
 
w
it
h
 
T
h
M
A
A
/D
M
A
 
+ 
Je
ff
am
in
 (
50
0e
r)
 +
 L
y
si
n
e 
sp
o
ts
 
O
zo
n
o
ly
si
s 
+ 
B
o
ra
n
 d
im
et
h
y
l 
su
lp
h
id
e 
co
m
p
le
x
 r
ed
u
ct
io
n
 
  
P
a
tc
h
 
N
r 
V
7 
V
8 
V
9 
V
10
 
V
11
 
V
12
 
V
13
 
V
14
 
M
ea
n
 
S
td
 
D
ev
 
Table 6-1. Comparison of the general response of different cell lines to the surface chemistry done 
on the patches (for patches V1 to V 14) 
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Table 6-2. Comparison of the behaviour of the cell lines tested towards the PP foils in general and 
the PP foils with the highly charged peptides. 
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6.4 List of sequences of the peptide libraries used 
 
Lib Mixed 65:  LL XX12XX 
List of 400 spots on the membrane other than the control spots 
1 2 3 4 5 6 7 8 9 10 
XXAAXX XXCAXX XXDAXX XXEAXX XXFAXX XXGAXX XXHAXX XXIAXX XXKAXX XXLAXX 
XXACXX XXCCXX XXDCXX XXECXX XXFCXX XXGCXX XXHCXX XXICXX XXKCXX XXLCXX 
XXADXX XXCDXX XXDDXX XXEDXX XXFDXX XXGDXX XXHDXX XXIDXX XXKDXX XXLDXX 
XXAEXX XXCEXX XXDEXX XXEEXX XXFEXX XXGEXX XXHEXX XXIEXX XXKEXX XXLEXX 
XXAFXX XXCFXX XXDFXX XXEFXX XXFFXX XXGFXX XXHFXX XXIFXX XXKFXX XXLFXX 
XXAGXX XXCGXX XXDGXX XXEGXX XXFGXX XXGGXX XXHGXX XXIGXX XXKGXX XXLGXX 
XXAHXX XXCHXX XXDHXX XXEHXX XXFHXX XXGHXX XXHHXX XXIHXX XXKHXX XXLHXX 
XXAIXX XXCIXX XXDIXX XXEIXX XXFIXX XXGIXX XXHIXX XXIIXX XXKIXX XXLIXX 
XXAKXX XXCKXX XXDKXX XXEKXX XXFKXX XXGKXX XXHKXX XXIKXX XXKKXX XXLKXX 
XXALXX XXCLXX XXDLXX XXELXX XXFLXX XXGLXX XXHLXX XXILXX XXKLXX XXLLXX 
XXAMXX XXCMXX XXDMXX XXEMXX XXFMXX XXGMXX XXHMXX XXIMXX XXKMXX XXLMXX 
XXANXX XXCNXX XXDNXX XXENXX XXFNXX XXGNXX XXHNXX XXINXX XXKNXX XXLNXX 
XXAPXX XXCPXX XXDPXX XXEPXX XXFPXX XXGPXX XXHPXX XXIPXX XXKPXX XXLPXX 
XXAQXX XXCQXX XXDQXX XXEQXX XXFQXX XXGQXX XXHQXX XXIQXX XXKQXX XXLQXX 
XXARXX XXCRXX XXDRXX XXERXX XXFRXX XXGRXX XXHRXX XXIRXX XXKRXX XXLRXX 
XXASXX XXCSXX XXDSXX XXESXX XXFSXX XXGSXX XXHSXX XXISXX XXKSXX XXLSXX 
XXATXX XXCTXX XXDTXX XXETXX XXFTXX XXGTXX XXHTXX XXITXX XXKTXX XXLTXX 
XXAVXX XXCVXX XXDVXX XXEVXX XXFVXX XXGVXX XXHVXX XXIVXX XXKVXX XXLVXX 
XXAWXX XXCWXX XXDWXX XXEWXX XXFWXX XXGWXX XXHWXX XXIWXX XXKWXX XXLWXX 
XXAYXX XXCYXX XXDYXX XXEYXX XXFYXX XXGYXX XXHYXX XXIYXX XXKYXX XXLYXX 
                    
11 12 13 14 15 16 17 18 19 20 
XXMAXX XXNAXX XXPAXX XXQAXX XXRAXX XXSAXX XXTAXX XXVAXX XXWAXX XXYAXX 
XXMCXX XXNCXX XXPCXX XXQCXX XXRCXX XXSCXX XXTCXX XXVCXX XXWCXX XXYCXX 
XXMDXX XXNDXX XXPDXX XXQDXX XXRDXX XXSDXX XXTDXX XXVDXX XXWDXX XXYDXX 
XXMEXX XXNEXX XXPEXX XXQEXX XXREXX XXSEXX XXTEXX XXVEXX XXWEXX XXYEXX 
XXMFXX XXNFXX XXPFXX XXQFXX XXRFXX XXSFXX XXTFXX XXVFXX XXWFXX XXYFXX 
XXMGXX XXNGXX XXPGXX XXQGXX XXRGXX XXSGXX XXTGXX XXVGXX XXWGXX XXYGXX 
XXMHXX XXNHXX XXPHXX XXQHXX XXRHXX XXSHXX XXTHXX XXVHXX XXWHXX XXYHXX 
XXMIXX XXNIXX XXPIXX XXQIXX XXRIXX XXSIXX XXTIXX XXVIXX XXWIXX XXYIXX 
XXMKXX XXNKXX XXPKXX XXQKXX XXRKXX XXSKXX XXTKXX XXVKXX XXWKXX XXYKXX 
XXMLXX XXNLXX XXPLXX XXQLXX XXRLXX XXSLXX XXTLXX XXVLXX XXWLXX XXYLXX 
XXMMXX XXNMXX XXPMXX XXQMXX XXRMXX XXSMXX XXTMXX XXVMXX XXWMXX XXYMXX 
XXMNXX XXNNXX XXPNXX XXQNXX XXRNXX XXSNXX XXTNXX XXVNXX XXWNXX XXYNXX 
XXMPXX XXNPXX XXPPXX XXQPXX XXRPXX XXSPXX XXTPXX XXVPXX XXWPXX XXYPXX 
XXMQXX XXNQXX XXPQXX XXQQXX XXRQXX XXSQXX XXTQXX XXVQXX XXWQXX XXYQXX 
XXMRXX XXNRXX XXPRXX XXQRXX XXRRXX XXSRXX XXTRXX XXVRXX XXWRXX XXYRXX 
XXMSXX XXNSXX XXPSXX XXQSXX XXRSXX XXSSXX XXTSXX XXVSXX XXWSXX XXYSXX 
XXMTXX XXNTXX XXPTXX XXQTXX XXRTXX XXSTXX XXTTXX XXVTXX XXWTXX XXYTXX 
XXMVXX XXNVXX XXPVXX XXQVXX XXRVXX XXSVXX XXTVXX XXVVXX XXWVXX XXYVXX 
XXMWXX XXNWXX XXPWXX XXQWXX XXRWXX XXSWXX XXTWXX XXVWXX XXWWXX XXYWXX 
XXMYXX XXNYXX XXPYXX XXQYXX XXRYXX XXSYXX XXTYXX XXVYXX XXWYXX XXYYXX 
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Lib 17:  LL XXX12XXX  
 
(List of 400 spots on the membrane including the 25 control spots at the end) 
1 2 3 4 5 6 7 8 9 
XXXAAXXX XXXCAXXX XXXDAXXX XXXEAXXX XXXFAXXX XXXGAXXX XXXHAXXX XXXIAXXX XXXKAXXX 
XXXACXXX XXXCCXXX XXXDCXXX XXXECXXX XXXFCXXX XXXGCXXX XXXHCXXX XXXICXXX XXXKCXXX 
XXXADXXX XXXCDXXX XXXDDXXX XXXEDXXX XXXFDXXX XXXGDXXX XXXHDXXX XXXIDXXX XXXKDXXX 
XXXAEXXX XXXCEXXX XXXDEXXX XXXEEXXX XXXFEXXX XXXGEXXX XXXHEXXX XXXIEXXX XXXKEXXX 
XXXAFXXX XXXCFXXX XXXDFXXX XXXEFXXX XXXFFXXX XXXGFXXX XXXHFXXX XXXIFXXX XXXKFXXX 
XXXAGXXX XXXCGXXX XXXDGXXX XXXEGXXX XXXFGXXX XXXGGXXX XXXHGXXX XXXIGXXX XXXKGXXX 
XXXAHXXX XXXCHXXX XXXDHXXX XXXEHXXX XXXFHXXX XXXGHXXX XXXHHXXX XXXIHXXX XXXKHXXX 
XXXAIXXX XXXCIXXX XXXDIXXX XXXEIXXX XXXFIXXX XXXGIXXX XXXHIXXX XXXIIXXX XXXKIXXX 
XXXAKXXX XXXCKXXX XXXDKXXX XXXEKXXX XXXFKXXX XXXGKXXX XXXHKXXX XXXIKXXX XXXKKXXX 
XXXALXXX XXXCLXXX XXXDLXXX XXXELXXX XXXFLXXX XXXGLXXX XXXHLXXX XXXILXXX XXXKLXXX 
XXXAMXXX XXXCMXXX XXXDMXXX XXXEMXXX XXXFMXXX XXXGMXXX XXXHMXXX XXXIMXXX XXXKMXXX 
XXXANXXX XXXCNXXX XXXDNXXX XXXENXXX XXXFNXXX XXXGNXXX XXXHNXXX XXXINXXX XXXKNXXX 
XXXAPXXX XXXCPXXX XXXDPXXX XXXEPXXX XXXFPXXX XXXGPXXX XXXHPXXX XXXIPXXX XXXKPXXX 
XXXAQXXX XXXCQXXX XXXDQXXX XXXEQXXX XXXFQXXX XXXGQXXX XXXHQXXX XXXIQXXX XXXKQXXX 
XXXARXXX XXXCRXXX XXXDRXXX XXXERXXX XXXFRXXX XXXGRXXX XXXHRXXX XXXIRXXX XXXKRXXX 
XXXASXXX XXXCSXXX XXXDSXXX XXXESXXX XXXFSXXX XXXGSXXX XXXHSXXX XXXISXXX XXXKSXXX 
XXXATXXX XXXCTXXX XXXDTXXX XXXETXXX XXXFTXXX XXXGTXXX XXXHTXXX XXXITXXX XXXKTXXX 
XXXAVXXX XXXCVXXX XXXDVXXX XXXEVXXX XXXFVXXX XXXGVXXX XXXHVXXX XXXIVXXX XXXKVXXX 
XXXAWXXX XXXCWXXX XXXDWXXX XXXEWXXX XXXFWXXX XXXGWXXX XXXHWXXX XXXIWXXX XXXKWXXX 
XXXAYXXX XXXCYXXX XXXDYXXX XXXEYXXX XXXFYXXX XXXGYXXX XXXHYXXX XXXIYXXX XXXKYXXX 
         
 10 11   12 13 14 15  16 17 18 
XXXLAXXX XXXMAXXX XXXNAXXX XXXPAXXX XXXQAXXX XXXRAXXX XXXSAXXX XXXTAXXX XXXVAXXX 
XXXLCXXX XXXMCXXX XXXNCXXX XXXPCXXX XXXQCXXX XXXRCXXX XXXSCXXX XXXTCXXX XXXVCXXX 
XXXLDXXX XXXMDXXX XXXNDXXX XXXPDXXX XXXQDXXX XXXRDXXX XXXSDXXX XXXTDXXX XXXVDXXX 
XXXLEXXX XXXMEXXX XXXNEXXX XXXPEXXX XXXQEXXX XXXREXXX XXXSEXXX XXXTEXXX XXXVEXXX 
XXXLFXXX XXXMFXXX XXXNFXXX XXXPFXXX XXXQFXXX XXXRFXXX XXXSFXXX XXXTFXXX XXXVFXXX 
XXXLGXXX XXXMGXXX XXXNGXXX XXXPGXXX XXXQGXXX XXXRGXXX XXXSGXXX XXXTGXXX XXXVGXXX 
XXXLHXXX XXXMHXXX XXXNHXXX XXXPHXXX XXXQHXXX XXXRHXXX XXXSHXXX XXXTHXXX XXXVHXXX 
XXXLIXXX XXXMIXXX XXXNIXXX XXXPIXXX XXXQIXXX XXXRIXXX XXXSIXXX XXXTIXXX XXXVIXXX 
XXXLKXXX XXXMKXXX XXXNKXXX XXXPKXXX XXXQKXXX XXXRKXXX XXXSKXXX XXXTKXXX XXXVKXXX 
XXXLLXXX XXXMLXXX XXXNLXXX XXXPLXXX XXXQLXXX XXXRLXXX XXXSLXXX XXXTLXXX XXXVLXXX 
XXXLMXXX XXXMMXXX XXXNMXXX XXXPMXXX XXXQMXXX XXXRMXXX XXXSMXXX XXXTMXXX XXXVMXXX 
XXXLNXXX XXXMNXXX XXXNNXXX XXXPNXXX XXXQNXXX XXXRNXXX XXXSNXXX XXXTNXXX XXXVNXXX 
XXXLPXXX XXXMPXXX XXXNPXXX XXXPPXXX XXXQPXXX XXXRPXXX XXXSPXXX XXXTPXXX XXXVPXXX 
XXXLQXXX XXXMQXXX XXXNQXXX XXXPQXXX XXXQQXXX XXXRQXXX XXXSQXXX XXXTQXXX XXXVQXXX 
XXXLRXXX XXXMRXXX XXXNRXXX XXXPRXXX XXXQRXXX XXXRRXXX XXXSRXXX XXXTRXXX XXXVRXXX 
XXXLSXXX XXXMSXXX XXXNSXXX XXXPSXXX XXXQSXXX XXXRSXXX XXXSSXXX XXXTSXXX XXXVSXXX 
XXXLTXXX XXXMTXXX XXXNTXXX XXXPTXXX XXXQTXXX XXXRTXXX XXXSTXXX XXXTTXXX XXXVTXXX 
XXXLVXXX XXXMVXXX XXXNVXXX XXXPVXXX XXXQVXXX XXXRVXXX XXXSVXXX XXXTVXXX XXXVVXXX 
XXXLWXXX XXXMWXXX XXXNWXXX XXXPWXXX XXXQWXXX XXXRWXXX XXXSWXXX XXXTWXXX XXXVWXXX 
XXXLYXXX XXXMYXXX XXXNYXXX XXXPYXXX XXXQYXXX XXXRYXXX XXXSYXXX XXXTYXXX XXXVYXXX 
                  
19 20  Control spots      
XXXWAXXX XXXYAXXX   XXXAAXXX XXXCCXXX         
XXXWCXXX XXXYCXXX   XXXCCXXX XXXGGXXX         
XXXWDXXX XXXYDXXX   XXXDDXXX XXXQQXXX         
XXXWEXXX XXXYEXXX   XXXEEXXX XXXRRXXX         
XXXWFXXX XXXYFXXX   XXXFFXXX XXXWWXXX         
XXXWGXXX XXXYGXXX   XXXGGXXX           
XXXWHXXX XXXYHXXX   XXXHHXXX           
XXXWIXXX XXXYIXXX   XXXIIXXX           
XXXWKXXX XXXYKXXX   XXXKKXXX           
XXXWLXXX XXXYLXXX   XXXLLXXX           
XXXWMXXX XXXYMXXX   XXXMMXXX           
XXXWNXXX XXXYNXXX   XXXNNXXX           
XXXWPXXX XXXYPXXX   XXXPPXXX           
XXXWQXXX XXXYQXXX   XXXQQXXX           
XXXWRXXX XXXYRXXX   XXXRRXXX           
XXXWSXXX XXXYSXXX   XXXSSXXX           
XXXWTXXX XXXYTXXX   XXXTTXXX           
XXXWVXXX XXXYVXXX   XXXVVXXX           
XXXWWXXX XXXYWXXX   XXXWWXXX           
XXXWYXXX XXXYYXXX   XXXYYXXX           
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Lib 20 Filter 3: PNA Lib 1 LL  
1 2 3 4 5 6 7 8 9 
XBaaBBX XBaBaBX XXaaaXX XXcaaXX XXgaaXX XXtaaXX XaXaaXX XcXaaXX XgXaaXX 
XBacBBX XBaBcBX XXaacXX XXcacXX XXgacXX XXtacXX XaXacXX XcXacXX XgXacXX 
XBagBBX XBaBgBX XXaagXX XXcagXX XXgagXX XXtagXX XaXagXX XcXagXX XgXagXX 
XBatBBX XBaBtBX XXaatXX XXcatXX XXgatXX XXtatXX XaXatXX XcXatXX XgXatXX 
XBcaBBX XBcBaBX XXacaXX XXccaXX XXgcaXX XXtcaXX XaXcaXX XcXcaXX XgXcaXX 
XBccBBX XBcBcBX XXaccXX XXcccXX XXgccXX XXtccXX XaXccXX XcXccXX XgXccXX 
XBcgBBX XBcBgBX XXacgXX XXccgXX XXgcgXX XXtcgXX XaXcgXX XcXcgXX XgXcgXX 
XBctBBX XBcBtBX XXactXX XXcctXX XXgctXX XXtctXX XaXctXX XcXctXX XgXctXX 
XBgaBBX XBgBaBX XXagaXX XXcgaXX XXggaXX XXtgaXX XaXgaXX XcXgaXX XgXgaXX 
XBgcBBX XBgBcBX XXagcXX XXcgcXX XXggcXX XXtgcXX XaXgcXX XcXgcXX XgXgcXX 
XBggBBX XBgBgBX XXaggXX XXcggXX XXgggXX XXtggXX XaXggXX XcXggXX XgXggXX 
XBgtBBX XBgBtBX XXagtXX XXcgtXX XXggtXX XXtgtXX XaXgtXX XcXgtXX XgXgtXX 
XBtaBBX XBtBaBX XXataXX XXctaXX XXgtaXX XXttaXX XaXtaXX XcXtaXX XgXtaXX 
XBtcBBX XBtBcBX XXatcXX XXctcXX XXgtcXX XXttcXX XaXtcXX XcXtcXX XgXtcXX 
XBtgBBX XBtBgBX XXatgXX XXctgXX XXgtgXX XXttgXX XaXtgXX XcXtgXX XgXtgXX 
XBttBBX XBtBtBX XXattXX XXcttXX XXgttXX XXtttXX XaXttXX XcXttXX XgXttXX 
                  
10 11 12 13 14 15 16 17 18 
XtXaaXX XaXaXaX XcXaXaX XgXaXaX XtXaXaX XaaXaXX XcaXaXX XgaXaXX XtaXaXX 
XtXacXX XaXaXcX XcXaXcX XgXaXcX XtXaXcX XaaXcXX XcaXcXX XgaXcXX XtaXcXX 
XtXagXX XaXaXgX XcXaXgX XgXaXgX XtXaXgX XaaXgXX XcaXgXX XgaXgXX XtaXgXX 
XtXatXX XaXaXtX XcXaXtX XgXaXtX XtXaXtX XaaXtXX XcaXtXX XgaXtXX XtaXtXX 
XtXcaXX XaXcXaX XcXcXaX XgXcXaX XtXcXaX XacXaXX XccXaXX XgcXaXX XtcXaXX 
XtXccXX XaXcXcX XcXcXcX XgXcXcX XtXcXcX XacXcXX XccXcXX XgcXcXX XtcXcXX 
XtXcgXX XaXcXgX XcXcXgX XgXcXgX XtXcXgX XacXgXX XccXgXX XgcXgXX XtcXgXX 
XtXctXX XaXcXtX XcXcXtX XgXcXtX XtXcXtX XacXtXX XccXtXX XgcXtXX XtcXtXX 
XtXgaXX XaXgXaX XcXgXaX XgXgXaX XtXgXaX XagXaXX XcgXaXX XggXaXX XtgXaXX 
XtXgcXX XaXgXcX XcXgXcX XgXgXcX XtXgXcX XagXcXX XcgXcXX XggXcXX XtgXcXX 
XtXggXX XaXgXgX XcXgXgX XgXgXgX XtXgXgX XagXgXX XcgXgXX XggXgXX XtgXgXX 
XtXgtXX XaXgXtX XcXgXtX XgXgXtX XtXgXtX XagXtXX XcgXtXX XggXtXX XtgXtXX 
XtXtaXX XaXtXaX XcXtXaX XgXtXaX XtXtXaX XatXaXX XctXaXX XgtXaXX XttXaXX 
XtXtcXX XaXtXcX XcXtXcX XgXtXcX XtXtXcX XatXcXX XctXcXX XgtXcXX XttXcXX 
XtXtgXX XaXtXgX XcXtXgX XgXtXgX XtXtXgX XatXgXX XctXgXX XgtXgXX XttXgXX 
XtXttXX XaXtXtX XcXtXtX XgXtXtX XtXtXtX XatXtXX XctXtXX XgtXtXX XttXtXX 
                  
19 20 21 22 23 24 25 26  
XaXXaaX XcXXaaX XgXXaaX XtXXaaX XaaXXaX XcaXXaX XgaXXaX XtaXXaX   
XaXXacX XcXXacX XgXXacX XtXXacX XaaXXcX XcaXXcX XgaXXcX XtaXXcX   
XaXXagX XcXXagX XgXXagX XtXXagX XaaXXgX XcaXXgX XgaXXgX XtaXXgX   
XaXXatX XcXXatX XgXXatX XtXXatX XaaXXtX XcaXXtX XgaXXtX XtaXXtX   
XaXXcaX XcXXcaX XgXXcaX XtXXcaX XacXXaX XccXXaX XgcXXaX XtcXXaX   
XaXXccX XcXXccX XgXXccX XtXXccX XacXXcX XccXXcX XgcXXcX XtcXXcX   
XaXXcgX XcXXcgX XgXXcgX XtXXcgX XacXXgX XccXXgX XgcXXgX XtcXXgX   
XaXXctX XcXXctX XgXXctX XtXXctX XacXXtX XccXXtX XgcXXtX XtcXXtX   
XaXXgaX XcXXgaX XgXXgaX XtXXgaX XagXXaX XcgXXaX XggXXaX XtgXXaX   
XaXXgcX XcXXgcX XgXXgcX XtXXgcX XagXXcX XcgXXcX XggXXcX XtgXXcX   
XaXXggX XcXXggX XgXXggX XtXXggX XagXXgX XcgXXgX XggXXgX XtgXXgX   
XaXXgtX XcXXgtX XgXXgtX XtXXgtX XagXXtX XcgXXtX XggXXtX XtgXXtX   
XaXXtaX XcXXtaX XgXXtaX XtXXtaX XatXXaX XctXXaX XgtXXaX XttXXaX   
XaXXtcX XcXXtcX XgXXtcX XtXXtcX XatXXcX XctXXcX XgtXXcX XttXXcX   
XaXXtgX XcXXtgX XgXXtgX XtXXtgX XatXXgX XctXXgX XgtXXgX XttXXgX   
XaXXttX XcXXttX XgXXttX XtXXttX XatXXtX XctXXtX XgtXXtX XttXXtX   
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Lib Varsha 1:  Repeat of RR 25 spots 
 
Positive Spots: 
 
 1.  X X D R R R X X 
 2.  X X K R R D X X 
 3.  X X K R R H X X 
 4.  X X K R R K X X 
 5.  X X K R R P X X 
 6.  X X K R R R X X 
 7.  X X K R R S X X 
 8.  X X P R R C X X 
 9.  X X R R R A X X 
 10.  X X R R R H X X 
 11.  X X R R R M X X 
 12.  X X R R R N X X 
 13.  X X S R R R X X 
 14.  X X T R R K X X 
 15.  X X V R R C X X 
 16. X X V R R K X X 
 17.  X X W R R F X X 
 18. X X W R R G X X 
 19. X X W R R M X X 
 20. X X W R R R X X 
 
Negative Spots: 
 21. X X E R R K X X 
 22. X X P R R W X X 
 23. X X R R R E X X 
 24. X X W R R A X X 
 25. X X W R R Y X X 
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Lib Varsha 1:   Repeat of PNA 25 spots 
 
Positive Spots: 
 
 1.  X t g B g B X  
 2.  X g g B B c X 
 3.  X g B B g t X 
 4.  X g g B t B X 
 5.  X c B B g g X 
 6.  X B g t g B X 
 7.  X B t g g B X 
 8.  X c B g g B X 
 9.  X g B g t B X 
 10.  X t B g g B X 
 11.  X t B g B g X 
 12.  X g B B t g X 
 13.  X g B g c B X 
 14.  X t g B B g X 
 15. X g a B g B X 
 
Negative Spots: 
 16.  X B g t a B X 
 17.  X B c a c B X 
 18.  X B c c a B X 
 19.  X B t g B B X 
 20.  X B c t a B X 
 21.  X B a a B B X 
 22.  X a B a a B X 
 23.  X c B t B t X 
 24. X B t t t B X 
 25.  X B g g g B X 
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6.5 Sequence of pET Hu La 
NCBI Human La Protein Sequence : 1619bp 
5 prime  
ggagtcgttgttgttgctgtttgtgagcctgtgcggcggcttctgtgggccggaaccttaaagatagc
cgcaatggctgaaaatggtgataatgaaaagatggctgccctggaggccaaaatctgtcatcaaattg
agtattattttggcgacttcaatttgccacgggacaagtttctaaaggaacagataaaactggatgaa
ggctgggtacctttggagataatgataaaattcaacaggttgaaccgtctaacaacagactttaatgt
aattgtggaagcattgagcaaatccaaggcagaactcatggaaatcagtgaagataaaactaaaatca
gaaggtctccaagcaaacccctacctgaagtgactgatgagtataaaaatgatgtaaaaaacagatct
gtttatattaaaggcttcccaactgatgcaactcttgatgacataaaagaatggttagaagataaagg
tcaagtactaaatattcagatgagaagaacattgcataaagcatttaagggatcaatttttgttgtgt
ttgatagcattgaatctgctaagaaatttgtagagacccctggccagaagtacaaagaaacagacctg
ctaatacttttcaaggacgattactttgccaaaaaaaatgaagaaagaaaacaaaataaagtggaagc
taaattaagagctaaacaggagcaagaagcaaaacaaaagttagaagaagatgctgaaatgaaatctc
tagaagaaaagattggatgcttgctgaaattttcgggtgatttagatgatcagacctgtagagaagat
ttacacatacttttctcaaatcatggtgaaataaaatggatagacttcgtcagaggagcaaaagaggg
gataattctatttaaagaaaaagccaaggaagcattgggtaaagccaaagatgcaaataatggtaacc
tacaattaaggaacaaagaagtgacttgggaagtactagaaggagaggtggaaaaagaagcactgaag
aaaataatagaagaccaacaagaatccctaaacaaatggaagtcaaaaggtcgtagatttaaaggaaa
aggaaagggtaataaagctgcccagcctgggtctggtaaaggaaaagtacagtttcagggcaagaaaa
cgaaatttgctagtgatgatgaacatgatgaacatgatgaaaatggtgcaactggacctgtgaaaaga
gcaagagaagaaacagacaaagaagaacctgcatccaaacaacagaaaacagaaaatggtgctggaga
ccagtagtttagtaaaccaattttttattcattttaaataggttttaaacgacttttgtttgcggggc
ttttaaaaggaaaaccgaattaggtccacttcaatgtccacctgtgagaaaggaaaaatttttttgtt
gtttaacttgtctttttgttatgcaaatgagatttctttgaatgtattgttctgtttgtgttatttca
gatgattcaaatatcaaaaggaagattcttccattaaattgcctttgtaatatgagaatgtattagta
caaactaactaataaaatatatactatatgaaaagagcaaaaaaaaaaaaaaaaa  
3 prime 
 
Amino acids sequence of the Human La protein (P05455) 
 
1 maengdnekm aaleakichq ieyyfgdfnl prdkflkeqi kldegwvple 
imikfnrlnr 
 
61 lttdfnvive alskskaelm eisedktkir rspskplpev tdeykndvkn 
rsvyikgfpt 
 
121 datlddikew ledkgqvlni qmrrtlhkaf kgsifvvfds iesakkfvet 
pgqkyketdl 
 
181 lilfkddyfa kkneerkqnk veaklrakqe qeakqkleed aemksleeki 
gcllkfsgdl 
 
241 ddqtcredlh ilfsnhgeik widfvrgake giilfkekak ealgkakdan 
ngnlqlrnke 
 
301 vtwevlegev ekealkkiie dqqeslnkwk skgrrfkgkg kgnkaaqpgs 
gkgkvqfqgk 
 
361 ktkfasddeh dehdengatg pvkrareetd keepaskqqk tengagdq 
 
The amino acids in red are deleted in the Mutant La Δ2 protein.  
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